0001144204-18-059482.txt : 20181114 0001144204-18-059482.hdr.sgml : 20181114 20181113202402 ACCESSION NUMBER: 0001144204-18-059482 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20180930 FILED AS OF DATE: 20181114 DATE AS OF CHANGE: 20181113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-55723 FILM NUMBER: 181180028 BUSINESS ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 BUSINESS PHONE: 858-605-9055 MAIL ADDRESS: STREET 1: 15150 AVENUE OF SCIENCE, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92128 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 10-Q 1 tv507009_10q.htm FORM 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ____ to ____

Commission file number: 000-55723

GUARDION HEALTH SCIENCES, INC.

(Exact name of Registrant as specified in its charter)

Delaware

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

47-4428421

(State or other jurisdiction of
incorporation or organization)

(Address and telephone number
of principal executive offices)

(I.R.S. Employer

Identification No.)

15150 Avenue of Science, Suite 200

San Diego, California 92128

Telephone: 858-605-9055

(Address and telephone number of principal executive offices)

Not applicable

(Former name, former address, and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). x Yes ¨ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	¨	Accelerated filer	¨
Non-accelerated filer	x	Smaller reporting company	x
		Emerging growth company	x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). ¨ Yes x No

As of November 9, 2018, there were 40,329,475 shares of the Registrant’s common stock, par value $0.001 per share, issued and outstanding. Registrant’s common stock is not publicly traded.

TABLE OF CONTENTS

		Page No.
PART I – FINANCIAL INFORMATION

ITEM 1.	CONDENSED CONSOLIDATED FINANCIAL STATEMENTS	4

	Balance Sheets – As of September 30, 2018 (Unaudited) and December 31, 2017	4

	Statements of Operations (Unaudited) – Three and Nine Months Ended September 30, 2018 and 2017	5

	Statement of Stockholders’ Equity (Unaudited) – Nine Months Ended September 30, 2018	6

	Statements of Cash Flows (Unaudited) – Nine Months Ended September 30, 2018 and 2017	7

	Notes to Condensed Consolidated Financial Statements (Unaudited)	8

ITEM 2.	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	18

ITEM 3.	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	27

ITEM 4.	CONTROLS AND PROCEDURES	27

PART II – OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS	28

ITEM 1A.	RISK FACTORS	28

ITEM 2.	UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS	28

ITEM 3.	DEFAULTS UPON SENIOR SECURITIES	28

ITEM 4.	MINE SAFETY DISCLOSURES	28

ITEM 5.	OTHER INFORMATION	28

ITEM 6.	EXHIBITS	28

SIGNATURES		29

Introductory Comment

Throughout this Quarterly Report on Form 10-Q, the terms “we,” “us,” “our,” “our company,” “Guardion,” the “Company” and the “Registrant” refer to Guardion Health Sciences, Inc.

FORWARD LOOKING STATEMENTS

This Quarterly Report on Form 10-Q (this “Report”) contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements relate to future events or future predictions, including events or predictions relating to the Company’s future financial performance, and are based on current expectations, estimates, forecasts and projections about the Company, its future performance, its beliefs and management’s assumptions. They are generally identifiable by use of the words “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “feel,” “confident,” “estimate,” “intend,” “predict,” “forecast,” “potential” or “continue” or the negative of such terms or other variations on these words or comparable terminology. These statements involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to implement its business plan and its ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s recent filings with the U. S. Securities and Exchange Commission (the “SEC”), including the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and in other documents the Company files with the SEC from time to time. These filings are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, in each case, except to the extent required by applicable law.

Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance or achievements. The Company will not update or revise the forward-looking statements except to the extent required by applicable law.

PART I – FINANCIAL INFORMATION

ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

Guardion Health Sciences, Inc.

Condensed Consolidated Balance Sheets

	September 30,			December 31,
	2018			2017
	(Unaudited)
Assets

Current assets
Cash	$	1,101,790		$	4,735,230
Accounts receivable		17,011			72,771
Inventories		381,268			154,730
Prepaid expenses		38,736			117,164

Total current assets		1,538,805			5,079,895

Deposits		11,751			10,470
Property and equipment, net		261,871			95,597
Intangible assets, net		509,763			620,741
Goodwill		1,563,520			1,563,520

Total assets	$	3,885,710		$	7,370,223

Liabilities and Stockholders’ Equity

Current liabilities
Accounts payable and accrued liabilities	$	268,121		$	311,236
Accrued expenses and deferred rent		22,433			12,043
Line of credit		-			30,535
Due to related parties		108,018			146,133

Total current liabilities		398,572			499,947

Commitments and contingencies

Stockholders’ Equity

Preferred stock, $0.001 par value; 10,000,000 shares authorized		-			-
Common stock, $0.001 par value; 90,000,000 shares authorized; 40,329,475 and 40,183,475 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively		40,329			40,183
Additional paid-in capital		36,603,982			33,696,049
Accumulated deficit		(33,157,173	)		(26,865,956	)

Total stockholders’ equity		3,487,138			6,870,276

Total liabilities and stockholders’ equity	$	3,885,710		$	7,370,223

See accompanying notes to condensed consolidated financial statements.

Guardion Health Sciences, Inc.

Condensed Consolidated Statements of Operations

	Three Months Ended September 30,						Nine Months Ended September 30,
	2018			2017			2018			2017
	(Unaudited)			(Unaudited)			(Unaudited)			(Unaudited)
Revenue	$	294,230		$	62,698		$	708,047		$	178,610

Cost of goods sold		125,406			30,094			292,461			82,420

Gross profit		168,824			32,604			415,586			96,190

Operating expenses
Research and development		4,793			105,561			199,500			131,330
Sales and marketing		240,028			116,440			1,224,491			294,774
General and administrative		1,064,645			1,392,524			3,779,325			2,758,331

Total operating expenses		1,309,466			1,614,525			5,203,316			3,184,435

Loss from operations		(1,140,642	)		(1,581,921	)		(4,787,730	)		(3,088,245	)

Other expenses:
Interest expense		545			2,462			2,090			20,817
Warrants - extension of expiration dates		1,007,006			-			1,501,397			-

Total other expenses		1,007,551			2,462			1,503,487			20,817

Net loss		(2,148,193	)		(1,584,383	)		(6,291,217	)		(3,109,062	)

Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend		-			(249,820	)		-			(335,337	)
Dividend declared		-			(78,616	)		-			(159,798	)
Net loss attributable to common shareholders	$	(2,148,193	)	$	(1,912,819	)	$	(6,291,217	)	$	(3,604,197	)

Net loss per common share – basic and diluted	$	(0.05	)	$	(0.07	)	$	(0.16	)	$	(0.14	)
Weighted average common shares outstanding – basic and diluted		40,329,475			25,825,907			40,324,662			25,469,112

See accompanying notes to condensed consolidated financial statements.

Guardion Health Sciences, Inc.

Condensed Consolidated Statement of Stockholders’ Equity

(Unaudited)

	Common Stock
	Shares		Amount		Additional Paid-In Capital		Accumulated Deficit			Total Stockholders’ Equity
Balance at December 31, 2017		40,183,475	$	40,183	$	33,696,049	$	(26,865,956	)	$	6,870,276
Fair value of vested stock options		-		-		1,405,222		-			1,405,222
Issuance of common stock – warrant exercises		146,000		146		1,314		-			1,460
Warrants - extension of expiration dates		-		-		1,501,397		-			1,501,397
Net loss		-		-		-		(6,291,217	)		(6,291,217	)
Balance at September 30, 2018		40,329,475	$	40,329	$	36,603,982	$	(33,157,173	)	$	3,487,138

See accompanying notes to condensed consolidated financial statements.

Guardion Health Sciences, Inc.

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended September 30,
	2018			2017
	(Unaudited)			(Unaudited)
Operating Activities
Net loss	$	(6,291,217	)	$	(3,109,062	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		223,014			47,869
Accrued interest expense included in notes payable		-			14,792
Stock-based compensation		1,405,222			987,932
Stock-based compensation – related parties		-			196,051
Warrants – extension of expiration dates		1,501,397			-
Changes in operating assets and liabilities:
(Increase) decrease in -
Accounts receivable		55,761			(1,831	)
Inventories		(226,537	)		(40,741	)
Deposits and prepaid expenses		77,147			2,169
Increase (decrease) in -
Accounts payable and accrued expenses		(43,117	)		51,626
Accrued and deferred rent costs		10,390			(63,550	)

Net cash used in operating activities		(3,287,940	)		(1,914,745	)

Investing Activities
Purchase of property and equipment		(228,311	)		(25,203	)
Purchase of intellectual property		(50,000	)		-
Cash assumed upon acquisition		-			4,895

Net cash used in investing activities		(278,311	)		(20,308	)

Financing Activities
Proceeds from issuance of promissory notes		-			100,000
Payments on promissory notes		-			(124,000	)
Payments on line of credit		(30,535	)		-
Proceeds from issuance of preferred stock		-			3,105,000
Proceeds from exercise of warrants		1,460			-
(Decrease) increase in due to related parties		(38,114	)		61,288

Net cash (used in) provided by financing activities		(67,189	)		3,142,288

Cash:
Net (decrease) increase		(3,633,440	)		1,207,235
Balance at beginning of period		4,735,230			62,520
Balance at end of period	$	1,101,790		$	1,269,755

Supplemental disclosure of cash flow information:
Cash paid for-
Interest	$	-		$	1,965
Income taxes	$	-		$	-

Non-cash financing activities:
Issuance of common stock dividends on preferred stock	$	-		$	159,798
Fair Value of common shares issued for acquisition allocated to:
Intangible assets	$	-		$	674,400
Goodwill	$	-		$	1,563,520
Other assets	$	-		$	49,580

See accompanying notes to condensed consolidated financial statements.

Guardion Health Sciences, Inc.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

Nine Months Ended September 30, 2018 and 2017

Organization and Business Operations

Organization and Business

Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.

The Company is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment.

The Company also developed a proprietary medical device called the MapcatSF^®that accurately measures the macular pigment optical density.

On September 29, 2017, the Company completed its acquisition of substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS visual acuity testing. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing.

In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). TDSI will be dedicated to the pursuit of early predictors resulting in, the Company believes, valuable therapeutic intervention for practitioners and their patients, and additional revenue streams generated from the testing and sale of Company products to appropriate customers. The Company is currently setting up the operations of TDSI and hopes to launch its services in upcoming quarters.

The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities.

Going Concern and Liquidity

The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $6,291,217 and utilized cash in operating activities of $3,287,940 during the nine months ended September 30, 2018. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

The Company’s independent registered public accounting firm has also included explanatory language in their opinion accompanying the Company’s audited financial statements for the year ended December 31, 2017. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.

The Company will continue to incur significant expenses for continued commercialization activities related to Lumega-Z, the MapcatSF^® medical device, and VectorVision products. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new complementary products or product lines. The Company is continuing to attempt to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Summary of Significant Accounting Policies

Basis of Presentation

The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC. The condensed consolidated balance sheet as of December 31, 2017 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.

In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2018.

Use of Estimates

The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

These estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.

Intangible Assets

In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships.

In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing.

The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis.

Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations.

Impairment of Long-Lived Assets

The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of September 30, 2018 and December 31, 2017, the Company had not deemed any long-lived assets as impaired and was not aware of the existence of any indicators of impairment at such dates.

Segment Information

The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.

Revenue Recognition

The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally.

In September 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09 (ASU No. 2014-09) regarding revenue recognition. The new standard provides authoritative guidance clarifying the principles for recognizing revenue and developing a common revenue standard for U.S. generally accepted accounting principles. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. The ASU became effective January 1, 2018.

Due to the nature of the products sold by the Company, the adoption of the new standard has had no quantitative effect on the financial statements. However, the guidance requires additional disclosures to help readers of financial statements better understand the nature, amount, timing, and uncertainty of revenue that is recognized.

The Company previously recognized revenue when risk of loss transferred to its customers and collection of the receivable was reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase, although for all periods presented, returns have been insignificant.

Under the new guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied.

All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time.

Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.

The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis.

The following table presents the Company’s revenues disaggregated by product type:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Lumega-Z and supplements	$	86,082	$	62,698	$	238,213	$	178,610
VectorVision medical devices and supplies		208,148		-		469,834		-
	$	294,230	$	62,698	$	708,047	$	178,610

Research and Development Costs

Research and development costs consist primarily of fees paid to consultants and outside service providers and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include stock compensation expense, are expensed as incurred and totaled $199,500 and $131,330 for the nine months ended September 30, 2018 and 2017, respectively.

Stock-Based Compensation

The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.

Stock-based payments to officers, directors, consultants, contractors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.

The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The Company recognizes stock compensation expense, on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.

Net Loss per Share

The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock, if applicable. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants, options, and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share.

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Warrants		2,521,348		2,983,666
Options		2,725,000		650,000
Estimated shares issuable upon conversion of convertible notes payable		-		31,250
Shares issuable upon conversion of convertible preferred stock		-		6,981,938
		5,246,348		10,646,854

Recent Accounting Pronouncements

In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The adoption of ASU 2016-02 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.

In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.

In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

In August 2018, the FASB issued Accounting Standards Update 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 provides guidance on modifying the disclosure requirements on fair value measurements as part of the disclosure framework project. The guidance modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. The guidance will be effective for the Company on January 1, 2020, including interim periods, with early adoption permitted. The adoption of ASU 2018-13 is not expected to have any impact on the Company’s financial statement presentation or disclosures.

The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.

VectorVision Acquisition

On September 29, 2017, the Company, through a wholly-owned subsidiary, completed the acquisition of substantially all of the assets and certain liabilities of VectorVision, Inc., an Ohio corporation (“VectorVision”), in exchange for 3,050,000 shares of the Company’s common stock, valued at $2,287,500, pursuant to the terms of an Asset Purchase and Reorganization Agreement dated September 29, 2017 (the “VectorVision Agreement”). The VectorVision Agreement was entered into on an arm’s-length basis. The wholly-owned subsidiary that acquired the business is called VectorVision Ocular Health, Inc., a Delaware corporation, doing business as VectorVision. With respect to the 3,050,000 shares of common stock, 250,000 shares are held back by the Company through November 28, 2019 as security for VectorVision’s indemnification obligations to the Company and the remaining 2,800,000 shares were issued to VectorVision at the closing of the transaction. Per the VectorVision Agreement, the 2,800,000 shares were subsequently distributed to the two VectorVision shareholders in proportion to their shareholdings in VectorVision. The shares represented approximately 11% of the Company’s issued and outstanding common stock immediately following consummation of the transaction. The shares held back as security are included in the Company’s weighted average common shares outstanding for per-share calculations.

VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS (Early Treatment Diabetic Retinopathy Study) visual acuity testing. VectorVision developed and commercialized its CSV-1000 medical device to conduct contrast sensitivity testing and it developed and commercialized its ESV-3000 medical device to conduct ETDRS visual acuity testing. The patented standardization system provides the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. The Company believes VectorVision’s CSV-1000 device to be the standard of care for clinical trials. The VectorVision transaction expanded the Company’s technical portfolio and the Company believes it further established the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases.

In accordance with ASC 805, the Company utilized the acquisition method of accounting, whereby the purchase consideration is allocated to specific tangible and intangible assets at their estimated fair values on the date of acquisition. The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed:

	Fair Values
Common stock consideration	$	2,287,500
Liabilities assumed		108,722
Total purchase consideration		2,396,222

Cash		(4,895	)
Accounts receivable		(50,105	)
Inventory		(93,293	)
Prepaid assets		(551	)
Property and equipment		(9,458	)
Intangible assets		(674,400	)
Goodwill	$	1,563,520

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the expected revenue and benefits of the combined company.

The following unaudited pro forma financial information gives effect to the Company’s acquisition of VectorVision as if the acquisition had occurred on January 1, 2017 and had been included in the Company’s consolidated statements of operations during the three and nine-month periods ended September 30, 2017:

	Three Months Ended September 30,			Nine Months Ended September 30,
	2017			2017
Pro forma net revenues	$	198,496		$	565,289
Pro forma net loss attributable to common shareholders	$	(1,879,947	)	$	(3,705,586	)
Pro forma net loss per share	$	(0.07	)	$	(0.13	)

Inventories

Inventories consisted of the following:

	September 30,		December 31,
	2018		2017
Raw materials	$	312,981	$	133,354
Finished goods		68,287		21,376
	$	381,268	$	154,730

Property and Equipment, net

Property and equipment consisted of the following:

	September 30,			December 31,
	2018			2017
Leasehold improvements	$	98,357		$	98,357
Testing equipment		249,447			150,603
Furniture and fixtures		148,754			50,300
Computer equipment		47,476			16,464
Office equipment		8,193			8,193
		552,227			323,917
Less accumulated depreciation and amortization		(290,356	)		(228,320	)
	$	261,871		$	95,597

For the nine months ended September 30, 2018 and 2017, depreciation expense was $62,036 and $47,869, respectively, of which $23,854 and $22,044 were included in research and development expense, $7,242 and $0 were included in sales and marketing expense, and $30,940 and $25,825 were included in general and administrative expense, respectively.

Acquisition of Intellectual Property

On January 26, 2018, the Company acquired the rights to the trademark GLAUCO-HEALTH as well as the name “International Eye Wellness Institute” (together, the “IP Assets”) from an unrelated third party. The purchase included all rights, title, and interest in and to the IP Assets, including (a) the right to register and use the IP Assets; (b) all goodwill associated with the IP Assets; (c) all income, royalties, and damages hereafter due or payable with respect to the IP Assets; (d) all rights to sue for past, present, and future infringements or misappropriations of the IP Assets; and (e) and all other intellectual property rights owned or claimed by the seller or embodied in the IP Assets. In exchange for these rights, the Company paid the seller $50,000 in cash.

ASC 350-30-20 defines a defensive intangible asset as an acquired intangible asset in a situation in which an entity does not intend to actively use the asset but intends to hold (lock up) the asset to prevent others from obtaining access to the asset. The Company determined that the acquired intangible asset met the definition of a defensive intangible asset. The Company accounted for the $50,000 payment as an acquired intangible asset as of the closing of the agreement. As the Company can renew the underlying rights to the IP Assets indefinitely at nominal cost, the assets have been classified as a non-amortizable intangible asset on the Company’s balance sheet at September 30, 2018. The Company will evaluate the status of the assets for impairment annually or more frequently if warranted.

On January 26, 2018 the Company entered into a consulting agreement with the principal of the seller to assist with the development of the IP Assets and other assets acquired by the Company in the transaction. In conjunction with the consulting agreement, the Company granted a stock option on January 26, 2018 to the consultant to purchase a total of 500,000 shares of the common stock of the Company (see Note 8).

Related Party Transactions

Due to and from related parties represents unreimbursed expenses and compensation incurred on behalf of, and amounts loaned to the Company by, Michael Favish, the Company’s Chief Executive Officer, as well as other stockholders. The advances are unsecured, non-interest bearing and are due on demand. As of September 30, 2018 and December 31, 2017, the Company had $108,018 and $146,133, respectively, due to related parties.

Stockholders’ Equity

Preferred Stock

Series A

During 2016, the Company sold 1,170,000 shares of the Company's Series A Senior Convertible Preferred Stock (the "Series A Preferred Stock") to various investors. The purchase price of the Series A Preferred Stock was $1.00 per share, for an aggregate purchase price of $1,170,000. In addition, during 2016, the Company issued 535,154 shares of its Series A Preferred Stock with a fair value of $784,888 upon conversion of $535,149 of notes payable and accrued interest. The Series A Preferred Stock had a stated value of $1.00 per share and accrued an annual dividend at the rate of 8% of the stated value, calculated quarterly, paid in shares of common stock at the rate of $0.60 per share.

During the nine months ended September 30, 2017, the Company declared dividends of $102,029 on its Series A Preferred Stock which were satisfied in full through the issuance of an aggregate of 170,075 shares of common stock.

Series B

Beginning in March 2017 and through September 30, 2017, the Company sold 3,105,000 shares of the Company's Series B Convertible Preferred Stock (the "Series B Preferred Stock") to various investors. The purchase price of the Series B Preferred Stock was $1.00 per share, for an aggregate purchase price of $3,105,000. The Series B Preferred Stock had a stated value of $1.00 per share and accrued an annual dividend at the rate of 6% of the stated value, calculated quarterly, paid in shares of common stock at the rate of $0.75 per share.

During the nine months ended September 30, 2017, the Company declared dividends of $57,769 on its Series B Preferred Stock which were satisfied in full through the issuance of an aggregate of 77,045 shares of common stock.

On November 3, 2017, the Company completed the issuance and sale of an aggregate of 4,347,827 shares of common stock (see below). The completion of the private placement triggered, at the Company's election, the automatic conversion of the Series A Preferred Stock and the Series B Preferred Stock into shares of common stock. Accordingly, immediately following the completion of the private placement, the Company effected the conversion of all outstanding shares of Series A Preferred Stock and the Series B Preferred Stock into 6,981,938 shares of common stock (excluding accrued but unpaid dividends) effective November 3, 2017. On April 26, 2018, the Company filed a Certificate of Elimination with the Secretary of the State of Delaware, withdrawing the respective Certificates of Designation that established the right, privileges and preferences of the Series A Preferred Stock and Series B Preferred Stock, thereby making all 10,000,000 authorized shares of preferred stock available for issuance.

Common Stock

On November 3, 2017, the Company completed the issuance and sale of an aggregate of 4,347,827 shares of common stock, par value $0.001 per share, at a purchase price of $1.15 per share. Total gross proceeds were $5,000,001. These shares were sold in a private placement to certain purchasers pursuant to a Stock Purchase Agreement dated as of November 3, 2017. Pursuant to the agreement, the purchasers have customary preemptive rights to participate in future equity and equity-linked issuances by the Company up to the extent necessary to maintain such purchaser’s pro rata ownership percentage in the Company’s securities, subject to customary exceptions. The preemptive rights terminate at the earlier of (i) May 3, 2019, (ii) such time as the Purchasers hold less than five percent (5%) of the issued and outstanding shares of the Company’s common stock, or (iii) such time as the shares of common stock of the Company shall become listed or approved for listing on a national securities exchange.

Warrants

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2017		2,983,666
Granted		-
Forfeitures		-
Expirations		(316,318	)
Exercised		(146,000	)
September 30, 2018, all exercisable		2,521,348

In January 2018, an investor exercised warrants for 146,000 shares of common stock. The warrants were exercisable for $0.01 per share, and the Company received $1,460 in cash. The Company issued the shares and recorded the cash received as additional equity.

On April 30, 2018, The Company offered a one-month exercise period extension to stockholders who held warrants to purchase shares of common stock of the Company that were scheduled to expire on May 1, 2018. Pursuant to the terms of a Note and Warrant Purchase Agreement entered into by the Company and such holders, such warrants were issued upon the conversion of certain promissory notes into common stock on May 1, 2015. Four of the warrant holders did not extend their warrants, resulting in the expiration of 151,006 warrants on May 1, 2018. Six warrant holders extended the term of an aggregate of 403,085 warrants by one month to June 1, 2018. The exercise price of such warrants is $1.00 per share.

On May 31, 2018, the six warrant holders noted above were offered a further extension of the exercise period for their warrants. One holder did not extend, resulting in the expiration of 30,237 warrants on June 1, 2018. The Company and five warrant holders extended the term of an aggregate of 372,848 warrants. These warrants are now scheduled to expire on the earlier of (a) May 31, 2019 or (b) sixty days following the date on which the common stock of the Company becomes listed or approved for listing on a national securities exchange. The exercise price of such warrants remains unchanged at $1.00 per share, but cashless exercise provisions have been eliminated from such warrants.

On September 21, 2018, the Company extended warrants to purchase shares of common stock of the Company that were scheduled to expire at dates ranging from September 30, 2018 through January 25, 2019 held by two stockholders. Pursuant to the terms of a Promissory Note and Loan Agreements entered into by the Company and such holders, the warrants were originally issued as inducement to lend money to the Company. The warrant holders extended the expiration dates of an aggregate of 600,000 warrants. These warrants are now scheduled to expire on February 15, 2019. The exercise price of $0.25 per share and all other terms of the warrants remain unchanged.

Management applied the guidance in ASC 718 – Compensation-Stock Compensation which indicates that a modification to the terms of an award should be treated as an exchange of the original award for a new award with the resulting total compensation cost equal to the grant-date fair value of the original award plus the incremental value of the modification to the award. Under ASC 718, the calculation of the incremental value is based on the excess of the fair value of the new (modified) award based on current circumstances over the fair value of the original award measured immediately before its terms are modified based on current circumstances. The Company recognized expense of $1,501,397 during the nine months ended September 30, 2018 relating to the extension of the exercise periods of the warrants based upon a Black-Scholes option-pricing model using stock prices of $1.15 and $1.80, volatility of 118% and 119%, and average risk-free rates of 2.61 and 2.89. The expense is reflected as Warrants - extension of expiration dates in the Company’s statements of operations.

As of September 30, 2018, the Company had an aggregate of 2,521,348 outstanding warrants to purchase shares of its common stock with a weighted average exercise price of $0.43, weighted average remaining life of 0.5 years and aggregate intrinsic value of $3,461,453, based upon a stock valuation of $1.80 per share. The intrinsic value is calculated as the difference between the market value of the underlying common stock and the exercise price of the warrants.

Stock Options

A summary of the Company’s stock option activity is as follows:

	Shares
December 31, 2017		2,125,000
Granted		600,000
Forfeitures		-
Exercised		-
September 30, 2018, outstanding		2,725,000
September 30, 2018, exercisable		2,400,000

On September 30, 2017, the Company entered into a consulting agreement pursuant to which the Company granted a total of 1,250,000 common stock options. 650,000 of the options with a fair value of $486,070 vested immediately, and the remaining 600,000 options vested ratably over twelve months on a quarterly basis with compensation cost measured as the fair value at the end of each reporting period. The options are non-qualified, have an exercise price of $1.00 per share, and will expire 5 years from the grant date. As of December 31, 2017, the Company had recognized compensation cost of $658,383 relating to the vesting of 800,000 options. During the nine months ended September 30, 2018, the Company recognized stock compensation costs of $394,239 related to the vesting of 450,000 options based upon a graded vesting schedule. As of September 30, 2018, the 1,250,000 options were fully vested and exercisable.

On December 30, 2017, the Company entered into a consulting agreement pursuant to which the Company granted a total of 750,000 common stock options. 250,000 of the options with a fair value of $312,275 vested immediately, and the remaining 500,000 options vested ratably over six months on a quarterly basis with compensation cost measured as the fair value at the end of each reporting period, using a Black Scholes option-pricing model and a graded vesting schedule. The options are non-qualified, have an exercise price of $1.25 per share, and will expire 5 years from the grant date. During the nine months ended September 30, 2018, the Company recognized stock compensation costs of $413,877 related to the vesting of 500,000 options. As of September 30, 2018, the 750,000 options were fully vested and exercisable.

On January 26, 2018, the Company entered into an agreement with a consultant to develop products based on certain intellectual property owned by the Company (see Note 6). In conjunction with the consulting agreement, the Company granted a stock option to the consultant to purchase a total of 500,000 shares of the common stock of the Company. 250,000 shares of the option with a fair value of $287,500 vested immediately, 125,000 shares vest on December 31, 2018 and the remaining 125,000 shares vest on December 31, 2019 provided the consultant is still an active service provider. As of September 30, 2018, the 250,000 options that remain to vest were valued in total at $449,863 based upon a Black-Scholes option-pricing model. Compensation cost is measured as the fair value at the end of each reporting period and cost is amortized based upon a graded vesting schedule. The options are non-qualified, have an exercise price of $1.25 per share, and will expire 5 years from the grant date. During the nine months ended September 30, 2018, the Company recognized stock compensation costs of $529,323 related to the 500,000 options.

On July 25, 2018, the Company entered into an agreement with a consultant to develop products based on certain intellectual property owned by the Company. In conjunction with the consulting agreement, the Company granted a stock option to the consultant to purchase a total of 100,000 shares of the common stock of the Company. 25,000 shares of the option with a fair value of $44,994 vested immediately, while the remaining 75,000 shares vest on completion of certain performance conditions to the reasonable satisfaction of the Company. Specifically, 50,000 shares vest upon completion of design and construction of the AcQviz device, and the remaining 25,000 shares vest upon integration of the AcQviz send/receive functionality with vision testing software platform. As of September 30, 2018, the 75,000 options that remain to vest were valued in total at $134,983 based upon a Black-Scholes option-pricing model. As of September 30, 2018, the completion of all performance conditions was considered probable. Because completion of the performance conditions is considered probable, compensation cost is measured as the fair value at the end of each reporting period and cost is amortized based upon an accelerated attribution model using Management’s estimates of anticipated timing for completion of the conditions. The options are non-qualified, have an exercise price of $1.25 per share, and will expire 5 years from the grant date. During the nine months ended September 30, 2018, the Company recognized stock compensation costs of $67,783 related to the 100,000 options.

As of September 30, 2018, options were valued based upon the Black-Scholes option-pricing model, with a stock price of $1.80, volatility of 121%, and an average risk-free rate of 2.88%.

As of September 30, 2018, the Company had an aggregate of 325,000 remaining unvested options outstanding, with estimated fair value of $584,846. The Company remeasures unvested options for non-employees to fair value at the end of each reporting period. The aggregate intrinsic value of options outstanding as of September 30, 2018 was $1,823,750.

Commitments and Contingencies

The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed financial statements at September 30, 2018 with respect to such matters, including the matter noted below.

On or about July 26, 2017, the Company received a payment demand from a former consultant to the Company alleging that the consultant was owed approximately $192,000 for services rendered. On January 29, 2018, the Company filed a lawsuit against the consultant and its related entities in the United States District Court for the Southern District of California (Case No. 18CV200-W-KSC) seeking declaratory relief regarding advisory fees and ownership interest in the Company. On March 6, 2018, the consultant and its related entities filed counterclaims against the Company, seeking payment for services rendered and seeking declaratory relief regarding ownership interest in the Company. The parties subsequently settled the disputes in their entirety. The Case was dismissed with prejudice on August 29, 2018.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Presentation of Information

As used in this Quarterly Report on Form 10-Q, the terms “we,” “us” “our” and the “Company” mean Guardion Health Sciences, Inc. unless the context requires otherwise. The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this report and our audited financing statements for the year ended December 31, 2017, and the notes thereto, which are set forth in the 2017 Form 10-K. All dollar amounts refer to U.S. dollars unless otherwise indicated.

Overview

Guardion Health Sciences, Inc. (the “Company” or “we”) was formed in December 2009 in California as a limited liability company under the name P4L Health Sciences, LLC, and it subsequently changed its name to Guardion Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name to Guardion Health Sciences, Inc.

The Company is a specialty health sciences company formed to develop, formulate and distribute condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z^® that replenishes and restores the macular protective pigment. A depleted macular protective pigment is a modifiable risk factor for retina-based diseases such as age-related macular degeneration (“AMD”), computer vision syndrome (“CVS”) and diabetic retinopathy. This risk may be modified by taking Lumega-Z to maintain a healthy macular protective pigment. Additional research has also shown a depleted macular protective pigment to be a biomarker for neurodegenerative diseases such as Alzheimer’s disease and dementia.

In September 2017, the Company, through its wholly-owned subsidiary VectorVision Ocular Health, Inc., acquired substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and early treatment diabetic retinopathy study (“ETDRS”) visual acuity testing. VectorVision’s standardization system is designed to provide the practitioner or researcher with the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing for use by eye doctors in clinical trials, for real-world vision evaluation, and industrial vision testing. The acquisition expands the Company’s technical portfolio. The Company believes the acquisition of VectorVision, adding the CSV-1000 and ESV-3000 to its product portfolio, further establishes its position at the forefront of early detection, intervention and monitoring of a range of eye diseases.

The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities.

The Company invented a proprietary technology, embodied in the Company’s medical device, the MapcatSF^®that accurately measures the macular pigment optical density (“MPOD”). On November 8, 2016, the United States Patent and Trademark Office (“USPTO”) issued patent number 9,486,136 for the MapcatSF invention. Using the MapcatSF to measure the MPOD allows one to monitor the increase in the density of the macular protective pigment after taking Lumega-Z. The MapcatSF is a non-mydriatic, non-invasive device that accurately measures the MPOD, the lens optical density and lens equivalent age, thereby creating an evidence-based protocol that is shared with the patient. A non-mydriatic device is one that does not require dilation of the pupil for it to function. The MapcatSF is the first medical device using a patented “single fixation” process and “automatic lens density correction” that produces accurate serialized data.

Lumega-Z is a medical food product that has a patent-pending formula that replenishes and restores the macular protective pigment simultaneously delivering critical and essential nutrients to the eye. Management believes, based on review of products on the market and knowledge of the industry, that Lumega-Z is the first liquid ocular health formula to be classified as a medical food (as defined in Section 5(b) of the “Orphan Drug Act”). However, the FDA has not monitored nor approved Lumega-Z as a medical food. Formulated by Dr. Sheldon Hendler in 2010, modifications were made over a two-year period to improve the taste and method of delivery. The current formulation has been delivered to patients and used in clinics since 2014.

Medical foods are not considered to be either dietary or nutritional supplements. The Company believes that there is an increasing level of acceptance of medical foods as a primary therapy by patients and healthcare providers to treat pain syndromes, sleep and cognitive disorders, obesity, hypertension, and viral infection. In clinical practice, medical foods are being prescribed as both a standalone therapy and as an adjunct therapy to low doses of commonly prescribed drugs. The Company believes that medical foods will continue to grow in importance over the coming years.

By combining the MapcatSF medical device, the newly acquired VectorVision standardized vision testing technology and Lumega-Z medical food, the Company has developed, based on Management’s knowledge of the industry, what it believes to be the only reliable three-pronged, evidence-based protocol for replenishing and restoring the macular protective pigment, increasing overall retinal health and measuring the related improvements in visual function.

Recent Developments

Patents

On July 10, 2018, the USPTO issued US Patent No. 10,016,128, titled Method and Apparatus for Visual Acuity Testing. This patent describes an invention pertaining to automatic light calibration of the display screens used for vision testing. The Company owns this patent, and its VectorVision CSV-1000 and ESV-3000 devices each embody this invention.

On July 17, 2018, the USPTO issued US Patent No. 10,022,045, also titled Method and Apparatus for Visual Acuity Testing, which describes a methodology to continuously calibrate display monitors to automatically hold display luminance constant for vision testing. This second patent also covers a methodology to compensate for other testing factors, such as room illumination and when patients view the vision test through a mirror, which is a common practice in eye doctors’ offices worldwide. The Company also owns this patent, and its VectorVision CSV-1000 and ESV-3000 devices each embody this invention.

These patents serve as the basis for developing follow-on products to the CSV-1000, including the CSV-2000, in which the proprietary standardized contrast sensitivity test patterns can be presented to the patient using a computer monitor as opposed to the current calibrated backlit system. The Company also anticipates commercializing these proprietary methodologies for use with other types of vision tests so that other tests can be properly calibrated to adhere to recognized government vision test lighting standards.

Prior to the issuance of US Patent No. 9,486,136, the Company filed a continuation application, Patent Application 15/346,010, covering new embodiments around the MapcatSF^® device. These new embodiments contain improvements related to the accuracy of intensity measurements made with the device, as well as updated features around photodiode detector calibrations.

Transcranial Doppler Solutions

In August 2018, the Company formed a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”), to further the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases. TDSI will be dedicated to the pursuit of early predictors resulting in, the Company believes valuable therapeutic intervention for practitioners and their patients, and additional revenues stream generated from the testing and sale of Company products to appropriate customers. TDSI will provide a service that makes TCD (as defined below) testing convenient by being in various medical facilities. A Transcranial Doppler ultrasound (“TCD”) has been accepted as a safe, non-invasive, and lower-cost technique that uses a low-frequency transducer probe to assess intracerebral blood flow, within the brain and to the eyes. Studies have shown the ability of TCD to predict stroke risks as well as other potential cardiovascular events. TCD also plays an important role in detecting changes in the ophthalmic artery blood flow, which is important to help evaluate the course of common eye disorders. Blood velocities and intensities can be measured using TCD, which provides an effective way to determine more accurately the state of pathology in early stages of common eye disorders such as glaucoma and other eye diseases that cause visual field defects. Published medical resources indicate a strong relationship between ocular circulation and visual function in patients with glaucoma, diabetes, and macular disease, which are the three leading causes of acquired irreversible blindness throughout the world. A TCD is also highly repeatable, the results of which provide an effective tool for ophthalmologists to treat their patients. Through the monitoring of blood flow in the intracranial vessels, including the ophthalmic artery, the TCD results will in turn provide an evidence-based protocol for Guardion’s medical foods, including the Company’s soon to be released new GlaucoCetin product. The Company is currently setting up the operations of TDSI and hopes to launch its services in upcoming quarters.

GlaucoCetin

The Company has developed a new medical food product, GlaucoCetin, which the Company believes is the first vision-specific medical food designed to support and protect the mitochondrial function of optic nerve cells in patients with glaucoma. GlaucoCetin combines a unique set of ingredients, specifically designed to stop or potentially reverse the underlying cause of optic nerve loss, and ultimately vision loss, in patients with glaucoma. During the glaucomatous disease process, the metabolism for the optic nerve cells start to fail because of dysfunctional mitochondria. Mitochondria is responsible for energy production in these cells. When mitochondria are unable to function, the nerve cells do not have enough energy to operate, and they eventually die, causing vision loss.

The precursor formula of GlaucoCetin (previously known as GlaucoHealth) has been under development for many years and has been proven in clinical studies to reverse mitochondrial damage in glaucoma patients. In an IRB-approved, IND registered study conducted at the New York Eye and Ear Infirmary, GlaucoHealth reversed mitochondrial metabolic dysfunction as determined by the Retinal Metabolic Analyzer, which measures retinal flavoprotein activity, a direct measure of mitochondrial activity.

The Company’s GlaucoCetin product was developed in collaboration with Dr. Robert Ritch, a world-renowned glaucoma specialist from Manhattan Eye and Ear Infirmary and Mount Sinai Medical Center in New York City. Dr. Ritch has also been a member of the Company’s Medical Advisory Board for the past three years. The Company is preparing to launch GlaucoCetin in the fourth quarter of 2018.

Going Concern

Recent Accounting Pronouncements

See Note 2 to the condensed consolidated financial statements for managements’ discussion of recent accounting pronouncements.

Critical Accounting Policies and Estimates

The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). The preparation of its financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates. The Company’s financial statements included herein include all adjustments, consisting of only normal recurring adjustments, necessary to present fairly its financial position, results of operations and cash flows.

The following critical accounting policies affect the more significant judgments and estimates used in the preparation of the Company’s financial statements.

Intangible Assets

In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships.

In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. The Company’s goodwill and other intangible assets are subject to periodic impairment testing.

The Company utilized the services of an independent third-party valuation firm to assist it in identifying intangible assets and in estimating their fair values. The useful lives for its intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-line basis.

Impairment of Long-Lived Assets

Stock-Based Compensation

The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereas the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.

The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. Until the Company has established a trading market for its common stock, estimated volatility is based on the average historical volatilities of comparable public companies in a similar industry. The expected dividend yield is based on the current yield at the grant date. The Company has never declared or paid dividends on its common stock and has no plans to do so for the foreseeable future.

The fair value of common stock was determined based on management’s judgment. In order to assist management in calculating such fair value, the Company retained a third-party valuation firm in determining the value of the Company. The third-party valuation firm’s input was utilized in determining the related per unit or share valuations of the Company’s equity used during 2017. Management used a valuation of $0.88 per share for the six months ended June 30, 2017. Internal valuations are based on various inputs, including valuation reports prepared by third-party valuation firms and are impacted by the dilutive effect of the issuance of common shares as compensation during the periods. There are numerous acceptable ways to estimate company value, including using net tangible assets, a market-based approach, or discounted cash flows. The Company considered alternative methods and concluded that due to the lack of suitably comparable market data, the discounted cash flows method was the most appropriate. A discounted cash flows (i.e. free cash flows to equity) methodology was applied by the third-party valuation firm to assist management in their determination of the $0.88 used during 2017. This methodology used multiple years of balance sheet and income statement projections along with the following primary assumptions:

	Six Months Ended
	June 30, 2017
Discount rate		16	%
Risk free rate		2.48	%
Rate of return		16	%
Sustainable growth rate		5	%
Company survival probability		65	%
Liquidation value	$	0

Due to the availability of historical data from the Company’s recent preferred stock sales, Management used a valuation of $0.75 for accounting purposes during the third quarter of 2017. Management used a valuation of $1.80 for the nine months ended September 30, 2018. Management considered business and market factors affecting the Company during 2018, including capital raising efforts, its proprietary technology, and other factors. Based on this evaluation, management believes that its valuations are appropriate for accounting purposes at September 30, 2018 and 2017, respectively.

Plan of Operations

General Overview

Based on the availability of sufficient funding, the Company intends to increase its commercialization activities and:

further the commercial production of the MapcatSF, starting with the manufacture of at least 15 new units for sale or lease;

expand the Company’s domestic sales and marketing efforts, which include revamping its web site and new promotional materials;

explore sales and marketing opportunities in foreign markets such as Asia and Europe;

increase production of Lumega-Z as is necessary to support the additional sales resulting from the deployment of additional MapcatSF units and increased marketing and promotional activity;

commence certain FDA electrical safety testing of the MapcatSF;

increase focus on intellectual property protection and strategy;

expand the sales and marketing of the VectorVision product line;

	·	develop the TCDS business and operations; and
	·	explore opportunities and channels to enter the expansive market opportunity in China for non-pharmacologic treatments of macular degeneration, glaucoma and diabetic retinopathy.

The FDA and other regulatory bodies require electronic medical devices to comply with IEC 60601 standards. The International Electrical Commission (“IEC”) established technical standards for the safety and effectiveness of medical electrical equipment. Adherence to these standards is required for commercialization of electrical medical equipment. As a medical device powered by electricity, the MapcatSF will need to undergo testing to demonstrate compliance with the IEC 60601 standards. This testing is typically conducted by a Nationally Recognized Testing Laboratory (“NRTL”), which is an independent laboratory recognized by the Occupational Safety and Health Administration (“OSHA”) to test products to the specifications of applicable product safety standards. The Company is in discussions with its contract manufacturer of the MapcatSF to engage an NRTL at the appropriate juncture prior to commercialization of the MapcatSF. The relevant predicate device for the MapcatSF is the MPS II, the applicable Class I product code for the MapcatSF is HJW and the applicable Code of Federal Regulation is 886.1050. The FDA does not require test documents to be submitted to the FDA for a Class I medical device, but that the evidence of such testing be placed in a Design History file and be kept internally at the company or manufacturer and readily available should the FDA or other regulatory bodies request to review the testing documents. While the FDA does not require that a Class I medical device have formal validation, the Company expects to complete applicable IEC 60601-1 testing prior to commercialization because the Company believes in marketing a product that has evidence that it is safe and effective.

Results of Operations

In November 2017, the Company received gross proceeds of $5,000,001 pursuant to the issuance and sale of 4,347,827 shares of common stock. During 2018, the Company has deployed significant efforts and capital resources to focus on development and commercialization activities related to its medical foods, the MapcatSF^® medical device, the VectorVision CSV-1000 and ESV-3000 medical devices, and its newly incorporated subsidiary, Transcranial Doppler Solutions, Inc., which was formed to provide Transcranial Doppler ultrasound services on patients at medical facilities to further the Company’s position at the forefront of early detection, intervention and monitoring of a range of eye diseases.

Substantial resources were devoted in 2018 to the redesign and improvement of the sales and marketing infrastructure. The Company now has dedicated sales personnel located in and responsible for key strategic sales territories in the United States. In conjunction with hiring sales staff, the Company procured equipment and supplies to support the sales staff and incurs travel expenses related to their sales activities. The Company developed an ecommerce platform and has upgraded and added new website access for products and information. The Company’s first targeted marketing campaign for Lumega-Z began in the second quarter of 2018. The Company also dedicated resources to attend certain trade shows to increase the presence of the Company and VectorVision in pertinent industries. Engineering and product development efforts in 2018 have resulted in the first group of commercially available upgraded MapcatSF^® devices. The acquisition and development of intellectual property has enabled both the improvement of existing products and the development of new ones. Specifically, the Company believes that VectorVision’s CSV-2000, an upgraded, digital version of the CSV-1000 device, will contribute to the Company’s revenue beginning in 2019. Additionally, the development of the GlaucoCetin medical food product has led to an expected product launch in the fourth quarter of 2018. Once fully operational, the Company believes that the Transcranial Doppler subsidiary will provide ultrasound services for the monitoring of blood flow in intracranial vessels, which results the Company hopes will in turn provide an evidence-based protocol for the new GlaucoCetin medical food product.

Through September 30, 2018, the Company had limited operations and has primarily been engaged in product development, commercialization, and raising capital. The Company has incurred and will continue to incur significant expenditures for the development of its products and intellectual property, which includes both medical foods and medical diagnostic equipment for the treatment of various eye diseases. The Company had limited revenue during the nine-month periods ended September 30, 2018 and 2017. In the fourth quarter of 2017, the Company began recognizing product revenue from the sale of VectorVision products in addition to sales of its proprietary product, Lumega-Z.

Comparison of Three Months Ended September 30, 2018 and 2017

	Three Months Ended September 30,
	2018			2017			Change
Revenue	$	294,230		$	62,698		$	231,532		369	%
Cost of goods sold		125,406			30,094			95,312		317	%
Gross Profit		168,824			32,604			136,220		418	%
Operating Expenses:
Research and development		4,793			105,561			(100,768	)	(95	)%
Sales and marketing		240,028			116,440			123,588		106	%
General and administrative		1,064,645			1,392,524			(327,879	)	(24	)%
Total Operating Expenses		1,309,466			1,614,525			(305,059	)	(19	)%
Loss from Operations		(1,140,642	)		(1,581,921	)		441,279		(28	)%
Other Expense:
Interest expense		545			2,462			(1,917	)	(78	)%
Warrants - extension of expiration dates		1,007,006			-			1,007,006		-	%
Net Loss	$	(2,148,193	)	$	(1,584,383	)	$	(563,810	)	36	%

Revenue

For the three months ended September 30, 2018, revenue from product sales was $294,230 compared to $62,698 for the three months ended September 30, 2017, resulting in an increase of $231,532 or 369%. The increase reflects both an increased customer base for Lumega-Z as the Company expands into new clinics and sales of VectorVision products. $86,082, or 29% of revenue in the third quarter of 2018 was generated by sales of Lumega-Z products, representing a 37% increase in Lumega-Z sales over the prior period. Management expects continued growth in prescribing clinics and Lumega-Z revenue going forward. As of September 30, 2018, the Company had a sales backlog of approximately $87,000 in VectorVision products that are expected to be delivered during the fourth quarter of 2018.

The following table presents the Company’s revenues disaggregated by product type:

	Three Months Ended September 30,
	2018		2017
Lumega-Z and supplements	$	86,082	$	62,698
VectorVision medical devices and supplies		208,148		-
	$	294,230	$	62,698

Cost of Goods Sold

For the three months ended September 30, 2018, cost of goods sold was $125,406 compared to $30,094 for the three months ended September 30, 2017, resulting in an increase of $95,312 or 317%. The increase reflects the additional sales recorded in 2018.

Gross Profit

For the three months ended September 30, 2018, gross profit was $168,824 compared to $32,604 for the three months ended September 30, 2017, resulting in an increase of $136,220 or 418%. The increase is primarily due to the sales of VectorVision products, which did not occur in the prior period.

Research and Development

For the three months ended September 30, 2018, research and development costs were $4,793 compared to $105,561 for the three months ended September 30, 2017, resulting in a decrease of $100,768 or 95%. The decrease was due to development costs associated with the Company’s MapcatSF^® medical device that were incurred in the prior period.

Sales and Marketing

For the three months ended September 30, 2018, sales and marketing expenses were $240,028 compared to $116,440 for the three months ended September 30, 2017. The increase in sales and marketing expenses of $123,588 or 106% compared to the prior period was primarily due to increases for amortization expense and costs associated with trade shows.

General and Administrative

For the three months ended September 30, 2018, general and administrative expenses were $1,064,645 compared to $1,392,524 for the three months ended September 30, 2017. The decrease of $327,879 or 24% compared to the prior period was primarily due to a decrease in stock compensation expense during the current period. Legal and travel costs also decreased during the current period but were substantially offset by increases in labor and consulting.

Interest Expense

For the three months ended September 30, 2018, interest expense was $545 compared to $2,462 for the three months ended September 30, 2017. The decrease of $1,917, or 78%, was due to the repayment or conversion of promissory notes and convertible debt that had been outstanding during 2017.

Warrants – Extension of Expiration Dates

During September 2018, the Company extended warrants to purchase shares of common stock of the Company that were scheduled to expire at dates ranging from September 30, 2018 through January 25, 2019 held by two stockholders. The Company recognized expense of $1,007,006 relating to the extension of the exercise period of the warrants using a Black-Scholes option-pricing model to estimate fair value.

Net Loss

For the three months ended September 30, 2018, the Company incurred a net loss of $2,148,193, compared to a net loss of $1,584,383 for the three months ended September 30, 2017. The increase in net loss of $563,810 or 36% compared to the prior year period was due to the $1,007,006 non-cash expense related to the extension of warrant expiration dates, partially offset by a $320,000 decrease in stock compensation expense decrease as well as reduced development costs associated with the Company’s MapcatSF^® medical device.

Comparison of Nine Months Ended September 30, 2018 and 2017

	Nine Months Ended September 30,
	2018			2017			Change
Revenue	$	708,047		$	178,610		$	529,437		296	%
Cost of goods sold		292,461			82,420			210,041		255	%
Gross Profit		415,586			96,190			319,396		332	%
Operating Expenses:
Research and development		199,500			131,330			68,170		52	%
Sales and marketing		1,224,491			294,774			929,717		315	%
General and administrative		3,779,325			2,758,331			1,020,994		37	%
Total Operating Expenses		5,203,316			3,184,435			2,018,881		63	%
Loss from Operations		(4,787,730	)		(3,088,245	)		(1,699,485	)	55	%
Other Expense:
Interest expense		2,090			20,817			(18,727	)	(90	)%
Warrants - extension of expiration dates		1,501,397			-			1,501,397		-	%
Net Loss	$	(6,291,217	)	$	(3,109,062	)	$	(3,182,155	)	102	%

Revenue

For the nine months ended September 30, 2018, revenue from product sales was $708,047 compared to $178,610 for the nine months ended September 30, 2017, resulting in an increase of $529,437 or 296%. The increase reflects both an increased customer base for Lumega-Z as the Company expands into new clinics and sales of VectorVision products. $238,213, or 34% of revenue in 2018 was generated by sales of Lumega-Z products, representing a 33% increase in Lumega-Z sales over the prior period. Management expects continued growth in prescribing clinics and Lumega-Z revenue going forward. As of September 30, 2018, the Company had a sales backlog of approximately $87,000 in VectorVision products that are expected to be delivered during the fourth quarter of 2018.

The following table presents the Company’s revenues disaggregated by product type:

	Nine Months Ended September 30,
	2018		2017
Lumega-Z and supplements	$	238,213	$	178,610
VectorVision medical devices and supplies		469,834		-
	$	708,047	$	178,610

Cost of Goods Sold

For the nine months ended September 30, 2018, cost of goods sold was $292,461 compared to $82,420 for the nine months ended September 30, 2017, resulting in an increase of $210,041 or 255%. The increase reflects the additional sales recorded in 2018.

Gross Profit

For the nine months ended September 30, 2018, gross profit was $415,586 compared to $96,190 for the nine months ended September 30, 2017, resulting in an increase of $319,396 or 332%. The increase is primarily due to the sales of VectorVision products, which did not occur in the prior period.

Research and Development

For the nine months ended September 30, 2018, research and development costs were $199,500 compared to $131,330 for the nine months ended September 30, 2017, resulting in an increase of $68,170 or 52%. The increase was due to engineering development costs associated with the Company’s MapcatSF^® medical device during the first quarter of 2018.

Sales and Marketing

For the nine months ended September 30, 2018, sales and marketing expenses were $1,224,491 compared to $294,774 for the nine months ended September 30, 2017. The increase in sales and marketing expenses of $929,717 or 315% compared to the prior period was primarily due to costs associated with engagement of a third party contract sales organization, increased amortization expense, and increased costs associated with trade shows and marketing.

General and Administrative

For the nine months ended September 30, 2018, general and administrative expenses were $3,779,325 compared to $2,758,331 for the nine months ended September 30, 2017. The increase of $1,020,994 or 37% compared to the prior period was primarily due to increased labor costs related to new employees, benefits expenses, and the inclusion of the VectorVision employees in our consolidated financials. Stock compensation and professional services costs also increased during the period.

Interest Expense

For the nine months ended September 30, 2018, interest expense was $2,090 compared to $20,817 for the nine months ended September 30, 2017. The decrease of $18,727, or 90%, was due to the repayment or conversion of promissory notes and convertible debt that had been outstanding during 2017.

Warrants – Extension of Expiration Dates

During April, May and September of 2018, the Company and certain stockholders who held warrants to purchase shares of common stock of the Company that were scheduled to expire at various dates in 2018 and early 2019 extended the termination dates of such warrants. The Company recognized expense of $1,501,397 relating to the extension of the exercise period of the warrants using a Black-Scholes option-pricing model to estimate fair value.

Net Loss

For the nine months ended September 30, 2018, the Company incurred a net loss of $6,291,217, compared to a net loss of $3,109,062 for the nine months ended September 30, 2017. The increase in net loss of $3,182,155 or 102% compared to the prior year period was due to the non-cash expenses related to stock compensation, amortization expense, and to the extension of warrant expiration dates, as well as to the increased costs associated with the sales team, professional services, marketing and promotional activities, trade show visibility, and the internal labor force. Expenses were offset in part by increased revenue and gross profit.

Liquidity and Capital Resources

Since its formation in 2009, the Company has devoted substantial effort and capital resources to the development and commercialization activities related to its lead product Lumega-Z and its MapcatSF medical device. As a result of these and other activities, the Company utilized cash in operating activities of $3,287,940 during the nine months ended September 30, 2018. The Company had positive working capital of $1,140,233 at September 30, 2018 due primarily to the sale of its common stock in November 2017. As of September 30, 2018, the Company had cash in the amount of $1,101,790 and no available borrowings. The Company’s financing has historically come from the issuance of convertible notes, promissory notes and from the sale of common and preferred stock and exercise of warrants.

The financial statements have been prepared assuming the Company will continue as a going concern. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.

The Company will continue to incur significant expenses for continued commercialization activities related to Lumega-Z, the MapcatSF^® medical device, and VectorVision products. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new complementary products or product lines. The Company is continuing attempts to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

Sources and Uses of Cash

The following table sets forth the Company’s major sources and uses of cash for each of the following periods:

	Nine Months Ended September 30,
	2018			2017
Net cash used in operating activities	$	(3,287,940	)	$	(1,914,745	)
Net cash used in investing activities		(278,311	)		(20,308	)
Net cash (used in) provided by financing activities		(67,189	)		3,142,288
Net (decrease) increase in cash	$	(3,633,440	)	$	1,207,235

Operating Activities

Net cash used in operating activities was $3,287,940 during the nine months ended September 30, 2018, versus $1,914,745 used during the comparable prior year period. The increase in 2018 was due primarily to higher sales, marketing, professional services, and labor costs.

Investing Activities

Net cash used in investing activities was $278,311 for the nine months ended September 30, 2018 and $20,308 for the nine months ended September 30, 2017. In January 2018, we acquired the rights to a trademark portfolio for $50,000. In addition, we purchased a trade show booth in February and have invested in MapCat equipment and internal-use software development.

Financing Activities

Net cash used in financing activities was $67,189 for the nine months ended September 30, 2018 was due to the Company payoff of a $30,535 line of credit balance that had been assumed from the VectorVision transaction as well as payment of 38,114 due to related parties. Financing activities for the comparable prior year period provided proceeds of $100,000 from the issuance of short-term loans, offset by payments of principal and interest on loans of $124,000, $3,105,000 in proceeds from the issuance of Series B Preferred Stock, and an increase of $61,288 in amounts due to related parties.

Off-Balance Sheet Arrangements

At September 30, 2018 and December 31, 2017, we did not have any transactions, obligations or relationships that could be considered off-balance sheet arrangements.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not applicable.

ITEM 4. CONTROLS AND PROCEDURES

As of the end of the period covered by this Quarterly Report on Form 10-Q, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon this evaluation, the Chief Executive Officer and Chief Accounting Officer each concluded that the Company’s disclosure controls and procedures are effective to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms, and that such information has been accumulated and communicated to the Company’s management, including the Company’s Chief Executive Officer and Chief Accounting Officer, in a manner that allows timely decisions regarding required disclosure. There have been no changes in the Company’s internal control over financial reporting identified in connection with the evaluation that occurred during the third quarter ended in 2018 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

The Company is periodically the subject of various pending or threatened legal actions and claims arising out of its operations in the normal course of business. Regardless of the outcome, such proceedings or claims can have an adverse impact on the Company because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements at September 30, 2018 with respect to such matters, including the matter noted below.

On or about July 26, 2017, the Company received a payment demand from a former consultant to the Company alleging that the consultant is owed approximately $192,000 for services rendered. The parties settled the disputes in their entirety and the case was dismissed with prejudice on August 29, 2018.

ITEM 1A. RISK FACTORS

Not required for smaller reporting companies.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

Not applicable.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5. OTHER INFORMATION

Not applicable.

ITEM 6. EXHIBITS

A list of exhibits required to be filed as part of this report is set forth in the Index to Exhibits, which is presented elsewhere in this document, and is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 14th day of November, 2018.

Signature	Title	Date

/s/ Michael Favish	CEO, President and	November 14, 2018
Michael Favish	Chairman of the Board (Principal Executive Officer)

/s/ John Townsend	Controller and Chief Accounting Officer	November 14, 2018
John Townsend	(Principal Accounting Officer)

INDEX TO EXHIBITS

Exhibit No.		Description

31.1		Certification of Chief Executive Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Accounting Officer pursuant to Rule 13a – 14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*		Certification of Chief Executive Officer and Chief Accounting Officer pursuant to 18.U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes Oxley Act of 2002
101		The following materials from the Company’s Quarterly Report on Form 10-Q for the period ended September 30, 2018, formatted in XBRL (eXtensible Business Reporting Language), (i) Balance Sheets, (ii) Statements of Income, (iii) Statements of Comprehensive Income, (iv) Statements of Cash Flows, (v) Statement of Stockholders’ Equity and (vi) Notes to Financial Statements

A certification furnished pursuant to Item 601(b)(2) of the Regulation S-K will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the registrant specifically incorporates it by reference.

EX-31.1 2 tv507009_ex31-1.htm EXHIBIT 31.1

Exhibit 31.1

CERTIFICATION

I, Michael Favish, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2018	/s/ Michael Favish
	Michael Favish
	Chief Executive Officer
	(Principal Executive Officer)

EX-31.2 3 tv507009_ex31-2.htm EXHIBIT 31.2

Exhibit 31.2

CERTIFICATION

I, John Townsend, certify that:

I have reviewed this quarterly report on Form 10-Q of Guardion Health Sciences, Inc.;

(a)

(b)

(c)

(d)

(a)

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 14, 2018	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-32.1 4 tv507009_ex32-1.htm EXHIBIT 32.1

Exhibit 32.1

CERTIFICATIONS PURSUANT TO

18 U.S.C. SECTION 1350,

AS ENACTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Guardion Health Sciences, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2018 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of Michael Favish, Chief Executive Officer of the Company, and John Townsend, Controller and Chief Accounting Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as enacted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

November 14, 2018	/s/ Michael Favish
	Michael Favish
	Chief Executive Officer
	(Principal Executive Officer)


November 14, 2018	/s/ John Townsend
	John Townsend
	Controller and Chief Accounting Officer
	(Principal Accounting Officer)

EX-101.INS 5 cik0001642375-20180930.xml XBRL INSTANCE DOCUMENT 0001642375 2018-01-01 2018-09-30 0001642375 2018-09-30 0001642375 2017-12-31 0001642375 2018-07-01 2018-09-30 0001642375 2017-07-01 2017-09-30 0001642375 2017-01-01 2017-09-30 0001642375 2016-12-30 2017-09-29 0001642375 2017-09-29 0001642375 2018-11-09 0001642375 2017-09-30 0001642375 2018-09-21 0001642375 2018-01-31 0001642375 2016-01-01 2016-12-31 0001642375 2018-01-01 2018-01-26 0001642375 2017-12-30 0001642375 2018-01-01 2018-01-31 0001642375 2018-01-26 0001642375 2017-09-01 2017-09-30 0001642375 2018-04-26 0001642375 2018-04-01 2018-04-30 0001642375 2018-05-02 2018-05-31 0001642375 2018-05-31 0001642375 2018-04-30 0001642375 2018-03-29 2018-06-01 0001642375 2016-12-31 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2018-01-01 2018-09-30 0001642375 cik0001642375:LumegazAndSupplementsMember 2018-01-01 2018-09-30 0001642375 cik0001642375:VectorvisionMedicalDevicesAndSuppliesMember 2018-01-01 2018-09-30 0001642375 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001642375 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2018-01-01 2018-09-30 0001642375 cik0001642375:ConversionOfPreferredStockMember 2018-01-01 2018-09-30 0001642375 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0001642375 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0001642375 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0001642375 us-gaap:WarrantMember 2018-01-01 2018-09-30 0001642375 cik0001642375:NonQualifiedStockOptionsMember 2018-01-01 2018-09-30 0001642375 cik0001642375:ConsultantMember cik0001642375:NonQualifiedStockOptionsMember 2018-01-01 2018-09-30 0001642375 us-gaap:LeaseholdImprovementsMember 2018-09-30 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2018-09-30 0001642375 us-gaap:FurnitureAndFixturesMember 2018-09-30 0001642375 us-gaap:ComputerEquipmentMember 2018-09-30 0001642375 us-gaap:OfficeEquipmentMember 2018-09-30 0001642375 cik0001642375:July2018OptionsMember 2018-09-30 0001642375 us-gaap:WarrantMember 2018-09-30 0001642375 cik0001642375:NonQualifiedStockOptionsMember cik0001642375:ConsultantMember 2018-09-30 0001642375 cik0001642375:NonQualifiedStockOptionsMember 2018-09-30 0001642375 us-gaap:LeaseholdImprovementsMember 2017-12-31 0001642375 us-gaap:OtherMachineryAndEquipmentMember 2017-12-31 0001642375 us-gaap:FurnitureAndFixturesMember 2017-12-31 0001642375 us-gaap:ComputerEquipmentMember 2017-12-31 0001642375 us-gaap:OfficeEquipmentMember 2017-12-31 0001642375 us-gaap:PropertyPlantAndEquipmentMember 2017-01-01 2017-09-30 0001642375 cik0001642375:LumegazAndSupplementsMember 2017-01-01 2017-09-30 0001642375 cik0001642375:VectorvisionMedicalDevicesAndSuppliesMember 2017-01-01 2017-09-30 0001642375 us-gaap:WarrantMember 2017-01-01 2017-09-30 0001642375 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-09-30 0001642375 us-gaap:ConvertibleDebtSecuritiesMember 2017-01-01 2017-09-30 0001642375 cik0001642375:ConversionOfPreferredStockMember 2017-01-01 2017-09-30 0001642375 us-gaap:SeriesAPreferredStockMember 2017-01-01 2017-09-30 0001642375 us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-09-30 0001642375 us-gaap:DividendDeclaredMember us-gaap:SeriesBPreferredStockMember 2017-01-01 2017-09-30 0001642375 cik0001642375:LumegazAndSupplementsMember 2017-07-01 2017-09-30 0001642375 cik0001642375:VectorvisionMedicalDevicesAndSuppliesMember 2017-07-01 2017-09-30 0001642375 cik0001642375:LumegazAndSupplementsMember 2018-07-01 2018-09-30 0001642375 cik0001642375:VectorvisionMedicalDevicesAndSuppliesMember 2018-07-01 2018-09-30 0001642375 cik0001642375:VectorvisionIncMember 2016-12-30 2017-09-29 0001642375 cik0001642375:VectorvisionIncMember 2017-09-29 0001642375 us-gaap:IntellectualPropertyMember 2018-01-01 2018-01-26 0001642375 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-01-01 2018-01-26 0001642375 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-01-01 2018-01-26 0001642375 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-01-01 2018-01-26 0001642375 us-gaap:SeriesAPreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:PreferredStockMember 2016-01-01 2016-12-31 0001642375 us-gaap:SeriesAPreferredStockMember 2016-12-31 0001642375 us-gaap:SeriesBPreferredStockMember 2017-04-01 2017-09-30 0001642375 us-gaap:SeriesBPreferredStockMember 2017-09-30 0001642375 us-gaap:CommonStockMember 2017-11-01 2017-11-03 0001642375 us-gaap:PrivatePlacementMember 2017-11-01 2017-11-03 0001642375 us-gaap:PrivatePlacementMember 2017-11-03 0001642375 us-gaap:SeriesBPreferredStockMember 2017-11-03 0001642375 us-gaap:WarrantMember 2018-04-30 0001642375 srt:MinimumMember 2018-05-31 0001642375 srt:MaximumMember 2018-05-31 0001642375 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MinimumMember 2018-05-31 0001642375 us-gaap:MeasurementInputPriceVolatilityMember srt:MinimumMember 2018-05-31 0001642375 us-gaap:MeasurementInputPriceVolatilityMember srt:MaximumMember 2018-05-31 0001642375 us-gaap:MeasurementInputRiskFreeInterestRateMember srt:MaximumMember 2018-05-31 0001642375 cik0001642375:NonQualifiedStockOptionsMember 2017-09-01 2017-09-30 0001642375 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2017-09-01 2017-09-30 0001642375 cik0001642375:NonQualifiedStockOptionsMember cik0001642375:ConsultantMember 2017-12-01 2017-12-30 0001642375 cik0001642375:NonQualifiedStockOptionsMember cik0001642375:ConsultantMember 2017-12-30 0001642375 cik0001642375:July2018OptionsMember 2018-07-01 2018-07-25 0001642375 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2018-07-01 2018-07-25 0001642375 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2018-07-01 2018-07-25 0001642375 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2018-07-01 2018-07-25 0001642375 cik0001642375:July2018OptionsMember 2018-09-01 2018-09-30 0001642375 us-gaap:CommonStockMember 2017-12-31 0001642375 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001642375 us-gaap:RetainedEarningsMember 2017-12-31 0001642375 us-gaap:CommonStockMember 2018-09-30 0001642375 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001642375 us-gaap:RetainedEarningsMember 2018-09-30

1101790

4735230

17011

72771

38736

117164

1538805

5079895

11751

10470

261871

95597

509763

620741

1563520

3885710

7370223

268121

311236

22433

12043

30535

398572

499947

40329

40183

36603982

33696049

-33157173

-26865956

3487138 6870276

3885710

7370223

294230

62698

708047

178610

125406

30094

292461

82420

168824

32604

415586

96190

4793

105561

199500

131330

240028

116440

1224491

294774

1064645

1392524

3779325

2758331

1309466

1614525

5203316

3184435

-1140642

-1581921

-4787730

-3088245

545

2462

2090

20817

1007006

-1007551

-2462

-1503487

-20817

-2148193

-1584383

-6291217

0 249820 0 335337

78616

159798

-2148193

-1912819

-6291217

-3604197

-0.05

-0.07

-0.16

-0.14

40329475

25825907

40324662

25469112

40183475

40183

33696049

-26865956

6870276

1405222

146000 146 1314 0 1460

1501397

-6291217

40329475

40329

36603982

-33157173

3487138

-3109062

223014

47869

14792

1405222

987932

0 196051

1501397

-55761

1831

226537

40741

-77147

-2169

-43117

51626

10390

-63550

-3287940

-1914745

228311

25203

50000

-278311

-20308

100000

124000

30535

3105000

1460

-38114

61288

-67189

3142288

-3633440

1207235

62520

1269755

1965

159798

54000

86082

62698

238213

178610

208148

469834

2521348

2983666

2725000

650000

31250

6981938

5246348

10646854

3050000

0.11

2287500

108722

2396222

4895

50105

93293

551

9458

674400

1563520

198496

565289

-1879947

-3705586

-0.07

-0.13

312981

133354

68287

21376

381268

154730

98357

249447

150603

148754

50300

47476

16464

8193

552227

323917

290356

228320

62036

47869

23854

22044

7242

30940

25825

50000

500000

108018

146133

1170000

1.00

1170000

535154

784888

535149

1.00

0.08

0.60

102029

170075

3105000

1.00

3105000

1.00

0.06

0.75

57769

77045

4347827

10000000

4347827

0.001

1.15

5000001

2983666

0 0

316318

146000 146000

0.01

1460 151006 403085

1.00

2019-05-31 30237 372848 1.00

1.15

2.61

2521348

0.43

P6M 3461453

1.80

2125000

600000

2725000

2400000

1250000

650000

486070

600000

1.00

P5Y

658383

800000

394239

450000

750000

250000

312275

500000

1.25

413877

250000

287500

125000

250000

449863

1.25

P5Y

529323

1.80

1.21

0.0288

325000

584846

1823750

192000

0.001

10000000

0.001

10000000

0.001

90000000

0.001

90000000

40329475

40183475

40329475

40183475

4895

674400

49580

<div style="text-align:left;"><table style="border: none; margin-bottom: 0.001pt; width: 100%; table-layout: fixed; border-spacing: 0px;"><tr><td style="padding: 0pt 0px; vertical-align: top; width: 0.5in;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1.</div></div></div></td><td style="padding: 0pt 0px; vertical-align: top;;width:94%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: justify; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organization and Business Operations</div></div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Organization and Business</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Guardion Health Sciences, Inc. (the “Company”) was formed in December 2009 as a California limited liability company under the name P4L Health Sciences, LLC. On June 30, 2015, the Company converted from a California limited liability company to a Delaware corporation, changing its name from Guardion Health Sciences, LLC to Guardion Health Sciences, Inc.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company is a specialty health sciences company that develops, formulates and distributes condition-specific medical foods with an initial medical food product on the market under the brand name Lumega-Z<div style="vertical-align: super;font-size: smaller;display:inline;">®</div> that replenishes and restores the macular protective pigment.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company also developed a proprietary medical device called the MapcatSF<div style="vertical-align: super;font-size: smaller;display:inline;">® </div>that accurately measures the macular pigment optical density.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On September 29, 2017, the Company completed its acquisition of substantially all of the assets and certain liabilities of VectorVision, Inc., a company that specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS visual acuity testing. VectorVision develops, manufactures and sells equipment and supplies for standardized vision testing.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the Company created a wholly owned subsidiary, Transcranial Doppler Solutions, Inc. (“TDSI”). TDSI will be dedicated to the pursuit of early predictors resulting in, the Company believes, valuable therapeutic intervention for practitioners and their patients, and additional revenue streams generated from the testing and sale of Company products to appropriate customers. The Company is currently setting up the operations of TDSI and hopes to launch its services in upcoming quarters.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Going Concern and Liquidity</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The financial statements have been prepared assuming the Company will continue as a going concern. The Company had a net loss of $6,291,217 and utilized cash in operating activities of $3,287,940 during the nine months ended September 30, 2018. The Company expects to continue to incur net losses and negative operating cash flows in the near-term. As a result, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern within one year of the date that the financial statements are issued.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s independent registered public accounting firm has also included explanatory language in their opinion accompanying the Company’s audited financial statements for the year ended December 31, 2017. The Company’s financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company will continue to incur significant expenses for continued commercialization activities related to Lumega-Z, the MapcatSF<div style="vertical-align: super;font-size: smaller;display:inline;">®</div> medical device, and VectorVision products. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new complementary products or product lines. The Company is continuing to attempt to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="text-align:left;"><table style="border-spacing: 0px; border-collapse: collapse; margin-bottom: 0px; margin-top: 0px; width: 100%; table-layout: fixed;"><tr style="vertical-align: top;"><td style="padding: 0px; width: 0in;"></td><td style="width: 0.5in; padding-left: 0px; padding-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2.</div> </div></div></td><td style="padding-left: 0px; padding-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Summary of Significant Accounting Policies</div> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Basis of Presentation</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The accompanying condensed consolidated financial statements are unaudited. These unaudited interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC. The condensed consolidated balance sheet as of December 31, 2017 included herein was derived from the audited consolidated financial statements as of that date, but does not include all disclosures, including notes, required by GAAP.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to fairly present the Company's financial position and results of operations for the interim periods reflected. Except as noted, all adjustments contained herein are of a normal recurring nature. The results of operations for the interim periods presented are not necessarily indicative of the results of operations to be expected for the full fiscal year ending December 31, 2018.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; text-indent: 0.5in; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of the financial statements in conformity with GAAP requires management to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">These estimates and assumptions include estimates for reserves of uncollectible accounts, inventory obsolescence, depreciable lives of property and equipment, analysis of impairments of recorded long-term tangible and intangible assets, realization of deferred tax assets, accruals for potential liabilities and assumptions made in valuing stock instruments issued for services.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Intangible Assets</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In accordance with Accounting Standard Codification (“ASC”) 350 – Intangibles – Goodwill and Other, the Company determined whether these assets are expected to have indefinite (such as goodwill) or limited useful lives, and for those with limited lives, the Company established an amortization period and method of amortization. Its goodwill and other intangible assets are subject to periodic impairment testing.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company utilized the services of an independent third-party valuation firm to assist in identifying intangible assets and in estimating their fair values. The useful lives for the Company’s intangible assets other than goodwill were estimated based on Management’s consideration of various factors, including assumptions that market participants might use about sales expectations as well as potential effects of obsolescence, competition, technological progress and the regulatory environment. Because the future pattern in which the economic benefits of these intangible assets may not be reliably determined, amortization expense is generally calculated on a straight-</div>line basis.</div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Amortization expense for the identifiable intangible assets associated with the VectorVision acquisition is approximately $54,000 per quarter and is included with general and administrative expenses in the Company’s Statements of Operations.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Impairment of Long-Lived Assets</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company reviews long-lived assets, including property and equipment, identifiable intangible assets, and goodwill for impairment at each fiscal year end or when events or changes in circumstances indicate the carrying value of these assets may exceed their current fair values. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized for the amount by which the carrying amount of the asset exceeds the fair value of the assets. Assets to be disposed of are separately presented in the balance sheet and reported at the lower of the carrying amount or fair value less costs to sell and are no longer depreciated. The Company has not historically recorded any impairment to its long-lived assets. In the future, if events or market conditions affect the estimated fair value to the extent that a long-lived asset is impaired, the Company will adjust the carrying value of these long-lived assets in the period in which the impairment occurs. As of September 30, 2018 and December 31, 2017, the Company had not deemed any long-lived assets as impaired and was not aware of the existence of any indicators of impairment at such dates.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Segment Information</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company operates and manages its business as one reporting and operating segment, which is the business of developing and commercializing a variety of products that support the detection, intervention and monitoring of a range of eye diseases. The Company’s chief executive officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In September 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09 (ASU No. 2014-09) regarding revenue recognition. The new standard provides authoritative guidance clarifying the principles for recognizing revenue and developing a common revenue standard for U.S. generally accepted accounting principles. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. The ASU became effective January 1, 2018.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Due to the nature of the products sold by the Company, the adoption of the new standard has had no quantitative effect on the financial statements. However, the guidance requires additional disclosures to help readers of financial statements better understand the nature, amount, timing, and uncertainty of revenue that is recognized.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company previously recognized revenue when risk of loss transferred to its customers and collection of the receivable was reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase, although for all periods presented, returns have been insignificant.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the new guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company’s revenues disaggregated by product type:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.1in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lumega-Z and supplements</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86,082</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">238,213</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">VectorVision medical devices and supplies</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">208,148</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">469,834</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">294,230</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">708,047</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Research and Development Costs</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Research and development costs consist primarily of fees paid to consultants and outside service providers and other expenses relating to the acquisition, design, development and testing of the Company’s medical foods and related products. Research and development expenditures, which include stock compensation expense, are expensed as incurred and totaled $199,500 and $131,330 for the nine months ended September 30, 2018 and 2017, respectively.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Stock-Based Compensation</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company periodically issues stock-based compensation to officers, directors, contractors and consultants for services rendered. Such issuances vest and expire according to terms established at the issuance date.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Stock-based payments to officers, directors, consultants, contractors, and employees, which include grants of employee stock options, are recognized in the financial statements based on their fair values. Stock option grants, which are generally time vested, will be measured at the grant date fair value and charged to operations on a straight-line basis over the vesting period. The fair value of stock options is determined utilizing the Black-Scholes option-pricing model, which is affected by several variables, including the risk-free interest rate, the expected dividend yield, the expected life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date and the estimated volatility of the common stock over the term of the equity award.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company accounts for stock option and warrant grants issued and vesting to non-employees in accordance with the authoritative guidance of the FASB whereby the value of the stock compensation is based upon the measurement date as determined at either a) the date at which a performance commitment is reached, or b) at the date at which the necessary performance to earn the equity instruments is complete. Non-employee stock-based compensation charges generally are amortized over the vesting period using a graded vesting basis. In certain circumstances where there are no future performance requirements by the non-employee, grants are immediately vested and the total stock-based compensation charge is recorded in the period of the measurement date.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company recognizes stock compensation expense, on stock purchases at a price less than fair value, and for fully-vested stock issued to consultants and other service providers, for the excess of fair value of the stock over the price paid for the stock. The Company recognizes the fair value of stock-based compensation within its statements of operations with classification depending on the nature of the services rendered. The Company will issue new shares to satisfy stock option exercises.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Net Loss per Share</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s computation of basic and diluted net loss per common share is measured as net loss divided by the weighted average common shares outstanding during the respective periods, excluding unvested restricted common stock, if applicable. Shares of restricted stock are included in the basic weighted average number of common shares outstanding from the time they vest. Potential common shares such as from unexercised warrants, options, and shares of common stock issuable upon conversion of convertible debt and convertible preferred stock outstanding that have an anti-dilutive effect are excluded from the calculation of diluted net loss per share. The Company’s basic and diluted net loss per share is the same for all periods presented because all shares of common stock issuable upon exercise of warrants, options, and conversion of convertible debt and convertible preferred stock outstanding are anti-dilutive as they decrease loss per share.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:center;"><table style="border: none; border-collapse: collapse; margin-bottom: 0in; width: 80%; margin-top: 0in;;margin : 0px auto;;text-align:left;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Warrants</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 14.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,521,348</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 14.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,983,666</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Options</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,725,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">650,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated shares issuable upon conversion of convertible notes payable</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">31,250</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Shares issuable upon conversion of convertible preferred stock</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,981,938</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,246,348</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,646,854</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Recent Accounting Pronouncements</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In February 2016, the FASB issued Accounting Standards Update No. 2016-02 (ASU 2016-02), Leases (Topic 842). ASU 2016-02 requires a lessee to record a right-of-use asset and a corresponding lease liability, initially measured at the present value of the lease payments, on the balance sheet for all leases with terms longer than 12 months, as well as the disclosure of key information about leasing arrangements. ASU 2016-02 requires recognition in the statement of operations of a single lease cost, calculated so that the cost of the lease is allocated over the lease term, generally on a straight-line basis. ASU 2016-02 requires classification of all cash payments within operating activities in the statement of cash flows. Disclosures are required to provide the amount, timing and uncertainty of cash flows arising from leases. A modified retrospective transition approach is required for lessees for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements, with certain practical expedients available. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early application is permitted. The adoption of ASU 2016-02 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In July 2017, the FASB issued Accounting Standards Update No. 2017-11, Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features; (Part II) Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception (“ASU 2017-11”). ASU 2017-11 allows companies to exclude a down round feature when determining whether a financial instrument (or embedded conversion feature) is considered indexed to the entity’s own stock. As a result, financial instruments (or embedded conversion features) with down round features may no longer be required to be accounted for as derivative liabilities. A company will recognize the value of a down round feature only when it is triggered and the strike price has been adjusted downward. For equity-classified freestanding financial instruments, an entity will treat the value of the effect of the down round as a dividend and a reduction of income available to common shareholders in computing basic earnings per share. For convertible instruments with embedded conversion features containing down round provisions, entities will recognize the value of the down round as a beneficial conversion discount to be amortized to earnings. ASU 2017-11 is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The guidance in ASU 2017-11 is to be applied using a full or modified retrospective approach. The adoption of ASU 2017-11 is not currently expected to have any impact on the Company’s financial statement presentation or disclosures.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In June 2018, the FASB issued Accounting Standards Update 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Revenue from Contracts with Customers (Topic 606). ASU 2018-07 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Early adoption is permitted. The Company will adopt the provisions of ASU 2018-07 in the quarter beginning January 1, 2019. The adoption of ASU 2018-07 is not expected to have any impact on the Company’s financial statement presentation or disclosures.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In August 2018, the FASB issued Accounting Standards Update 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement (“ASU 2018-13”). ASU 2018-13 provides guidance on modifying the disclosure requirements on fair value measurements as part of the disclosure framework project. The guidance modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. The guidance will be effective for the Company on January 1, 2020, including interim periods, with early adoption permitted. The adoption of ASU 2018-13 is not expected to have any impact on the Company’s financial statement presentation or disclosures.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s management does not believe that any other recently issued, but not yet effective, authoritative guidance, if currently adopted, would have a material impact on the Company’s financial statement presentation or disclosures.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-style:italic;display:inline;"><div style="font-weight:bold;display:inline;">Revenue Recognition</div></div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company’s revenue is comprised of sales of medical foods and dietary supplements to consumers through a direct sales/credit card process. In addition, the Company sells medical device equipment and supplies to customers both in the U.S. and internationally.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">In September 2014, the Financial Accounting Standards Board issued Accounting Standards Update No. 2014-09 (ASU No. 2014-09) regarding revenue recognition. The new standard provides authoritative guidance clarifying the principles for recognizing revenue and developing a common revenue standard for U.S. generally accepted accounting principles. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods and services to customers in an amount that reflects the consideration to which the entity expects to be entitled in the exchange for those goods or services. The ASU became effective January 1, 2018.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Due to the nature of the products sold by the Company, the adoption of the new standard has had no quantitative effect on the financial statements. However, the guidance requires additional disclosures to help readers of financial statements better understand the nature, amount, timing, and uncertainty of revenue that is recognized.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company previously recognized revenue when risk of loss transferred to its customers and collection of the receivable was reasonably assured, which generally occurs when the product is shipped. A product is not shipped without an order from the customer and credit acceptance procedures performed. The Company allows for returns within 30 days of purchase, although for all periods presented, returns have been insignificant.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Under the new guidance, revenue is recognized when control of promised goods or services is transferred to the Company’s customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. The Company reviews its sales transactions to identify contractual rights, performance obligations, and transaction prices, including the allocation of prices to separate performance obligations, if applicable. Revenue and costs of sales are recognized once products are delivered to the customer’s control and performance obligations are satisfied.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">All products sold by the Company are distinct individual products and consist of medical foods, supplemental formulas, medical devices and related supplies. The products are offered for sale as finished goods only, and there are no performance obligations required post-shipment for customers to derive the expected value from them. Contracts with customers contain no incentives or discounts that could cause revenue to be allocated or adjusted over time.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Control of products sold transfers to customers upon shipment from the Company’s facilities, and the Company’s performance obligations are satisfied at that time. Shipping and handling activities are performed before the customer obtains control of the goods and therefore represent a fulfillment activity rather than a promised service to the customer. Payment for sales of Lumega-Z is generally made by approved credit cards. Payments for medical device sales are generally made by check, credit card, or wire transfer. Historically the Company has not experienced any significant payment delays from customers.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The Company provides a 30-day right of return to its retail Lumega-Z customers. A right of return does not represent a separate performance obligation, but because customers are allowed to return products, the consideration to which the Company expects to be entitled is variable. Upon evaluation of historical Lumega-Z and VectorVision product returns, the Company determined that less than one percent of products is returned, and therefore believes it is probable that such returns will not cause a significant reversal of revenue in the future. Due to the insignificant amount of historical returns as well as the standalone nature of the Company’s products and assessment of performance obligations and transaction pricing for the Company’s sales contracts, the Company does not currently maintain a contract asset or liability balance at this time. The Company assesses its contracts and the reasonableness of its conclusions on a quarterly basis.</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company’s revenues disaggregated by product type:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.1in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lumega-Z and supplements</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86,082</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">238,213</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">VectorVision medical devices and supplies</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">208,148</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">469,834</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">294,230</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">708,047</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table presents the Company’s revenues disaggregated by product type:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:left;"><table style="border: none;border-collapse: collapse;margin-bottom: .001pt;width: 100%;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Three Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Nine Months Ended</div></div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: center; margin-right: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 48.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.1in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Lumega-Z and supplements</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">86,082</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">238,213</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 10.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">VectorVision medical devices and supplies</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">208,148</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">469,834</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 7.2pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">294,230</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">62,698</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">708,047</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">178,610</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:</div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:center;"><table style="border: none; border-collapse: collapse; margin-bottom: 0in; width: 80%; margin-top: 0in;;margin : 0px auto;;text-align:left;"><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="6" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;width: 64.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Warrants</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 14.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,521,348</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 2.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 14.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,983,666</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;width: 1.0%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Options</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,725,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">650,000</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Estimated shares issuable upon conversion of convertible notes payable</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">31,250</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Shares issuable upon conversion of convertible preferred stock</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">-</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #ffffff;border-bottom: solid #000000 1.0pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">6,981,938</div></div></td><td style="background: #ffffff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 1.0pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 9.0pt;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-indent: -0.13in; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">5,246,348</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: #cceeff;border-bottom: double #000000 2.5pt;border-left-style: none;border-right-style: none;border-top-style: none;padding-bottom: 0pt;padding-left: 0;padding-right: 0;padding-top: 0pt;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">10,646,854</div></div></td><td style="background: #cceeff;border-bottom: none;border-left: none;border-right: none;border-top: none;padding-bottom: 2.5pt;padding-left: 0;padding-right: 0;padding-top: 0;vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed:<table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:center;"><table style="border: none; margin-bottom: 0in; width: 70%; border-spacing: 0px; margin-top: 0in;;margin : 0px auto;;text-align:left;"><tr><td style="padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Fair Values</div></div></div></td><td style="padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 80%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Common stock consideration</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 2%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 16%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">2,287,500</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Liabilities assumed</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">108,722</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 0px 9pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total purchase consideration</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2,396,222</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Cash</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(4,895</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Accounts receivable</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(50,105</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Inventory</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(93,293</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Prepaid assets</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(551</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(9,458</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Intangible assets</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(674,400</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Goodwill</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 2.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">1,563,520</div></div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 1.25pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

With respect to the 3,050,000 shares of common stock, 250,000 shares are held back by the Company through November 28, 2019 as security for VectorVision’s indemnification obligations to the Company and the remaining 2,800,000 shares were issued to VectorVision at the closing of the transaction. Per the VectorVision Agreement, the 2,800,000 shares were subsequently distributed to the two VectorVision shareholders in proportion to their shareholdings in VectorVision.

<div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Property and equipment consisted of the following: </div></div><div style="font-family: "times new roman", serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-align: justify; margin-right: 0px; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="text-align:center;"><table style="border: none; margin-bottom: 0in; width: 80%; border-spacing: 0px; margin-top: 0in;;margin : 0px auto;;text-align:left;"><tr><td style="padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">September 30,</div></div></div></td><td style="padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">December 31,</div></div></div></td><td style="padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2018</div></div></div></td><td style="padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td style="padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td><td colspan="2" style="padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: center; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2017</div></div></div></td><td style="padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="white-space: pre-line; font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;"> </div></div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 50%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Leasehold improvements</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 2%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 18%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">98,357</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 2%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 18%;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">98,357</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; width: 1%;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Testing equipment</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">249,447</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">150,603</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Furniture and fixtures</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">148,754</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">50,300</div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Computer equipment</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">47,476</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">16,464</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Office equipment</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,193</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">8,193</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">552,227</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">323,917</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr><tr><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Less accumulated depreciation and amortization</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(290,356</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 1pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(204, 238, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 1pt solid rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">(228,320</div></div></td><td style="background: rgb(204, 238, 255); padding: 0px 0px 0.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">)</div></div></td></tr><tr><td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">261,871</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 1.25pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 2.5pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">$</div></div></td><td style="background: rgb(255, 255, 255); padding: 0pt 0px 0in; vertical-align: bottom; border-bottom: 2.5pt double rgb(0, 0, 0);"><div style="font-family: "times new roman", serif; font-size: 10pt; text-align: right; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">95,597</div></div></td><td style="background: rgb(255, 255, 255); padding: 0px 0px 1.25pt; vertical-align: bottom;"><div style="font-family: "times new roman", serif; font-size: 10pt; margin-right: 0px; margin-bottom: 0px; margin-top: 0px; line-height: normal; background: none;"><div style="font-family: "times new roman", serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div></td></tr></table><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div><div style="clear:both;"></div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>

100000

25000

44994

75000

134983

1.25

P5Y

67783

100000

6981938

75000

50000

25000

500000

750000

500000

1250000

0 1563520 10-Q false 2018-09-30 2018 Q3 Guardion Health Sciences, Inc. 0001642375 --12-31 Non-accelerated Filer 40329475 true false true 600000

0.25

1.80

118

119

2.89

iso4217:USD xbrli:shares xbrli:pure iso4217:USD xbrli:shares

EX-101.SCH 6 cik0001642375-20180930.xsd XBRL TAXONOMY EXTENSION SCHEMA 1001 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 1002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:definitionLink link:calculationLink 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:definitionLink link:calculationLink 1004 - Statement - Condensed Consolidated Statements of Operations link:presentationLink link:definitionLink link:calculationLink 1005 - Statement - Condensed Consolidated Statement of Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1006 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:definitionLink link:calculationLink 1007 - Disclosure - Organization and Business Operations link:presentationLink link:definitionLink link:calculationLink 1008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 1009 - Disclosure - VectorVision Acquisition link:presentationLink link:definitionLink link:calculationLink 1010 - Disclosure - Inventories link:presentationLink link:definitionLink link:calculationLink 1011 - Disclosure - Property and Equipment, net link:presentationLink link:definitionLink link:calculationLink 1012 - Disclosure - Acquisition of Intellectual Property link:presentationLink link:definitionLink link:calculationLink 1013 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 1014 - Disclosure - Stockholders' Equity link:presentationLink link:definitionLink link:calculationLink 1015 - Disclosure - Commitments and Contingencies link:presentationLink link:definitionLink link:calculationLink 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 1018 - Disclosure - VectorVision Acquisition (Tables) link:presentationLink link:definitionLink link:calculationLink 1019 - Disclosure - Inventories (Tables) link:presentationLink link:definitionLink link:calculationLink 1020 - Disclosure - Property and Equipment, net (Tables) link:presentationLink link:definitionLink link:calculationLink 1021 - Disclosure - Stockholders' Equity (Tables) link:presentationLink link:definitionLink link:calculationLink 1022 - Disclosure - Organization and Business Operations (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1023 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:definitionLink link:calculationLink 1024 - Disclosure - Summary of Significant Accounting Policies (Details 1) link:presentationLink link:definitionLink link:calculationLink 1025 - Disclosure - Summary of Significant Accounting Policies (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1026 - Disclosure - VectorVision Acquisition (Details) link:presentationLink link:definitionLink link:calculationLink 1027 - Disclosure - VectorVision Acquisition (Details 1) link:presentationLink link:definitionLink link:calculationLink 1028 - Disclosure - VectorVision Acquisition (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1029 - Disclosure - Inventories (Details) link:presentationLink link:definitionLink link:calculationLink 1030 - Disclosure - Property and Equipment, net (Details) link:presentationLink link:definitionLink link:calculationLink 1031 - Disclosure - Property and Equipment, net (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1032 - Disclosure - Acquisition of Intellectual Property (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1033 - Disclosure - Related Party Transactions (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1034 - Disclosure - Stockholders' Equity (Details) link:presentationLink link:definitionLink link:calculationLink 1035 - Disclosure - Stockholders' Equity (Details 1) link:presentationLink link:definitionLink link:calculationLink 1036 - Disclosure - Stockholders' Equity (Details Textual) link:presentationLink link:definitionLink link:calculationLink 1037 - Disclosure - Commitments and Contingencies (Details Textual) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 cik0001642375-20180930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 cik0001642375-20180930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 cik0001642375-20180930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information [Abstract] Document And Entity Information [Abstract] Document Information [Table] Class of Stock [Axis] Class of Stock [Domain] Document Information [Line Items] Document Type Amendment Flag Document Period End Date Document Fiscal Year Focus Document Fiscal Period Focus Entity Registrant Name Entity Central Index Key Current Fiscal Year End Date Entity Filer Category Entity Common Stock, Shares Outstanding Entity Emerging Growth Company Entity Ex Transition Period Entity Small Business Statement of Financial Position [Abstract] Statement [Table] Statement [Line Items] Assets [Abstract] Assets Assets, Current [Abstract] Current assets Cash and Cash Equivalents, at Carrying Value Cash Balance at beginning of period Balance at end of period Accounts Receivable, Net, Current Accounts receivable Inventory, Net Inventories Inventory, Net Prepaid Expense, Current Prepaid expenses Assets, Current Total current assets Prepaid Expense and Other Assets, Noncurrent Deposits Property, Plant and Equipment, Net Property and equipment, net Property, Plant and Equipment, Net, Total Intangible Assets, Net (Excluding Goodwill) Intangible assets, net Goodwill Assets Total assets Liabilities and Equity [Abstract] Liabilities and Stockholders' Equity Liabilities, Current [Abstract] Current liabilities Accounts Payable and Accrued Liabilities, Current Accounts payable and accrued liabilities Deferred Rent Credit, Current Accrued expenses and deferred rent Line of Credit, Current Line of credit Due to Officers or Stockholders, Current Due to related parties Liabilities, Current Total current liabilities Commitments and Contingencies Commitments and contingencies Members' and stockholders'equityDeficit [Abstract] Stockholders' Equity Preferred Stock, Value, Issued Preferred stock, $0.001 par value; 10,000,000 shares authorized Common Stock, Value, Issued Common stock, $0.001 par value; 90,000,000 shares authorized; 40,329,475 and 40,183,475 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively Additional Paid in Capital, Common Stock Additional paid-in capital Retained Earnings (Accumulated Deficit), Total Accumulated deficit Members And Stockholders Equity Deficit Total stockholders' equity Total of all stockholders' and members equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Liabilities and Equity, Total Total liabilities and stockholders' equity Short-term Debt, Type [Axis] Short-term Debt, Type [Domain] Preferred Stock, Par or Stated Value Per Share Preferred Stock, Shares Authorized Common Stock, Par or Stated Value Per Share Common Stock, Shares Authorized Common Stock, Shares, Issued Common Stock, Shares, Outstanding Income Statement [Abstract] Cost of Goods and Services Sold, Total Cost of goods sold Gross Profit Gross profit Operating Expenses [Abstract] Operating expenses Research and Development Expense Research and development Selling and Marketing Expense, Total Sales and marketing General and Administrative Expense, Total General and administrative Operating Expenses, Total Total operating expenses Operating Income (Loss), Total Loss from operations Nonoperating Income (Expense) [Abstract] Other expenses: Interest Expense Interest expense Nonoperating Income (Expense) Total other expenses Fair Value Adjustment of Warrants Warrants - extension of expiration dates Warrants – extension of expiration dates Net Income (Loss) Attributable to Parent, Total Net loss Net loss Preferred Stock Dividends and Other Adjustments [Abstract] Adjustments related to Series A and Series B convertible preferred stock: Preferred Stock Accretion of deemed dividend Accretion of deemed dividend Amount of decrease to net income for accretion of deemed. Preferred Stock Dividends, Income Statement Impact Dividend declared Net Income (Loss) Available to Common Stockholders, Basic Net loss attributable to common shareholders Earnings Per Share, Basic and Diluted, Total Net loss per common share – basic and diluted Weighted Average Number of Shares Outstanding, Basic and Diluted Weighted average common shares outstanding – basic and diluted Revenues Revenue Statement of Stockholders' Equity [Abstract] Equity Components [Axis] Equity Component [Domain] Common Stock [Member] Additional Paid-in Capital [Member] Additional Paid-In Capital [Member] Retained Earnings [Member] Accumulated Deficit [Member] Debt Instrument [Axis] Debt Instrument, Name [Domain] Related Party Transaction [Axis] Related Party Transaction [Domain] Members' Equity, Total Beginning Balance Ending Balance Common Unit, Outstanding Beginning Balance (in shares) Ending Balance (in shares) Adjustments to Additional Paid in Capital, Share-based Compensation, Stock Options, Requisite Service Period Recognition Fair value of vested stock options Stock Issued During Period, Value Warrants Exercised Issuance of common stock – warrant exercises Equity impact of the value of new stock issued during the period as a result of warrants exercised. Stock Issued During Period, Shares Warrants Exercised Issuance of common stock – warrant exercises (in shares) Number of new stock issued during the period as a result of warrants exercised. Adjustments to Additional Paid in Capital, Warrant Issued Warrants - extension of expiration dates Statement of Cash Flows [Abstract] Extinguishment of Debt [Axis] Extinguishment of Debt, Type [Domain] Net Cash Provided by (Used in) Operating Activities [Abstract] Operating Activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Adjustments to reconcile net loss to net cash used in operating activities: Depreciation, Depletion and Amortization, Nonproduction, Total Depreciation and amortization Interest Expense, Debt Accrued interest expense included in notes payable Share-based Compensation Stock-based compensation Share-based Compensation, Related Party Transactions Stock-based compensation – related parties The aggregate amount of noncash, equity-based compensation expenses from a related party transactions. Increase (Decrease) in Operating Capital [Abstract] Changes in operating assets and liabilities: Increase (Decrease) in Operating Assets [Abstract] (Increase) decrease in - Increase (Decrease) in Accounts Receivable Accounts receivable Increase (Decrease) in Inventories, Total Inventories Increase (Decrease) in Prepaid Expense and Other Assets, Total Deposits and prepaid expenses Increase (Decrease) in Operating Liabilities [Abstract] Increase (decrease) in - Increase (Decrease) in Accounts Payable and Accrued Liabilities, Total Accounts payable and accrued expenses Increase (Decrease) in Deferred Liabilities, Total Accrued and deferred rent costs Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Net Cash Provided by (Used in) Investing Activities [Abstract] Investing Activities Payments to Acquire Property, Plant, and Equipment, Total Purchase of property and equipment Payments to Acquire Intangible Assets Purchase of intellectual property Net Cash Provided by (Used in) Investing Activities Net cash used in investing activities Cash Acquired from Acquisition Cash assumed upon acquisition Net Cash Provided by (Used in) Financing Activities [Abstract] Financing Activities Proceeds from Notes Payable Proceeds from issuance of promissory notes Repayments of Debt Payments on promissory notes Repayments of Lines of Credit Payments on line of credit Proceeds from Issuance of Preferred Stock and Preference Stock Proceeds from issuance of preferred stock Proceeds from Warrant Exercises Proceeds from exercise of warrants Proceeds from (Repayments of) Related Party Debt (Decrease) increase in due to related parties Net Cash Provided by (Used in) Financing Activities Net cash (used in) provided by financing activities Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] Cash: Cash and Cash Equivalents, Period Increase (Decrease), Total Net (decrease) increase Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Interest Paid, Excluding Capitalized Interest, Operating Activities Cash paid for - Interest Income Taxes Paid Cash paid for - Income taxes Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Non-cash financing activities: Stock Issued Issuance of common stock dividends on preferred stock Noncash or Part Noncash Acquisition, Value of Assets Acquired [Abstract] Fair value of common shares issued for acquisition allocated to: Noncash or Part Noncash Acquisition, Intangible Assets Acquired Intangible assets Noncash or Part Noncash Acquisition, Other Assets Acquired Other assets Non cash Or Part Non cash Acquisition Good will Acquired Goodwill The amount of goodwill that an Entity acquires in a noncash (or part noncash) acquisition Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] Business Combinations [Abstract] Business Combination Disclosure [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Text Block] Property, Plant and Equipment [Abstract] Property, Plant and Equipment Disclosure [Text Block] Goodwill and Intangible Assets Disclosure [Abstract] Intangible Assets Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Disclosure [Text Block] Stockholders' Equity Note [Abstract] Stockholders' Equity Note Disclosure [Text Block] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Text Block] Basis Of Presentation And Use Of Estimates Policy [Policy Text Block] Disclosure of accounting policy for basis of presentation and use of estimates. Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Segment Reporting, Policy [Policy Text Block] Revenue Recognition, Policy [Policy Text Block] Research and Development Expense, Policy [Policy Text Block] Compensation Related Costs, Policy [Policy Text Block] Earnings Per Share, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] Disaggregation of Revenue [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Business Acquisition, Pro Forma Information [Table Text Block] Schedule of Inventory, Current [Table Text Block] Property, Plant and Equipment [Table Text Block] Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Share-based Compensation, Stock Options, Activity [Table Text Block] Subsequent Event Type [Axis] Subsequent Event Type [Domain] Products and Services [Axis] Products and Services [Domain] Lumega-Z and supplements [Member] VectorVision medical devices and supplies [Member] Warrant [Member] Warrants [Member] Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Domain] Employee Stock Option [Member] Investment Type [Axis] Investments [Domain] Convertible Debt Securities [Member] Conversion of Preferred Stock [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets, Major Class Name [Domain] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Range [Axis] EX-101.PRE 10 cik0001642375-20180930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 11 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2018	Nov. 09, 2018
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q3
Entity Registrant Name	Guardion Health Sciences, Inc.
Entity Central Index Key	0001642375
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Common Stock, Shares Outstanding		40,329,475
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Small Business	true

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash	$ 1,101,790	$ 4,735,230
Accounts receivable	17,011	72,771
Inventories	381,268	154,730
Prepaid expenses	38,736	117,164
Total current assets	1,538,805	5,079,895
Deposits	11,751	10,470
Property and equipment, net	261,871	95,597
Intangible assets, net	509,763	620,741
Goodwill	1,563,520	1,563,520
Total assets	3,885,710	7,370,223
Current liabilities
Accounts payable and accrued liabilities	268,121	311,236
Accrued expenses and deferred rent	22,433	12,043
Line of credit	0	30,535
Due to related parties	108,018	146,133
Total current liabilities	398,572	499,947
Commitments and contingencies
Stockholders' Equity
Preferred stock, $0.001 par value; 10,000,000 shares authorized	0	0
Common stock, $0.001 par value; 90,000,000 shares authorized; 40,329,475 and 40,183,475 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	40,329	40,183
Additional paid-in capital	36,603,982	33,696,049
Accumulated deficit	(33,157,173)	(26,865,956)
Total stockholders' equity	3,487,138	6,870,276
Total liabilities and stockholders' equity	$ 3,885,710	$ 7,370,223

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	90,000,000	90,000,000
Common Stock, Shares, Issued	40,329,475	40,183,475
Common Stock, Shares, Outstanding	40,329,475	40,183,475

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenue	$ 294,230	$ 62,698	$ 708,047	$ 178,610
Cost of goods sold	125,406	30,094	292,461	82,420
Gross profit	168,824	32,604	415,586	96,190
Operating expenses
Research and development	4,793	105,561	199,500	131,330
Sales and marketing	240,028	116,440	1,224,491	294,774
General and administrative	1,064,645	1,392,524	3,779,325	2,758,331
Total operating expenses	1,309,466	1,614,525	5,203,316	3,184,435
Loss from operations	(1,140,642)	(1,581,921)	(4,787,730)	(3,088,245)
Other expenses:
Interest expense	545	2,462	2,090	20,817
Warrants - extension of expiration dates	1,007,006	0	1,501,397	0
Total other expenses	1,007,551	2,462	1,503,487	20,817
Net loss	(2,148,193)	(1,584,383)	(6,291,217)	(3,109,062)
Adjustments related to Series A and Series B convertible preferred stock:
Accretion of deemed dividend	0	(249,820)	0	(335,337)
Dividend declared	0	(78,616)	0	(159,798)
Net loss attributable to common shareholders	$ (2,148,193)	$ (1,912,819)	$ (6,291,217)	$ (3,604,197)
Net loss per common share – basic and diluted	$ (0.05)	$ (0.07)	$ (0.16)	$ (0.14)
Weighted average common shares outstanding – basic and diluted	40,329,475	25,825,907	40,324,662	25,469,112

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders' Equity - 9 months ended Sep. 30, 2018 - USD ($)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2017	$ 6,870,276	$ 40,183	$ 33,696,049	$ (26,865,956)
Beginning Balance (in shares) at Dec. 31, 2017		40,183,475
Fair value of vested stock options	1,405,222	$ 0	1,405,222	0
Issuance of common stock – warrant exercises	1,460	$ 146	1,314	0
Issuance of common stock – warrant exercises (in shares)		146,000
Warrants - extension of expiration dates	1,501,397	$ 0	1,501,397	0
Net loss	(6,291,217)	0	0	(6,291,217)
Ending Balance at Sep. 30, 2018	$ 3,487,138	$ 40,329	$ 36,603,982	$ (33,157,173)
Ending Balance (in shares) at Sep. 30, 2018		40,329,475

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Operating Activities
Net loss	$ (6,291,217)	$ (3,109,062)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	223,014	47,869
Accrued interest expense included in notes payable	0	14,792
Stock-based compensation	1,405,222	987,932
Stock-based compensation – related parties	0	196,051
Warrants – extension of expiration dates	1,501,397	0
(Increase) decrease in -
Accounts receivable	55,761	(1,831)
Inventories	(226,537)	(40,741)
Deposits and prepaid expenses	77,147	2,169
Increase (decrease) in -
Accounts payable and accrued expenses	(43,117)	51,626
Accrued and deferred rent costs	10,390	(63,550)
Net cash used in operating activities	(3,287,940)	(1,914,745)
Investing Activities
Purchase of property and equipment	(228,311)	(25,203)
Purchase of intellectual property	(50,000)	0
Cash assumed upon acquisition	0	4,895
Net cash used in investing activities	(278,311)	(20,308)
Financing Activities
Proceeds from issuance of promissory notes	0	100,000
Payments on promissory notes	0	(124,000)
Payments on line of credit	(30,535)	0
Proceeds from issuance of preferred stock	0	3,105,000
Proceeds from exercise of warrants	1,460	0
(Decrease) increase in due to related parties	(38,114)	61,288
Net cash (used in) provided by financing activities	(67,189)	3,142,288
Cash:
Net (decrease) increase	(3,633,440)	1,207,235
Balance at beginning of period	4,735,230	62,520
Balance at end of period	1,101,790	1,269,755
Supplemental disclosure of cash flow information:
Cash paid for - Interest	0	1,965
Cash paid for - Income taxes	0	0
Non-cash financing activities:
Issuance of common stock dividends on preferred stock	0	159,798
Fair value of common shares issued for acquisition allocated to:
Intangible assets	0	674,400
Goodwill	0	1,563,520
Other assets	$ 0	$ 49,580

XML 17 R7.htm IDEA: XBRL DOCUMENT

Organization and Business Operations

9 Months Ended

Sep. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

1.	Organization and Business Operations

Organization and Business

that replenishes and restores the macular protective pigment.

The Company also developed a proprietary medical device called the MapcatSF

that accurately measures the macular pigment optical density.

The Company has had limited operations to date and has been primarily engaged in research and development, product commercialization and capital raising activities.

Going Concern and Liquidity

The Company will continue to incur significant expenses for continued commercialization activities related to Lumega-Z, the MapcatSF

medical device, and VectorVision products. Development and commercialization of medical foods and medical devices involves a lengthy and complex process. Additionally, the Company’s long-term viability and growth may depend upon the successful development and commercialization of new complementary products or product lines. The Company is continuing to attempt to raise additional debt and/or equity capital to fund future operations, but there can be no assurances that the Company will be able to secure such additional financing in the amounts necessary to fully fund its operating requirements on acceptable terms or at all. If the Company is unable to access sufficient capital resources on a timely basis, the Company may be forced to reduce or discontinue its technology and product development programs and curtail or cease operations.

XML 18 R8.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

Summary of Significant Accounting Policies

Basis of Presentation

Use of Estimates

Intangible Assets

In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships.

line basis.

Impairment of Long-Lived Assets

Segment Information

Revenue Recognition

The following table presents the Company’s revenues disaggregated by product type:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Lumega-Z and supplements	$	86,082	$	62,698	$	238,213	$	178,610
VectorVision medical devices and supplies		208,148		-		469,834		-
	$	294,230	$	62,698	$	708,047	$	178,610

Research and Development Costs

Stock-Based Compensation

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Warrants		2,521,348		2,983,666
Options		2,725,000		650,000
Estimated shares issuable upon conversion of convertible notes payable		-		31,250
Shares issuable upon conversion of convertible preferred stock		-		6,981,938
		5,246,348		10,646,854

Recent Accounting Pronouncements

XML 19 R9.htm IDEA: XBRL DOCUMENT

VectorVision Acquisition

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Business Combination Disclosure [Text Block]

VectorVision Acquisition

	Fair Values
Common stock consideration	$	2,287,500
Liabilities assumed		108,722
Total purchase consideration		2,396,222

Cash		(4,895	)
Accounts receivable		(50,105	)
Inventory		(93,293	)
Prepaid assets		(551	)
Property and equipment		(9,458	)
Intangible assets		(674,400	)
Goodwill	$	1,563,520

Goodwill is calculated as the excess of the consideration transferred over the net assets recognized and represents the expected revenue and benefits of the combined company.

	Three Months Ended September 30,			Nine Months Ended September 30,
	2017			2017
Pro forma net revenues	$	198,496		$	565,289
Pro forma net loss attributable to common shareholders	$	(1,879,947	)	$	(3,705,586	)
Pro forma net loss per share	$	(0.07	)	$	(0.13	)

XML 20 R10.htm IDEA: XBRL DOCUMENT

Inventories

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Inventory Disclosure [Text Block]

Inventories

Inventories consisted of the following:

	September 30,		December 31,
	2018		2017
Raw materials	$	312,981	$	133,354
Finished goods		68,287		21,376
	$	381,268	$	154,730

XML 21 R11.htm IDEA: XBRL DOCUMENT

Property and Equipment, net

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment Disclosure [Text Block]

Property and Equipment, net

Property and equipment consisted of the following:

	September 30,			December 31,
	2018			2017
Leasehold improvements	$	98,357		$	98,357
Testing equipment		249,447			150,603
Furniture and fixtures		148,754			50,300
Computer equipment		47,476			16,464
Office equipment		8,193			8,193
		552,227			323,917
Less accumulated depreciation and amortization		(290,356	)		(228,320	)
	$	261,871		$	95,597

XML 22 R12.htm IDEA: XBRL DOCUMENT

Acquisition of Intellectual Property

9 Months Ended

Sep. 30, 2018

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets Disclosure [Text Block]

Acquisition of Intellectual Property

XML 23 R13.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2018

Related Party Transactions

XML 24 R14.htm IDEA: XBRL DOCUMENT

Stockholders' Equity

9 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

Stockholders’ Equity

Preferred Stock

Series A

Series B

Common Stock

Warrants

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2017		2,983,666
Granted		-
Forfeitures		-
Expirations		(316,318	)
Exercised		(146,000	)
September 30, 2018, all exercisable		2,521,348

The Company and five warrant holders extended the term of an aggregate

of 372,848 warrants. These warrants are now scheduled to expire on the earlier of (a) May 31, 2019 or (b) sixty days following the date on which the common stock of the Company becomes listed or approved for listing on a national securities exchange. The exercise price of such warrants remains unchanged at $1.00 per share, but cashless exercise provisions have been eliminated from such warrants.

of $1,501,397 d

uring the nine months ended September 30, 2018 relating to the extension of the exercise periods of the warrants based upon a Black-Scholes option-pricing model using stock prices

of $1.15

and $1.80, volatility of 118% and 119%, and average risk-free rates o

f 2.61

and 2.89. The expense is reflected as Warrants - extension of expiration dates in the Company’s statements of operations

Stock Options

A summary of the Company’s stock option activity is as follows:

	Shares
December 31, 2017		2,125,000
Granted		600,000
Forfeitures		-
Exercised		-
September 30, 2018, outstanding		2,725,000
September 30, 2018, exercisable		2,400,000

As of September 30, 2018, options were valued based upon the Black-Scholes option-pricing model, with a stock price of $1.80, volatility of 121%, and an average risk-free rate of 2.88%.

XML 25 R15.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies

9 Months Ended

Sep. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

Commitments and Contingencies

subsequently

settled the disputes in their entirety. The Case was dismissed with prejudice on August 29, 2018.

XML 26 R16.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Policies)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]

Basis of Presentation

Use of Estimates, Policy [Policy Text Block]

Use of Estimates

Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]

Intangible Assets

In connection with the VectorVision transaction, the Company identified and allocated estimated fair values to intangible assets including goodwill and customer relationships.

line basis.

Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]

Impairment of Long-Lived Assets

Segment Reporting, Policy [Policy Text Block]

Segment Information

Revenue Recognition, Policy [Policy Text Block]

Revenue Recognition

The following table presents the Company’s revenues disaggregated by product type:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Lumega-Z and supplements	$	86,082	$	62,698	$	238,213	$	178,610
VectorVision medical devices and supplies		208,148		-		469,834		-
	$	294,230	$	62,698	$	708,047	$	178,610

Research and Development Expense, Policy [Policy Text Block]

Research and Development Costs

Stock-Based Compensation

Earnings Per Share, Policy [Policy Text Block]

Net Loss per Share

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Warrants		2,521,348		2,983,666
Options		2,725,000		650,000
Estimated shares issuable upon conversion of convertible notes payable		-		31,250
Shares issuable upon conversion of convertible preferred stock		-		6,981,938
		5,246,348		10,646,854

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

XML 27 R17.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2018

Accounting Policies [Abstract]

Disaggregation of Revenue [Table Text Block]

The following table presents the Company’s revenues disaggregated by product type:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2018		2017		2018		2017
Lumega-Z and supplements	$	86,082	$	62,698	$	238,213	$	178,610
VectorVision medical devices and supplies		208,148		-		469,834		-
	$	294,230	$	62,698	$	708,047	$	178,610

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

The following table sets forth the number of shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive:

	September 30,
	2018		2017
Warrants		2,521,348		2,983,666
Options		2,725,000		650,000
Estimated shares issuable upon conversion of convertible notes payable		-		31,250
Shares issuable upon conversion of convertible preferred stock		-		6,981,938
		5,246,348		10,646,854

XML 28 R18.htm IDEA: XBRL DOCUMENT

VectorVision Acquisition (Tables)

9 Months Ended

Sep. 30, 2018

Business Combinations [Abstract]

Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]

The following table summarizes the allocation of preliminary fair values of the purchase consideration to the assets and liabilities assumed:

	Fair Values
Common stock consideration	$	2,287,500
Liabilities assumed		108,722
Total purchase consideration		2,396,222

Cash		(4,895	)
Accounts receivable		(50,105	)
Inventory		(93,293	)
Prepaid assets		(551	)
Property and equipment		(9,458	)
Intangible assets		(674,400	)
Goodwill	$	1,563,520

Business Acquisition, Pro Forma Information [Table Text Block]

	Three Months Ended September 30,			Nine Months Ended September 30,
	2017			2017
Pro forma net revenues	$	198,496		$	565,289
Pro forma net loss attributable to common shareholders	$	(1,879,947	)	$	(3,705,586	)
Pro forma net loss per share	$	(0.07	)	$	(0.13	)

XML 29 R19.htm IDEA: XBRL DOCUMENT

Inventories (Tables)

9 Months Ended

Sep. 30, 2018

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consisted of the following:

	September 30,		December 31,
	2018		2017
Raw materials	$	312,981	$	133,354
Finished goods		68,287		21,376
	$	381,268	$	154,730

XML 30 R20.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Tables)

9 Months Ended

Sep. 30, 2018

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

Property and equipment consisted of the following:

	September 30,			December 31,
	2018			2017
Leasehold improvements	$	98,357		$	98,357
Testing equipment		249,447			150,603
Furniture and fixtures		148,754			50,300
Computer equipment		47,476			16,464
Office equipment		8,193			8,193
		552,227			323,917
Less accumulated depreciation and amortization		(290,356	)		(228,320	)
	$	261,871		$	95,597

XML 31 R21.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2018

Stockholders' Equity Note [Abstract]

Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]

A summary of the Company’s warrant activity is as follows:

	Shares
December 31, 2017		2,983,666
Granted		-
Forfeitures		-
Expirations		(316,318	)
Exercised		(146,000	)
September 30, 2018, all exercisable		2,521,348

Share-based Compensation, Stock Options, Activity [Table Text Block]

A summary of the Company’s stock option activity is as follows:

	Shares
December 31, 2017		2,125,000
Granted		600,000
Forfeitures		-
Exercised		-
September 30, 2018, outstanding		2,725,000
September 30, 2018, exercisable		2,400,000

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

XML 32 R22.htm IDEA: XBRL DOCUMENT

Organization and Business Operations (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Net Cash Provided by (Used in) Operating Activities			$ (3,287,940)	$ (1,914,745)
Net Income (Loss) Attributable to Parent, Total	$ (2,148,193)	$ (1,584,383)	$ (6,291,217)	$ (3,109,062)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

XML 33 R23.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Revenues	$ 294,230	$ 62,698	$ 708,047	$ 178,610
Lumega-Z and supplements [Member]
Revenues	86,082	62,698	238,213	178,610
VectorVision medical devices and supplies [Member]
Revenues	$ 208,148	$ 0	$ 469,834	$ 0

XML 34 R24.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	5,246,348	10,646,854
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	31,250
Conversion of Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	6,981,938
Employee Stock Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,725,000	650,000
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,521,348	2,983,666

XML 35 R25.htm IDEA: XBRL DOCUMENT

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Research and Development Expense	$ 4,793	$ 105,561	$ 199,500	$ 131,330
Amortization of Intangible Assets			$ 54,000

XML 36 R26.htm IDEA: XBRL DOCUMENT

VectorVision Acquisition (Details) - USD ($)	9 Months Ended
VectorVision Acquisition (Details) - USD ($)	Sep. 29, 2017	Sep. 30, 2018	Dec. 31, 2017
Goodwill		$ 1,563,520	$ 1,563,520
VectorVision Inc [Member]
Common stock consideration	$ 2,287,500
Liabilities assumed	108,722
Total purchase consideration	2,396,222
Cash	(4,895)
Accounts receivable	(50,105)
Inventory	(93,293)
Prepaid assets	(551)
Property and equipment	(9,458)
Intangible assets	(674,400)
Goodwill	$ 1,563,520

XML 37 R27.htm IDEA: XBRL DOCUMENT

VectorVision Acquisition (Details 1) - USD ($)	3 Months Ended	9 Months Ended
VectorVision Acquisition (Details 1) - USD ($)	Sep. 30, 2017	Sep. 30, 2017
Pro forma net revenues	$ 198,496	$ 565,289
Pro forma net loss attributable to common shareholders	$ (1,879,947)	$ (3,705,586)
Pro forma net loss per share	$ (0.07)	$ (0.13)

XML 38 R28.htm IDEA: XBRL DOCUMENT

VectorVision Acquisition (Details Textual)	9 Months Ended
VectorVision Acquisition (Details Textual)	Sep. 29, 2017 USD ($) shares
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares \| shares	3,050,000
Business Acquisition, Equity Interest Issued or Issuable, Description	With respect to the 3,050,000 shares of common stock, 250,000 shares are held back by the Company through November 28, 2019 as security for VectorVision’s indemnification obligations to the Company and the remaining 2,800,000 shares were issued to VectorVision at the closing of the transaction. Per the VectorVision Agreement, the 2,800,000 shares were subsequently distributed to the two VectorVision shareholders in proportion to their shareholdings in VectorVision.
Equity Method Investment, Ownership Percentage	11.00%
VectorVision Inc [Member]
Business Combination, Consideration Transferred, Equity Interests Issued and Issuable \| $	$ 2,287,500

XML 39 R29.htm IDEA: XBRL DOCUMENT

Inventories (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Raw materials	$ 312,981	$ 133,354
Finished goods	68,287	21,376
Inventory, Net	$ 381,268	$ 154,730

XML 40 R30.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Property, Plant and Equipment, Gross, Total	$ 552,227	$ 323,917
Less accumulated depreciation and amortization	(290,356)	(228,320)
Property, Plant and Equipment, Net, Total	261,871	95,597
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross, Total	98,357	98,357
Testing equipment [Member]
Property, Plant and Equipment, Gross, Total	249,447	150,603
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross, Total	148,754	50,300
Computer Equipment [Member]
Property, Plant and Equipment, Gross, Total	47,476	16,464
Office Equipment [Member]
Property, Plant and Equipment, Gross, Total	$ 8,193	$ 8,193

XML 41 R31.htm IDEA: XBRL DOCUMENT

Property and Equipment, net (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
Property and Equipment, net (Details Textual) - USD ($)	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Depreciation, Depletion and Amortization, Nonproduction, Total			$ 223,014	$ 47,869
Research and Development Expense	$ 4,793	$ 105,561	199,500	131,330
General and Administrative Expense, Total	1,064,645	1,392,524	3,779,325	2,758,331
Selling and Marketing Expense, Total	$ 240,028	$ 116,440	1,224,491	294,774
Property, Plant and Equipment [Member]
Depreciation, Depletion and Amortization, Nonproduction, Total			62,036	47,869
Research and Development Expense			23,854	22,044
General and Administrative Expense, Total			30,940	25,825
Selling and Marketing Expense, Total			$ 7,242	$ 0

XML 42 R32.htm IDEA: XBRL DOCUMENT

Acquisition of Intellectual Property (Details Textual) - USD ($)	1 Months Ended	9 Months Ended
	Jan. 26, 2018	Sep. 30, 2018	Sep. 30, 2017
Payments to Acquire Intangible Assets		$ 50,000	$ 0
Intellectual Property [Member]
Stock Issued During Period, Shares, Issued for Services	500,000

XML 43 R33.htm IDEA: XBRL DOCUMENT

Related Party Transactions (Details Textual) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Related Party Transaction [Line Items]
Due to Officers or Stockholders, Current	$ 108,018	$ 146,133

XML 44 R34.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details)	9 Months Ended
Stockholders' Equity (Details)	Sep. 30, 2018 shares
Class of Warrant or Right [Line Items]
Membership Units or Shares, Balance	2,983,666
Membership Units or Shares, Granted	0
Membership Units or Shares, Forfeitures	0
Membership Units or Shares,Expirations	(316,318)
Membership Units or Shares, Exercised	(146,000)
Membership Units or Shares, Balance	2,521,348

XML 45 R35.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details 1)	9 Months Ended
Stockholders' Equity (Details 1)	Sep. 30, 2018 shares
Class of Warrant or Right [Line Items]
Beginning Balance	2,125,000
Granted	600,000
Forfeitures	0
Exercised	0
Ending Balance	2,725,000
September 30, 2018, exercisable	2,400,000

XML 46 R36.htm IDEA: XBRL DOCUMENT

Stockholders' Equity (Details Textual)		1 Months Ended								2 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended		12 Months Ended
Stockholders' Equity (Details Textual)	Nov. 03, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Jul. 25, 2018 USD ($) shares	May 31, 2018 $ / shares shares	Apr. 30, 2018 $ / shares shares	Jan. 31, 2018 USD ($) $ / shares shares	Jan. 26, 2018 USD ($) $ / shares shares	Dec. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Jun. 01, 2018 $ / shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Sep. 30, 2018 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) $ / shares shares	Dec. 31, 2016 USD ($) $ / shares shares	Sep. 21, 2018 $ / shares shares	Apr. 26, 2018 shares	Dec. 31, 2017 USD ($) $ / shares shares
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares		$ 0.001									$ 0.001			$ 0.001					$ 0.001
Shares Issued, Price Per Share \| $ / shares									$ 1.00			$ 1.00	$ 1.00		$ 1.00
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares						$ 0.01											$ 0.25
Class of Warrant or Right, Outstanding		2,521,348									2,521,348			2,521,348					2,983,666
Warrants Intrinsic Value \| $														$ 3,461,453
Share Price \| $ / shares		$ 1.80									$ 1.80			$ 1.80
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares														500,000
Debt Conversion, Original Debt, Amount \| $																$ 535,149
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate														2.88%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate														121.00%
Stock Issued \| $														$ 0	$ 159,798
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value \| $							$ 125,000							$ 584,846
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number		325,000						500,000			325,000			325,000					800,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $		$ 449,863									$ 449,863			$ 449,863
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														600,000
Stock Issued During Period, Shares Warrants Exercised						146,000
Stock Issued During Period, Value Warrants Exercised \| $						$ 1,460								$ 1,460
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		250,000							600,000		250,000	600,000	600,000	250,000	600,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $		$ 450,000									$ 450,000			$ 450,000					$ 658,383
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price \| $ / shares							$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period							5 years		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value \| $		$ 1,823,750									1,823,750			1,823,750
Preferred Stock, Capital Shares Reserved for Future Issuance																		10,000,000
Number Of Warrants Expired				30,237	151,006
Number Of Warrants Subject To Term Extension				372,848	403,085
Investment Warrants, Exercise Price \| $ / shares										$ 1.00
Investment Warrants Expiration Date				May 31, 2019
Fair Value Adjustment of Warrants \| $											$ 1,007,006	$ 0		1,501,397	$ 0
Stock or Unit Option Plan Expense \| $														$ 529,323
Number Of Warrants With Extended Expiration Date																	600,000
Non Qualified Stock Options [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares									650,000					394,239
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross									1,250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		1,250,000									1,250,000			1,250,000
Non Qualified Stock Options [Member] \| Consultant [Member]
Class of Warrant or Right [Line Items]
Share Price \| $ / shares								$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares								250,000						500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value \| $								$ 312,275
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								750,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $		$ 413,877									$ 413,877			$ 413,877
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number		750,000									750,000			750,000
July 2018 Options [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share \| $ / shares		$ 1.25									$ 1.25			$ 1.25
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares		100,000	25,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value \| $			$ 44,994
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value \| $		$ 134,983									$ 134,983			$ 134,983
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			100,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares		75,000									75,000			75,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options \| $		$ 67,783									$ 67,783			$ 67,783
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		5 years
Warrant [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights \| $ / shares		$ 0.43			$ 1.00						$ 0.43			$ 0.43
Warrants Weighted Average Remaining Life														6 months
Share-based Compensation Award, Tranche One [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			75,000				250,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value \| $									$ 486,070
Share-based Compensation Award, Tranche Two [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			50,000				125,000
Share-based Compensation Award, Tranche Three [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares			25,000				287,500
Common Stock [Member]
Class of Warrant or Right [Line Items]
Stock Issued During Period, Shares, Issued for Services	4,347,827
Stock Issued During Period, Shares Warrants Exercised														146,000
Stock Issued During Period, Value Warrants Exercised \| $														$ 146
Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Debt Conversion, Converted Instrument, Shares Issued																535,154
Stock Issued \| $																$ 784,888
Private Placement [Member]
Class of Warrant or Right [Line Items]
Common Stock, Par or Stated Value Per Share \| $ / shares	$ 0.001
Stock Issued During Period, Shares, Issued for Services	4,347,827
Shares Issued, Price Per Share \| $ / shares	$ 1.15
Share Price \| $ / shares	$ 1.80
Proceeds from Issuance of Private Placement \| $	$ 5,000,001
Maximum [Member]
Class of Warrant or Right [Line Items]
Share Price \| $ / shares				$ 1.80
Maximum [Member] \| Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				119
Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.89
Minimum [Member]
Class of Warrant or Right [Line Items]
Share Price \| $ / shares				$ 1.15
Minimum [Member] \| Measurement Input, Price Volatility [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				118
Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Class of Warrant or Right [Line Items]
Warrants and Rights Outstanding, Measurement Input				2.61
Series A Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share \| $ / shares																$ 1.00
Share Price \| $ / shares																$ 1.00
Stock Issued During Period, Shares, New Issues																1,170,000
Stock Issued During Period, Value, New Issues \| $																$ 1,170,000
Preferred Stock, Dividend Rate, Percentage																8.00%
Preferred Stock, Dividends Per Share, Declared \| $ / shares																$ 0.60
Common Stock Dividends, Shares															170,075
Dividends, Preferred Stock, Stock \| $															$ 102,029
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Shares Issued, Price Per Share \| $ / shares									$ 1.00			$ 1.00	$ 1.00		$ 1.00
Share Price \| $ / shares									$ 1.00			$ 1.00	$ 1.00		$ 1.00
Stock Issued During Period, Shares, New Issues													3,105,000
Stock Issued During Period, Value, New Issues \| $													$ 3,105,000
Preferred Stock, Dividend Rate, Percentage													6.00%
Preferred Stock, Dividends Per Share, Declared \| $ / shares													$ 0.75
Common Stock Dividends, Shares															77,045
Convertible Preferred Stock, Shares Issued upon Conversion	6,981,938
Series B Preferred Stock [Member] \| Dividend Declared [Member]
Class of Warrant or Right [Line Items]
Dividends, Preferred Stock, Stock \| $															$ 57,769

XML 47 R37.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies (Details Textual)	9 Months Ended
Commitments and Contingencies (Details Textual)	Sep. 30, 2018 USD ($)
Loss Contingency, Damages Sought, Value	$ 192,000

EXCEL 48 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 50 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 52 FilingSummary.xml IDEA: XBRL DOCUMENT 3.10.0.1 html 103 187 1 false 33 0 false 4 false false R1.htm 1001 - Document - Document And Entity Information Sheet http://www.guardionhealth.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 1002 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.guardionhealth.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 1003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.guardionhealth.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 1004 - Statement - Condensed Consolidated Statements of Operations Sheet http://www.guardionhealth.com/role/CondensedConsolidatedStatementsOfOperations Condensed Consolidated Statements of Operations Statements 4 false false R5.htm 1005 - Statement - Condensed Consolidated Statement of Stockholders' Equity Sheet http://www.guardionhealth.com/role/CondensedConsolidatedStatementOfStockholdersEquity Condensed Consolidated Statement of Stockholders' Equity Statements 5 false false R6.htm 1006 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.guardionhealth.com/role/CondensedConsolidatedStatementsOfCashFlows Condensed Consolidated Statements of Cash Flows Statements 6 false false R7.htm 1007 - Disclosure - Organization and Business Operations Sheet http://www.guardionhealth.com/role/OrganizationAndBusinessOperations Organization and Business Operations Notes 7 false false R8.htm 1008 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 1009 - Disclosure - VectorVision Acquisition Sheet http://www.guardionhealth.com/role/VectorvisionAcquisition VectorVision Acquisition Notes 9 false false R10.htm 1010 - Disclosure - Inventories Sheet http://www.guardionhealth.com/role/Inventories Inventories Notes 10 false false R11.htm 1011 - Disclosure - Property and Equipment, net Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNet Property and Equipment, net Notes 11 false false R12.htm 1012 - Disclosure - Acquisition of Intellectual Property Sheet http://www.guardionhealth.com/role/AcquisitionOfIntellectualProperty Acquisition of Intellectual Property Notes 12 false false R13.htm 1013 - Disclosure - Related Party Transactions Sheet http://www.guardionhealth.com/role/RelatedPartyTransactions Related Party Transactions Notes 13 false false R14.htm 1014 - Disclosure - Stockholders' Equity Sheet http://www.guardionhealth.com/role/StockholdersEquity Stockholders' Equity Notes 14 false false R15.htm 1015 - Disclosure - Commitments and Contingencies Sheet http://www.guardionhealth.com/role/CommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 1016 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies 16 false false R17.htm 1017 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 1018 - Disclosure - VectorVision Acquisition (Tables) Sheet http://www.guardionhealth.com/role/VectorvisionAcquisitionTables VectorVision Acquisition (Tables) Tables http://www.guardionhealth.com/role/VectorvisionAcquisition 18 false false R19.htm 1019 - Disclosure - Inventories (Tables) Sheet http://www.guardionhealth.com/role/InventoriesTables Inventories (Tables) Tables http://www.guardionhealth.com/role/Inventories 19 false false R20.htm 1020 - Disclosure - Property and Equipment, net (Tables) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables Property and Equipment, net (Tables) Tables http://www.guardionhealth.com/role/PropertyAndEquipmentNet 20 false false R21.htm 1021 - Disclosure - Stockholders' Equity (Tables) Sheet http://www.guardionhealth.com/role/StockholdersEquityTables Stockholders' Equity (Tables) Tables http://www.guardionhealth.com/role/StockholdersEquity 21 false false R22.htm 1022 - Disclosure - Organization and Business Operations (Details Textual) Sheet http://www.guardionhealth.com/role/OrganizationAndBusinessOperationsDetailsTextual Organization and Business Operations (Details Textual) Details http://www.guardionhealth.com/role/OrganizationAndBusinessOperations 22 false false R23.htm 1023 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 1024 - Disclosure - Summary of Significant Accounting Policies (Details 1) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetails1 Summary of Significant Accounting Policies (Details 1) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 24 false false R25.htm 1025 - Disclosure - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual Summary of Significant Accounting Policies (Details Textual) Details http://www.guardionhealth.com/role/SummaryOfSignificantAccountingPoliciesTables 25 false false R26.htm 1026 - Disclosure - VectorVision Acquisition (Details) Sheet http://www.guardionhealth.com/role/VectorvisionAcquisitionDetails VectorVision Acquisition (Details) Details http://www.guardionhealth.com/role/VectorvisionAcquisitionTables 26 false false R27.htm 1027 - Disclosure - VectorVision Acquisition (Details 1) Sheet http://www.guardionhealth.com/role/VectorvisionAcquisitionDetails1 VectorVision Acquisition (Details 1) Details http://www.guardionhealth.com/role/VectorvisionAcquisitionTables 27 false false R28.htm 1028 - Disclosure - VectorVision Acquisition (Details Textual) Sheet http://www.guardionhealth.com/role/VectorvisionAcquisitionDetailsTextual VectorVision Acquisition (Details Textual) Details http://www.guardionhealth.com/role/VectorvisionAcquisitionTables 28 false false R29.htm 1029 - Disclosure - Inventories (Details) Sheet http://www.guardionhealth.com/role/InventoriesDetails Inventories (Details) Details http://www.guardionhealth.com/role/InventoriesTables 29 false false R30.htm 1030 - Disclosure - Property and Equipment, net (Details) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetDetails Property and Equipment, net (Details) Details http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables 30 false false R31.htm 1031 - Disclosure - Property and Equipment, net (Details Textual) Sheet http://www.guardionhealth.com/role/PropertyAndEquipmentNetDetailsTextual Property and Equipment, net (Details Textual) Details http://www.guardionhealth.com/role/PropertyAndEquipmentNetTables 31 false false R32.htm 1032 - Disclosure - Acquisition of Intellectual Property (Details Textual) Sheet http://www.guardionhealth.com/role/AcquisitionOfIntellectualPropertyDetailsTextual Acquisition of Intellectual Property (Details Textual) Details http://www.guardionhealth.com/role/AcquisitionOfIntellectualProperty 32 false false R33.htm 1033 - Disclosure - Related Party Transactions (Details Textual) Sheet http://www.guardionhealth.com/role/RelatedPartyTransactionsDetailsTextual Related Party Transactions (Details Textual) Details http://www.guardionhealth.com/role/RelatedPartyTransactions 33 false false R34.htm 1034 - Disclosure - Stockholders' Equity (Details) Sheet http://www.guardionhealth.com/role/StockholdersEquityDetails Stockholders' Equity (Details) Details http://www.guardionhealth.com/role/StockholdersEquityTables 34 false false R35.htm 1035 - Disclosure - Stockholders' Equity (Details 1) Sheet http://www.guardionhealth.com/role/StockholdersEquityDetails1 Stockholders' Equity (Details 1) Details http://www.guardionhealth.com/role/StockholdersEquityTables 35 false false R36.htm 1036 - Disclosure - Stockholders' Equity (Details Textual) Sheet http://www.guardionhealth.com/role/StockholdersEquityDetailsTextual Stockholders' Equity (Details Textual) Details http://www.guardionhealth.com/role/StockholdersEquityTables 36 false false R37.htm 1037 - Disclosure - Commitments and Contingencies (Details Textual) Sheet http://www.guardionhealth.com/role/CommitmentsAndContingenciesDetailsTextual Commitments and Contingencies (Details Textual) Details http://www.guardionhealth.com/role/CommitmentsAndContingencies 37 false false All Reports Book All Reports cik0001642375-20180930.xml cik0001642375-20180930.xsd cik0001642375-20180930_cal.xml cik0001642375-20180930_def.xml cik0001642375-20180930_lab.xml cik0001642375-20180930_pre.xml http://fasb.org/srt/2018-01-31 http://xbrl.sec.gov/invest/2013-01-31 http://xbrl.sec.gov/dei/2018-01-31 http://fasb.org/us-gaap/2018-01-31 true true ZIP 54 0001144204-18-059482-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-18-059482-xbrl.zip M4$L#!!0 ( "2C;4T_/P021
W>+L8="R,>^#\]LZ[,9P;SG<#E_NU/SY)XWIT\^Q]_^[?_]M?_J]O] MA?DLM&/F&K.U\<:.[<^A[7R-TK>-_I5IP'^L0?>WX(XM9RSL]DQK8OS?YN!% M?_+"'/\_QO][_>O_9W2-^_O[*Q<&B&F *R=8=KLXR;=9Z/$7^&\#P/*C%P[_ M:IJF-1KT^N/A3\\6<;QZ\?PYOGZ;V*$+LRZ8[<4+'.(Y3F9.^X"!>-GC_M?" M.SCP51#>PI-F_SG^/+,CECZ.O[H\>T%]>/1<_)@]6AKZOD_/6M/I]#G]FCT: M\:H'85#K^?_Z]?V-LV!+N\O]*+9]IP +WP+[YO,\"@8]:[SM#?%$^H++5B%S M<#%KWYD^MT,G##SV/'\X?=T)$C\.UT5B1\H>*5[YY M6[CF?[U76#F)PRW, K]F8(=Q&0+X4IT=MSONDQ<1[8!/;&[0OGD1KU?LIV<1 M7ZX\9&_Z;A&R^4_/"L*@F^[VJV\1L.7S7'PX@1^S;['!@;4_FM87^ >?_1R8 MTR]]DSX_RY]F?LSC=?XW=_&;.6>A09"Q LHI^5^_^\]G?\N!^>OSS9=QP.?5 M,ZQ8R ,W_QMV7(%U^LM16%N]+WUBD_&Y8CWN6CW8-ZUA;8XO;F.,'VUC9,0: M*\0Z+U8I$&N\#['&;1/+NCAB-1>Y;1,+!0\1:$3$ZDW/G%@C$D/F'L3J3=O6 M3^=(I(*D+F#=CGZ"/34]/PE=T,IHO+:+]9E*C\VU;MD6P86VSGRMD,M=6J!9;J21#]F?TY.BOL-T3_'GIR5#17VS,JT%R%#Z/S8Y6C_#BK MVQNUJB*#%IU]8=?S%Y*K.%%B-QAU^PU)M:P M=9%[GD0J[J=AFU:NE"+GN(\VI4B;MDA?1BEP8XQ2B7)6V&]NC+X2L]BY,4:* MR&G-7#U#!TAAD5'; ?C*DZDO'\, !HK7'ST8_=IW?_YGPE=+@/-7.E%/(CS& M>VOS\!^VE[!7Z^LH8O%KSXZBZV\\>ACB229AMPA7^H4+4WY;>=SA$E3#Y?"[ MR"N0QX\OM@">/K*# *BTF0*V16X'L(L/TWLO,@4[Y,EN[7_!=2X258KCR%^ MD4 \"F.@F)LX\8?PAH5WW&'GS @ [HMJ> NGNR^V8/PD.> ?S(D#H!92\5?F MKKQ@S=A-'#A?/ZQBVA\Y$XAOWODN^\;!WX=V!/\9G'WK!9?,.<).1Q)BL%D[RC M'#=$_5)8H@KB]+<=*#]A-D :?IA_#-F^CS=UW_FM[Q6/;>VK,L)4,3Y(Q/K'8YCYS?[9# MG_NWT5/CB&K\GR0K5+B4%+#[,)>_? @_\=M%? FKOP5P[4JF"_Y;X/_/Q/:0 MW*[B/15D ,9E?[.7%V$<%F$MFH7;<7V2RP^6L4HEEA2M1(- 6+M$\VFHQTI?WS([8(O#<=\M5B.6E^8& 9+:Z9W2ZDIB%>DN+0%05,2Y[A3_,Y]QA>GU19%>1 MXK)7]S\2;XT?+MS8WV9S5Z)XV:NFXSB7NG)/V2,_B6/\:/& "V VS4 7+.[S M#B8Z5'(^H9*VN[9LK+0.E9QAJ.3$:ZY#)6<2*CGQ.NM0R:.'2DXMO76HY#%# M):UW5*OL>Z4+NAZ[H.M1^WO5,(4NZ#JQ#7[V'* +NLZIH.L<.407=#W1A=<% M76=3T'6.[*$+NAZ\H.M\V4 7=#U"0=/9(/?)/F!E>/65FJ$3^23+#&SS QL&9X]E #Y4/TM_(!O^.V:: 9\XJU:1I M(WU \^F^MRGHF-A#Q\0>\8J(:@[0,;$SBXF= 8?H1FB/V@CM#.[L;($#\Y"YS1 MC4!ZZ4^^]">\YZCZBH\O[^ 1SP/\$MM+4PD*J1/&D=?1Y"^C_>)2 &)E@4/* M. M><'*0)^-G]F98_.;RDYRF9UF@L=@@A->EVPI&0_XN9^5SNGFU@^WK:U]4@GP MX7Y[1P#5#/ QY'F6Q7>WS<+ MD/&FE_[AEKY80JFN93L%LOE::BW]2%JZ_57-KP#5W:A.VEBFU6M,BU?6?OF5 M^WR9++/LBD^V?WOV*14*D/AG 8?3+T?[=^DJRV%_N_SE4'&X\.5@=I2$)-7? M^:LD_L2CKV]#QO" -F01+$]<.&7:?#XM=[F\;9:*NCJ,.&I;_L- M&H+EY[!_!)X=WY_+/9P.O*" M^K#20-ICM> -)+:<;?^D-]84>9U49-^[VAJU)EIK% MUN;0X]9&7"!#Z#1XS1"Z6.9!BV4>D2FFE27WVD8XW6(W]Y!/<;]N\;H!G3/Y M8/DUI[Q6X-IUJ4[<]C[:W'WGO[97/+:]I[:J6\EPV2O\B<4V]YG[LQWZH,^B MI[:TU?A?X)H6;\;5\O=AY.^)K]'3\O?1Y>^)5UC+WT>0OT>M:29J[&AQ[;OX M'T3QSO8(N_BU'89K0(6NLJ$U?VL[,7=AO:>]OC5X9LC!/K%YB1^>&8G/Q2^_ MW[QY9KC,X4O;BWYZ9C[[FV6!ZI@"V'N!T +,PPJ8>PW%K].PA#>*X,Z.H*\8].R !$UN&DLJPQB+4]0!*=D6I!Z1W! M58B,]C#94B/$&J]D349%\A;/_'A !XAU:;#X72\ M/WR;3^YY93@GAQ-R:$['HWX.:!, C@=X>CAA1SUS M/+ .![@6J/X1JL(:CL >4+;.?C,?HQ*:S"PH4Y[W"/D/TG\XMLQ-V=MDUB,D M_K@_-GN]_M99I?WPT5ZC\0![#;X)$^:^Y_8,,Y YJU5&_2/D?6\TL7H5=DP# M.%H#_PC1W[>LGFKM' C^&UF*^0F^?PW_Y;4F8_\8Z=\;]!4FJ)WT0,B.$/M6 MSQSL"]E[;%_Z8;X#J"-DO+)+J^;:'Y8CQ'??'/:'^\"SD^L'QTBQ*4BQG@K. M-N9N LP1PFTPG4X'XZ; 8$B0TR50V-3Z-& T,D%^*-)C-P#'@GN$H0@* M=SHR!]-#P=V,:((YD"P3SXZ9"UH.@YEE<(^0S%VPBL' '"MKOQN"8^$]0GAW MP?X;#:?#T;[P%K,L9-D77E. "[ (/#>[];,6[".L5I 18ZL_^>OSO<%H"?8C M3-;1!)R!\>A V"NT;.4K99"/4#,EKVG7[,=!>DQ4=M/3V@?23^R.^4F%13#< MU$C55YAL-_ZG@T+D/9VL&0";JJCZGJ4=$8C1='+@_*--A5/HOMR, &-S8JIV MXGX ;*J0ZBOQ=IPH3$;6CA5X'43QASD&(XA=Q%TMT0UP3!FD335Q %-8O>' M'*EV0MWTAP*YJ1L.8)R^:4X'IX1Q4Q$J.#@5J"45L#_+6=/IT#1/#VI)$1R@0/M6 MOW\(J#?,\S ]WW=_M<.O#&,OM7"6E,$!IM; -'N*J5,__:% EI3! 2P*AO_ M/"60)>5P '/V>H/!U#HEE"7=L3]?@FD]'@_V!?(7YK/0]O"(P%URGT=Q:,?\ MCM5"VH(38)FCP6B@!))W '$4O"WX#%9_VAL6K(/3P3MIP<< =IKV>P]#WTD+ M+DEO/)ST^]9!\'Y8,?PMX^VRTS1IPT/I@_$_4DRBTK1[PM2"0V*-K,%07>5C M86K! 1GV3%C(%NG4@K_1MR:#07]O.KWSG6#)WH/-68:J!8>C:UG@\PYZ%6#E M,^\-6 LN2-<:3JRI>AC>!F M>"7=P7@R'JN65QN M>"G=/LF.H]5'%8-6-KI MJDZF3EMP4H8J/!L3[@5+"WY(;S#JM0-,"YX&#&2V TP+OD3/G%CC1M"\M7E( MAV;7[A])1&>X65_F,EM/6_ ?+-,([?AG-S3/3AL"TB$4+9F9O,)WT MS@"5%@S3,\"B!2NVWQ_V^^,C4*E.?$J?B,1VRBKPWBU7@$ )$ZL%T[TH\?&HP5K^]'7HHV _W Z5G,&#D6DH%.N[VSN87+VYT#)V9)) M&:_LB#ME7%HPZG?8 +NA:A6A%BS_K@6:&S Z#X1:.&S888L\,$(MG$MT^R-S M8$W;02A-Q_O(PK2Q%7?PY(U[2[!07#_%\,;MIA[?0?^XBW[ M+<%TR ]S>NU#$F-/ *R-VXG.WNYBA#-$*A[O?GLK,\D'8X7I#X/P%#CN[876 MX-@;3GK#J;I!S@?'O9W;+>LX&*G!G?/!<>\SGMIU'(RFEM4JCD(E_0XS*\^7 M4:C**CZV^5R#-;4F_<+>K(1614>F5U>G' ]VE$P?B\;.^I "='N 754ITV;# MN/TJ,P[%8GN=S1%->?:L?#@0_LH*['V+ 7;"D ?UH\]!S<)6=SQ56ZM_8C!P MQ&,FTTT_4FN=3\P);GT:L8Q=K7U0["7:^A91B[0?!O>S('>ST,-IM[8U,(>] M7N]I+D!MW*2X *>12D^4Z5LXR7A,GBU&CNGU=U&4,/=-$@)OB'=HKB@]C_WY M&PL='E58A:5V"*<1N#6FE348F68IKK\?2HU)0J?5#2C2++C4O@H"8C2D1#4F MK1.B-BCUD,JACQ[^.5&EV4G6Z23V.=&B]CQL'TDZ.AZI?:2P'$ ,7T)IT"RP M=F*F'YI67XWD[HU7RT1I9I4_($[;P8LX,,VBU!OE,?BO!32:V5BG M\K9WYYGL%WC:T37E9(&GS:#PD8&GRI8KI]P/&PU2#@QY[&C13K\5RBU"#H3_J#8P:0>-G3!L%RNE9BD'G9-:YM0LY%_6"8J"U9?Z#P:P5S,TI.!A/1M.]H=Q(NG[# M9N4TDE*GD^-282JFW!NB6F]PC\26P7A:GYB_"55UE* ,6#/O;+\H1O7 _XW&SSN4^,F@I]M,-XC1=R10AMX%?(F!:-4WU%E#RZ>CDS,JS\6L8.J%P;U+5F.<$%.4VDQ*/=JV9_:AU1:@!(+F8T2 M1?SWG5_N$U\&M@6]U1T.QZ-"N^'=@!P/> N:S)KT6P7[G7\'JQ.$%8T>!_4] M7?8Q$$;#_G@;Q H$1X#:@M(;;':@/AA2V6$];1-;V6F]C$(+ZK$['EN#K=1N M MHID&M!NW9[EFK$G0*W)NV1R[BUH'Z[@[YE;5VX)J"= +ER6YS]%VYHC7JC MT^*6KOE65-I0R.!9F]M0J0"D!'P&-#QOA8[6GP, TQK=U^M?P<3 MZIV?531? [QW-?"WH;'[/;"N!\5 7T. VD*C!?V-6>DPT/!8-&"KI(%HYY\) M#UGM511E-%I1ZV"'J!=U- :G+21:4/@];$K1.@Z;-U>406]!T0]-4VV*M1.( M!CL K9MHUPYH0]7UQD7>:0Y/2UC4=]+9JY*W;TZ.10(>=QASH[=AL/PMB%FJ M !EL+VLDR-QBZ 8"?P-H3;(]%AQ61L'(OG:.(MCG??K"T MX?MAI?P! !5N8RA#UH(ZV+C^H7;R R%L0=;7D*T6.I4!\3#7]AWV8;Y1].J[ MX@L&/U:V=A^4^^ZTMF^;0W4*O%KPY_J6.:S=],=C)^--:=9%A1IH+1>DR?0' M@UGN^7,4]Q\"H[ICU$!II:0K]P4ZQ-B?6-:@&NAMP+2#0 OZ;&3U)I/CX*^Q M*-YR'_;%=@.GO@'1/M6F8VLRW6G@5(#3%A(M:,R^->@5%N(P+*IO@14I7IM^ M=!F/%O1KMS_J]POM4/RC\*#!OVW/GR M/EFR6_M?>$M#LEIYE/&T=TC*1I@'AY!=W-B#0[FE6:-<4Z-P\%+T+!2Z<3@#V"S]@>'XM"L M\\TC+\&U#P!CUP)^QVZ8DX3DU(@KM)F+?BAF/R6Q5 ^;C4A >23E4Y=APZX3 M7V1@H<7,;GR@C5C2C6J M2CWQS3O?9=^8^SD@$RU-W_Z\7FUNL#HBCGO%&.6E$+&AD'H0(HXV3BLOA88- MZR9?!_X= U,;;&N,X>4 J)04!X&XFYO3[0))UJS=Z.E(UK=ZP\LC6ZE#RE9. MBVCHXK'(TV.U^KXK5:QV"IJ!$6E-^Y=GDC1LH;*; $/,Q;Y FZR^A?<7H MNJK)<'!""KQ*(CRBCBBO)Z*B0:%^T^!D)()/'T(Z,06!6NAE%E771P]+'44P M!$YHCX@$O6E#$O3-#>7>#L"%CHWT^J\L7N"!0+I//]S[L*T7? 6T<^!O^[8< M.B\UQI"A\S)VJZ34JM&\4I.4&@-1M7BPYC/NTYJ#.(JX2ZE]@4^%)C)9N8I& MX"BF1"KCMFGA5:]@P0U]YSNJT*M8JMW1B]YD/*Q:[Q9P/)!T2KXJ()C@5V5J M;=IR#T,MRYR,U6JUX[ ZD#[E0'BI"\8#\4Y_.NH=2 YK!_*RX]"_F/O.A8W( MY]S.8MTR)Q)93;WN'+ANR5QY(J:JP410C;9-I,)D.M]*H15Q/1E5D M6#\63^:U2!6TW33C3DO;H6F9IR)N#Q^6FHF](.I1*'"J)6B<\S\LM6@Y,5\/AI/3T+Q184&[ M^R@]_:U@Y,T(]6FI.AH/!COLQS;05"GY2Q"X]]SSRJAO]P]:MP:'HWXA@R@% M;(?#AW?;OPW"I2T/>LIXM'#MDC6=#*:CK7[<)AQ'@]U"$O%P-.RI:8HM@KVU ML'0=<:FJ-"O?K)T-VNH[^\3< NB),0 M P1O^3?\U"H76X/)>#AX"$2WZ_>3(SHT^QOUCR?"<[LE\$6<2;+P)&P[& _& MHX= ;0CC!P MK]=[")57ZONTAQG9[_6GUD% 7CM.LDRH)E;MT0J?/5;1K+5YZ+C4^VD/FO>F M9E^]!JLM(!\&\>VFR\XF/VJX\A2([]$)>-BP<=&7VHE589'UJ'RUILCR:\^. M=C>G'O7,OL(*[;<['C9L;'1*) _KEHRNLATZ>,#\AMTQ+R!HY%%2&OY"ZM17^(Q!M%N0^*:(]P.U]7(M[ =BV+!IU"DQ-/=%[Q<&_JCMX:9UEQCKBC&OYH[5XMCP+L,3XM@W M"SW^=F!P%++-HNHGW9AXO_!!R.[==6[81C.L8[K.;;TB37S_-DBKWRK WUIY M!A]&@C4QN]#SF!,GMI>N7&&A@*XQ>P]4=3>A?;7^U?XC"*N6KBX!>J-KV7XX M%BR$A'T.A&L31A]"]:9[F:!1IL@1X7W+G, CBHK?.?VQP!X1O;<&(ZO?/Q38 MK6OR&[NGGRKXK=8^&7T.\GXA7V Q,?^@OK(@J^(COOHP%UVLFMTU:(WWX*\, ME]+E!Y+U/H;B?D;ZKHSP]L8H[2"Z[5S2NBJ@6@=X@[4E0;QE:6MME1,L;04[ M-US5(A9%=V(6YV4MLI8*Y1DHC 3A48E7SOZM;RA6Q+\!XH=5I@[[0VM8N#1F M'WP:M_NH;T36-IX5QNAD,)DT:!-21/U#R&^YCW7BLUB4@E1@56NV%+#:KL=A M 0;3N@6H@*(D4FA+EF&K.CAX9!E"D!8#8>KL;S@V O/=3S#QEDJ2^F9D)Y 9 ME<4H9J&=W&X4=J.+>R MN>6P89NSDRD(LV>J=]!M@[W07BR_"R][14C.,H8-R\-/:MV &BS?%%@%?@OF M7*GMFSG8@O"KDR!.!-RKU>;5<97RUB72O*^Z3)3*MR-]>!?YAI4FH&^E XDE5B M#?>V2JHO$R@"6<9RTP [$1_7'*ZH*]D,@P+K"E4@>\E]"#_QV\6V6^)'I=:C MM6'YIDWF=H& X!;O8TWO!?T%_UUA,]6W&MVS74WIBMN-F>M!>XVD][PJX)HU M1#P"N&SNTJXM72Q\C6_<,I'QEC\BC^FN[^W0%0W=HI^_K;AHL1"]\X5D+*.V M=\?F6K]WU%V>.@*J,5-J&*7]TQ:M\V%[I6&6@@#_88]\,P8H=;6)1 \9N>$'K M_L&<^'/PF87+G[_%(%@J\NM&OHK M6SGQP2&B@[<4IRY:+_)F6H45%YFE8.B4,2ZIW.$7LY?RWS#;/G^#?T^[YK"+ M%V8WG.R(75'2EM50-6BHUL/[LA]X4U0V0M@'ZG%O@IT #]T46]9'X:0RW*5S MC+YLWH!4'Z5R:2_&;@9*LZC\J-00M4C8+[]RGR^39=8&_!/:0,&S^7Q: MF-&($A5QW-[52-'O^Z!ZE.-4ZJ%9FWS5M)]Y$\>I7=51:H.Y44MT M5A7@WZ MK5MCZ2/_Q? )YE[?L="^99_8TN;8O^ ]GY*0S MJ>PPH:W*N%3%:O>*D5@;/>1;A[E-@OPB5UTX#Y7%8:-2-\U#7>?19@)M^\"W M29NW03AG5!!<'S8I]=8\(B)T0K@;A_Z5FP&V^+2E%IEM8+TW6 \K&.I:5S:W M 38OESAKP2"IG'=L+A/D:*-HT+(\*,'\T)*RU"42R%%UW/M;X/_/Q/;XG,L# M/#E'H;S9L_W?[&7#[O1"Z3RP;)WM'GY6,_P_P%E@;K$7>)F<):OMH8?) M*=!MGYSI:F7E264OH-3^L8:D->R#4V*;9F?!/O@%3P\AP!*UW>V.1^:X= &MF.E@=0^X(>=")?:3FZ[F;;5NH]#J9!'^VJLMW)+ MRLK= )[>\'^WL"J;\!2N/4BO9A(Y"M7[+UM/&B[Z',2VI_[^.HCBWX+X?[,X M;ZJJ"L0R 2HS&9H5:HV&D_Y$\>\?!(,V-;H0'5CC^6W%G!BOO,*O=IN"I3Z: M^_J(DY8-GZ:8/+@&+W?IK(Z[M*_!^]-!KS]]. W^./NWU"MTCZK0P8:-/%&[.\SCS&CYQULH3ON H-2[+I]9AU_A\9[ MJ9OJ65*^TFWZ'@S]4CO8QR5_97O?WGCS-.LA'(%'L1CJ"N*;>@:EW@./93%4 MGP!4]L%]%"[;XGCT=IZ=/I(2W]$P]]&VZ,#J3\;CQ[803JVH2MUM:WJ-M!02 M^:X4T2[2;KU[?9D[:! 57J M%EQ-WNUYFR;]GO]C>R"TM0-O9OJ[L@/50MWPJRH3(/0C6I9O0T)@7\$ M'@SC\7C]J2HON]1B>>^2*KN/*#EY)O'.W)I8+N.]ZY3K)"@D\%D,+JL^)Q"_1WV M5ZFY^#[M-">8,GN:1*YZ PMOT'L-$,-#S'?6;^PEV!/139" ?5&#X]XECU7W M1/8*VV8G%/7-$YJ6UX\KRY3W2R>N%,7"?Q(@@Q9%6&^E@)M:O) MPR8$;5"Z<;+S65&Z\9UG)Z#T ?TBQM6UK4 M,OVQU*VLB3R6B4])W<;73)Z0NN(QD7A5AK!Q<*(&PH'9[TT'->W^U*D/@N[8 M"HT!X- _&KHM]6+C7I6$:IF =<5B>\'9./WK<%+6P'GM_I&(@DML*.^Z=!6M M[7VT.=B(LI^1+$JJX8/MYS:%Z\Z.Z3&U]6*&O;%HF03-',HOGUAL73S_H-TQ)+W."E5BAY'XT/A.@UNS7H3;D]\'0\&YL,B2%>. M[L2MA?+0YFA5@=0Z1LU:,V_?2]/AI#VL/H2WMB^OP\*\C,#C;GI5%C@1$4A M^O/#_"WW;=_AMI<)V.@-CQPOP++TSX#1*Z^B>>:DE&5?LXA_^W,O] M[BR(XV#YPB 3>!6_-.ZY&R]>&. F_>6E0>]W/7L=)/$+8\Z_,?>E(<;I1BO; M 7T"KZZ^*3.&V2SZSQW;DT ;<;#*9C:OAMS/!U30G -I MNG-[R;WU"^/?[>7JY3^3 ";B2Q89/KLW0#[:?OY#QXA8R.S8^ _/P(8 M+(XW5\#(H 1 HA6LV0ON([SU -X+1&:!YU:^8UWA6\_AM72$VL^Q>^BROQ3+ M/AW\Y<245#:)@08+GZ\U(S1C!%7P&6#.&Z^2"'Z,(N,#N-2B/]L!K/(\%Q;/ M2=)4P.=XS X!LGB1@Z\.=TF/UKS6NEC;SKI-]\',=K[>AD'BNU)E5+'/_8+' MC/@/@%B%H"N0:8P3LWT)-($4J/Y <&/Z]2'[ X'ZDS4R+WOY+E<8T><7Z#1R MY_02K+'8NJ3%UWOWHI?O,O;N+XD=NKB=_LYL+UX8-PYGOL.BCO'.=ZZ,'\"9 M$H#^:=+KF2\QMF3[Z^P;Z^6/QKT= 7SA$J-;OO&&.12:,GJF.37@)]MXC=GL M0>AS&RRN)<>>P1ZW9Y32 8C0B.#_@3MBX'2^O63&Q\'[,DCOW[^^,C[XQG\D M/C/Z@#3X4<,.O20!0\=+7$9FS(&632>/ WCR#?/L>SR> !Y>23;N&,X"77^, MO,:1 (T&KJ<; (GC;2?L17.V%DP7O7R7(9@^*YN:HQ2)5GBGN0>[=B%V5"1W M5+Z+%W9LN.*&;-AG*),2SX[A";057+R>E\^2F-[P18"[2Z/.N6. ^$*G%MX* MW,BXYS"![1MX^2Q,6O@5F#EP$RY-%SI*P -[J= R E?4@Z^VL.%X4&2]C#F)#"%;>.;MZ>1"H:Z\"0,;,=)@,F8AT!14]4-.2 VOQ&L8@FQ M'X%YI(6!%@9:&&PE-C@C-VP52X]G2A[)>-,C68(JIHM2P(.PE7/G8 Y;?(:I M%6AC>"A.//P2W[;I (M4MP-BP0;/*G5;." +3_T#-'<0_H-'Y*:@4]$! 52P MA:3)!'A'Z)KAN)3(@9Z)C*+ 0'A6%=H1/$[;GM_!UN\8MWBA6_$K+[C/'P;1 M05\BA#]_?O/IQKCC40+"0_P RTPEB%<%.!7K#!8JF=L.];BD02+F>9'!@#PK M$D;T7;):>8@OV'(*Z$#+.S%>.LM%L[J65!>]?):>&B:[RU<:?P,,"83=C(!'02L+9XX" 6B5A!!($)1.S0P &>!T> 1D2 MH1>3>#%%8_PB"C,&"S<[RH&!J>#U! 0K$6D;&+?/QT"P--"$L4A@)R64# M!(!""I_T&2,*-:V$F8@%1@ZL2+ $&*Z,#8\73+80( $"@":@<9,531-DIW4X M 1$39US ]S2\9R>^LR!M$V6W__GP-N@&'.:?B1W&..-%[SHM-"]Z^2Y#:*I; M;.Q#A[WH.H:D*?A4,5KPL2)]"UM5$=LU*+EC2K>!DQCP\-NI&!A_WG4 MZ4VM3L\:TY9.L!I-Q9SHP#9>NPQ"GVX"8L01H M%A$8!N#]* $D>:0]*4+$J#R=K(P,"_C,?? 0,D!E$,7''B]XGI,#16#.O> ^ MBP'Y8()T81F65\8U4D-X5122L46U,UDQ2!XO<2EF;$&R2PV M[%F0Q"K-4\?/&K^$">1ANPI_>17HR VI">19 X!I((P,JQ2 :D:@DD*J2='& MD!:G6IPV=6D*NY2#+%JA0/+Q\/B61]@^Q#56R0PL)#Q!@K4G>3+GX9+D QU^ M\51&@)3R0'[$0;@VX,-M J)$"AP.FWG%??)E'!F@WA#218&1N.1A56YV#-[@ MBR0CA #-4H[ZE@C %^1G8>C*(=T >#=.43'H8"^OAD.Y%;*Y!S)8Q*= VF(I MD#%/,'AML/F56R MM^[4:@\O\&_)NC7NN"J%80_>QPL2GD+3&>*I,;EZE)#]!'3X M'.9Z9.%].EH0D3RD=$587W "Z;_ L($+EZN8=(S-(Z:>.+AL1C \AS$9579G M84!X? X")55!>2BR8\R2U%0'+L0#%C\@MPC[Q*8*I.0=P6/BR"2 7>3@D$"2 MA0J,5)QT\E)06CY#TB$-""@\/2+0\/@A=T)"1I680J$*.P"\'C$G+!71#1-5 M/._*>%?46T"SQ$^ALVFA +HY[#(\J,DCHRP*DA!1Q.$-E!, RLR.>%0\*4(& M 'QA5SIBIX&9DS@,(8!=DNUIA#]FSL('Z7$K."A=6)5'X+O;$,^#B%D2/*GW M<"B'V9&Z,%OUJR"$J,C$BM=,85%17441IZCA? :S>)X48?0>_BT+]O#O;'RE MG+-I!5=>;]MVP6RA75@N,*\S$_,CS "+&]67V):N[SE!B>V&;I!?@C+Q[%4$ MHC7]U% 5[JS(55:K3KQCI67^6%6)9CZ1J9;?5E9V%BIU#3E(%^DB1TJ_>C!- M76'8/:T2S5Y!3!C;9,:V8EV]B(^YB#?)GK]!01Y&I6I27=6AZZ&[4V^ZQI>9E[$4,)!3B MYUC%AB$FC%*D;EE=V!S/R,"-%I%U"DI$RA7Z^J.:42HR-#%!W"'O M+4Q@Y)PC1=7;+58 II%T'/\&XQLBVD:IZ]^HP)?" TL>48!+G?3FY]>%.?$2 MC5!T8I0DRVD#5 A"D?3^6N;LC/!LI]D5&:V$KHRXX5T/![!*M @2 MS\6P2\AL@A[>^2/Q'2(,@8\X-V!C2<-(Q+CDF09U1DP)5Q43O/9]+$WX1 N$ M :*W0/8<;C@R4 "FNX,H"!.T2 KX88,]NC!8H6C,5XZ@),6!XT6WI$ M";# @GH7:'RG)A>G.[4!C22O8S$L?"E"@FY S*:<RH@=^0-R-A&XD\;L M (LU,=>9'A%IM7MV2_)=J=UWOLRZ%R?8>**1YYK(= "UD5=O]=/=E>!;*^3-9])UY,$D%)6$YE72K+5W2C0Y2>!3"*- M.5XA(T&6DH:3\J0B$DI\FLMC^*K1@8B@@YB\[R.;#(\M@( 1'DJEXA_AWA35 MDS,5@97[C;[DE-"1!7EUP$"+T.\YBO![1 +@9Z#7$OV'RPH@Z!B?WK+GLF51 M0PMO,\MZJ/5*A3N'CB[F*.3.J'0@(C6QPTO[*LJ)VEFY5X73XJIHE)]O]2-\FK7&G"X_BVG?B/-UX&[+"J"J#DJ7[ M*+G>64! FC'H3\>)2%8@Z\0AM]CE@&68NGH!R+",*I=D<&A)I275XT@J=<>4 MY(@,>.1KDC^*]C_Z%>&=J-A(?$SJP(Y8&$^4D4L*C6#I.&8V!S-PY%CD8..Q M#N:1A=AA Y_VN!P$:[M!N(F4H:R=!>;1V=Y:'G)P\-IX*+.AYI0S'&( *,]= M2R\?@7O? 01"D#8"SQ5X<:)F8U-2JL1:VBYE M;6,1/W&/"37DD-7E6DAI(:6%U'EX0/E5)8:X T.[0'K/ MGMOR7<:>?4=NC<\V#JD*N? QML6Q'=$JN)"UC'$W/N?H)*".];Q =+E)K0^7 MPKFD:$7;EI*25TYD;H/ I41MD64L6L:(:@%4VPN^TDI8;VB]H7=NZ,U#FHNP/5-,1>@/S2SWNB6]=+(=6]4^/X7=??2]51%6>$R-/GI M*.5^P?!W>=2>ABI"Y^:=]:I*(86$+ M^2>BFD<<>V"<@6B0MT6G)U3(0%B!5CJ'5/]&(\P=20U:]8R 6IS&U.L M(C5Q9!04C!S%TA'I,JI,RDYAJZO2-^<(I'P$!#+1$,DCVWL)-7H5'1)!6<80V<[%F8YFMA M=(KY=SP,?&KD;KQBCHT@B0-NJA-<8;EAB"L/BH8[PIZ%_>T'2Q"V,^:#1HG3 M3#F1ZK5!?2R>P\-WRN3"0)*GJJ].44/(D#A6\.7Y?H"#DX@J5RK4B\"$1O)U M56F S)S+#"KB*PG^LY<66MAK87]R87]=M>&R)!KIA-JB,41)7$=1X'#:BM7> MK=JL&N_@P+ZEWTC(PD;^\W#0,4T3C;6TI:A0 %&>T$C#RKTO&ZJ"H,"+.$2R M3G9HMB5W,Z\E1<'TH5E%[=ESEQ8.%[U\ER$<'B[JG/MIL$??XRG6>TI?UC%H MO8//<_DN8P>KOES([CB[EPU./-I>Z4EO[J_4G3YO-P5$7"CSI]!^4$(OX/4P M&[R%C0Q9##+=+QB8'7=".X?BLCRASAT>.LD2&P6*%B^BR[LH\[##D#Q(<@ES M=T/Q,=@WA[&T)[OLA%YT(S\5^VSER4 BQW?!/!&;2M 7!)M$7GQ#U0SRFHR0 M1WEF4P:4R.F1/C*-F7:FSSU,V%C8*B2AA&3I7"E]%M5@'<"2MXJ?K?/+/;)& M)]MF%G2(J!N)%/)E13U$F7DY8"\\+D([HE,,I:GK^<%.QM%,H7\*I&4!2BRL':A MU/@"[+$('?Q(0!(Q&7@42>.T=6"D-&\C+84K]/A&]W;!\;8T]+>]=9Z=0>P;]BY$-F)ME%6&H"W1Q02;Y"W*&[NZCP[ M;8IH4^1\G(D;)FZC>Y?7SFH'0N_:6Y2R)L%>A M*!WVU;QU.K3-NOA%8F=VI"' A4F8O4UYJ-0:+WU5[9Y(W]%1"Q/V>GXE$MU5 MEZRH.)N2\%G,9$Y-X>(F@COP.=IF,!H5&X94O8\)^&LR.['O7E3? -A9<(;) M^LQ)9+G@G#MX('^_"%*$Q#,YVL#U(AZ*E0MA)W/$\OH M3Q&W5:SDHZ64@3@%VC+14M\[3,.P]+ MY9.\$^Z3<+*UI:)W[3DNWV7LVCJ-G5Z\2+V3EZN0R["22+*H;##MRANXZ?I8 MEG7QQ[R/!.]:!"T/''.[ //!Y2$&7VBPYP[>-(DMA4,W[SJ-68.R#W(Q:"$N MK-VXY;OF_EJ@UF[HZN;J[3&AX6^G?:WUFI>"PPM,':E\RIW;YO6 M0&S/K EU57)O9+P*<'?+*K;*)WY?41'P;\$5C=HUI\8/US>_JU^H?%-);Q/ *9=HS>277GX$P=(N<'EJM(!(K7(DJB CS)AC+].+7W 5 M_\/V$]0W%]@E1LMN+;L?07:_R<^U1'.H5+YD0:$H\++S4FEQR6Y;;K!26U(4 MQ&QZ2:\?8$X:[G*9:";.V(+ZWHI7QM^#>Q!8LC8CDW-9$POU9@ZE@2/68S!O M18T-F3ADJNP;,2,BX:/EC98WC!3LCQ=Q8-'],)"R4TR<8PNIE<$(5VX MN>"K%:8J7*O?XM&W_(7R;+'P &PDNJ8D;QN:%8L2H,*_E9?OH'0C+]U-DW#==>BYX720@&5(2"S$-(P+7&%[!E8*F!7R<; M)V]6RWWEYBPMSK0XT^)L*[%_1RLBLWY26Z6CQLH4T48R!3M@A8%7X74I/@YY M=45Q5Y>6GXG SI[.6?7-QJI31L7P>_ADFPF2**%%=% ISQ60S0AFP"GIE6IDK.4CH5/L%#LFDUTJ3_2$%A#/B!PTD?I6/SZ?*VW, M,;,Q=_!%)EL6[<1$)V5A RG"A<6,/[H,4Z:4I4N7J;AVDA?H4K-JJ$36'GR. ML(>!%LE:)&N1O+T0R_.V.J]B>W(L8D?[S0=DN)O8RDMBO_M4:KMYK-%1SC+H MNW"9>#9\O7F7IDB?%?65Z>F#D)(%.1%@Q\&TC9=->>#HMHI*?REF?>SY+QU5 M>$6FT-;)BZQ;_ I$5A<-4SH%HI3 MX!XMZ;2DTY)N*[%?%RQ)1>"EEN-&[)ZNVR-(V_3:VEY]SSQ.GPF(^,%;MO)&!G9ODTK+=--^NC(_V.A.HV=%W M>DETL<2>FCABF0O6ZV("O7*N'64C"9]^X_@Z-S/+PSD+YGSMJ(-UJ 2(A_FA MSI7Q=[5THICC+V(6*/5#CBGZ(M%?O3-[)9$$,Q8C"\0K&2-IT:Q%LQ;->X0Y MTQ-GHV]V77LM'%UQE( !N#28"7_AI=69+,DWG'%=>B>[1T@5<#M<7'$#T4SV M(U%BIZ$PQ^[3>[AIAE2G=':=[.Z((H!(Q&1CX5/_CCJ(Y9UM *&\QBM'O>ZN M^S1D6=NWB_0,U9Z10,I;I671RLYHJBM%:\5I-7Q%PH)WI+LR"AO-+0SN9BI8PK MJTE)L7%YZT[VDBRFH_9I:6EI6I](Y@0&R,B<*,3("2693)_-KW3HD>%_EJ;) MR^<<+XG$W70(@VRBD=Y:K]6=5G=:W>U4=_, -0@%84E>2JT4U4H)*14C#!ED M51H4K4F%?;Q>L1<7O7QZ]S5'IO'.9D$,\FG9G2H*N$2?W3QT-=>18!K M^NGEQ@I>F:8%5+CG;KQ BIA_48;/+G&/W>(LV>OJ9 A;\1NYV.I71!KZ8H6Y M*OZMPDMQ]IT8RLS^3KDF^T)2.'X)AD2,)D#*;V*T$XN&"EYNM#&0![H+EE(% M+Z#3]T#*S['[D,QF71W ;IK9ODMF R!A"O^G9Z-G-8Q']V(:?S+I?Y)W%#Z4 M=5ME;JSZ > O?'WY8K"Y,8"N)@LK6;J*6R_#OCND)N_S(F3,^!4>743&SWB- M\V65X>F%S-I *)UD&I=5:EVG=9TVK#2S?>?,I@TKK8\?6!__!I^T777YZZCM M*JWJ+D;5/5<"I3IDJCE06_9/3MQ]AZ=4!VCMAGR[VV'H:8=A+^YH:$,>O F^ M7T,36V%H^U(+W*:!AK@:L%[M,4N)J'-0]?.@]K MHT$;#3K2H 6N%KC::- \K'E8&PW::#A3HT%'&K3 ?8H"=U=6C8+KGQR'L?G\ MY>F8W=Q@]/%53V'^/9E=%EL.)E=JM>7I)"_WL:/D"Z-K7EGAK#[\U-D)/.!=*F!\BLPU M&77,2>\IO/^GTK/Y39+'+DE5:<6IFU,RHF5$S MXV4J6FW%:2ON9,QEC2>=D64^11:[+%FE%>@GP<6)0,YD6?8_J,U0SH"X*TARJ.?0".50[*!AF-B<=:W!DLH#6S%KN MG:'>-X=JTQ [&J=K"7>=R?Q- -J!M0J]_Q4KN90 MS:'GS:':* 0 !Z-I9](?:,VLY=YW)_?-H=HTU/%" M+?$N1>*=5>O1WM6PQ)5'M1_5G'FYG'E.3*A%HV; [0SH!LG,8YDU*)A(6X-/ MT/0[20V=9B_M;-3GK4X'G5[_W OKM%[5>E4SH&; "V- K7FU8:<-.VW8Z>:E M6JUJM:H94#/@]\& 6O%JNT[;==JN>PR.&YN3CCG8?MNIUJM:KUZB7M4,J!E0 M&W9GJ'F?GIK5AITV['2+4ZU7M5[=G?SY/+9!K%70P_&8';X :B]R+3FM=;WR_;-H8KJ/Y(HYO-UY4YKM%_N%SQFQ*8 Q"ID7>)'X[O?1F>_?)>A M,:L %!81CP%'I_%+]T+8SP+/K7SG$XM@;SH+:L+[AMTQ+U@MF1\;KX,HWMZ- M]U(Y0&_@BUZ^R]C A7WE*OO*P7T%__8C'L7 6!PP!+"-8&[,&4"[LKD+8],3 MB1?;?BP:9 =)''&7(>#8-1O>#.[@[U#^&B]8:+!O*^9',$C(/. 6_Q8'@E\, MV_EGPB..#-0!:"*@<:< %8X1LXC> 4CPG=?!"* MB6DFYB(X;N+$T951BSE!Y_(X"5G4,6!_P3/<=[P$L8H#YRO@O$0$B-%39#J& M';+T#]>P(WPG"4/\C$ '( _A\Y^MZ;0S!,\3O_RSU;1 3# \S=L%;/E#(C6AT7NF=:$WH0/XPX@%:V8$W. ?7UUT9M%R[J+7K[+ MD'4/9JSA5T/HP+M@LPE9L:,RQ<@@J/,"S#HP4: 3%I^/1] MPP5S1.MLO?'UQM]*[!ME8Z_L-1KHT;9-G6[BP@[OB'VZ7'G!FI6-^MN0MCWX M$^DCTLX/5L@JD3#M89;@U@<477B1]O*<^["5.?@9L,_!2B?8!*@!/<%#8V[# MO^YL#X042!!E5#EK"@O.<,M\%I)40X*3@&$N/, ]SYB!7\#L* ES44(#D!Q1 M9A'"; &KS<@]"T!:$L-'"),-D(8V'6%^W$G/2DC8*P.EKC(T M$*A %Q!FX#BAJ(.Q7".)N$6]TP8W$E0<7QV5> MM@P@@>=S6$,88[8&CKI#*L"<(<>@-I!(+%0Z\-NQ[.\P>8Z'#(_1=T8.5SZFH MHWN':L8.!97CE%"PS;ZR.*<7_@ /@DN7ON]OKAUYAS@KT'Y)/NI=@%ZQAU!5 M#I$N%U*^"@NM5K1:T6JEL3V)AEN2V7V%70Y;$S84[56I),C>%"&=5%K"_H=% M[V;J!=6#, ;)T+OG\4($MY)X$83@:F+ QKA-N/A=;N"WUS>O0"""/ ,92,)8 ME2$5<2>>ZIID)86*5! 4Q!*BI2"?06TP3O$W^T=Z7CP3IQH(Q?X.@D2U#K9.K3LN!X. G\WP^,>8+QP0*:(>(6IF: 6$25,3HI#^$0 M?(DQ2B @P"X4?:8(*%2X"W>Q*LADN3TBD90LL\D-6BMHK:"U0F.MD)G[T=:@ M?V:5K9(0=B8>:H!$M*7I"-8K>"L+VU?,:.&,H*Z9)R"YNG+WBU&D>JDZ5R') M73I5Z61G!^P;REXZGRF8[(KMFDI% 1R=X*1OTQ/"XJ^@0&;?%AV!*O&$Z@[D M$8\CU2N"-Q1/A%2BX]E1Q,&+$^^YC$Y=\%Q'2#/?)@F;8E".QZBPDH]$Q"/. MB4!&,O(3$:IHOB[J]=3 C[1,U#)1R\3S.#3Y#?SF]P%(,) 3Q@UN8'UQ4+B@6-'O<43^ _<2M$)\V(1>N@G3J-."')9("4!& M^8,BSN:F#H_8Y?@,1O%N66&0B+)#P*8A/>\F81;2RQ(9I!,#=@W8,S+HE_C2 M1L)8'Y@NL; YLHA8Q^!SP\9[V1T,&%X)Z4%&A_*&L (%1'WS?PF0882Y'Y" M>1F,J>X\3IR9X+K2UJ#MO]]D'BN$)(SQC;$Y(OS7&N]5=O=J@H]'=0Y84XH MR9"R-(RJN5+(9&T7H.?9JPC033^55Y'[+XU[[L:+%\;$_,O&BL*/+\47!B&% M9PO!RY<*4%@6IH!4U1O^9 5J%U3VJ O4'JCP6U^%\1C,]AT*Z@,B2PWYMI:' M 4D T?_IV>A9#3_KNX1V%I5++?D$J\H/RB!7RSX.XUHM>;7DO6C)N^MN(VV_ M:OM5VZ_?-;-I*=JJ_=K3]JNV7Q^$9;%069NM6N ^38&K>5CS\*7SL#8:M-'P M\$;#]J;:6N!J@?M]"MRSNL?;W&#T:8'Y]V1V>88]&ER9?WD(RK+WOV0"V_[R\V'9K$V=+MFL=WHNTR'7L^D5?^;,:&EFU,QX-LSX M4 KXJ3>1[W6&/:O3'YS[Q8]:XFF)]UTSH[8%-3.>#3-JR:B9\7R84=N"#V4+ M3B?]SF@T>HI,IB7>94N\?6+2<_K?I<2D=1CZ(83?!U$]?9SH.SUC7<[)LA9W MCV#@:0;4#*@9\$P84#L5Y%2,>\..:1YY3ZGF*RW8M#*@94#.@9D#-@-JT M>WS3;C0TM6&GQ=JEB+7O-VM91X@?0MS]G%UY)+OT-6UKZ@?TMF: MEI:7*RTU VH&U QXW@RHO1 L*OY20LT+= T VH&U RH&5 SX$4SH#;I ,"^ MU>D-CXPK:Z;24NW\XLHG/^VH:OVB8\MG+_%N]HLH;US7=.8G<+H=D9:4^S.@ M;MBF.51SZ 5RJ'9ACH]*:YVL)=X92CS-@)H!MV3'[CTKH8ZM*WY]1S/ JM84PM,S8#;&= -$CS, M26U%P43:5M0LJEGTW%E4NS, X+#3&XPNH'>TULY:]&D&U QX80RH=:]F4M%&V^CLE^\RE&85@,(HXC'@Z#1^ M:=<%L)\87O=L7#L.<$T,X!D?P\"'SPY;LEW7<5XJ#^@M?-'+=QE;^)UOO&6S M,+'#M=$SK5''B!?,>'M]\XKJ>YBK;KJ;V/9=.W0CX_>5:\?,^"VXHK>Z9L_X MX?KF]_2/'SO&>V9'@-0/GX,5=XS)H/?CE:$\883LGPG',B(;P(XBQ@!0^!+X MQX6OA-\5S+M)Q P;?HX-F!I^@-_AI57@HW4+;$D8"_:,^[Q>-TQN,]C;GO> MVEC"3PD6'=DQH01;(T(9&: M_H8DZ!BWS(?ID."("T 2VK1TR&% QXC7H>%XL*Q\#DY)+&O&D,:.'2VR]2!2 M XH2(R2/$_,[0!VKSRI0I[?G7G /D[[)J XX .GEQ"ZRV2H,[KC+: ![B=P- M;,^7- -P&:J5,+:Y'Z^+H$ G)9I#OM4\@.@!POO B8P=LCB,(A6#,&$X6$M M([%0]@KFM)T%4C2#!!E+\'Y$GQU[A7J38,AQEFS'OO%(T " A8 -:?CF##]:P@T-,<#\[7D);G2.^?"DASW@C7@01*PQ[9?P,&*^1Y%[* M70 'O+?D(![=*^,S+KL;K%+&VX#8#X!6"8@9/X9A$$DG%GRSL $-VX<-#)1T MXE1R/$;,*C!0[V7MH6J')(ZO\,PAOT M@GQG,*%W /4[$JP1">^_,_<67TZ-'VOXXPOCAX]V&!OO?E1!19'X6LK5MYG$ M>.>#&DUR%6B\">Y]XQ/R,!AK=HP"XV4Z'@SXB0&QG$P+(FG>^2Z;HS'$ #BL MOH9A<;)?D31Q$,*RPFLN8TNJX*Z>&\9*@?LM\%?)#.2I\3- 3M1 1-.?:X:% MMQQ@AS#P/,3V':FL*,7*-FX<4'/&S]\<)F3Q#ZD([9DOI5#&1$PI<9?C_8CZ KZ.P)H0RMAEWX2N(-6+M"KJ!02)RN ! M$;1]@1Z)!QJ]:O9HU_31CX*2940CV.9K$&RIB3HK&D#PIRVX4)HA8*JZ&1-G M!C47YHT@[QKF @M-FI__$M939DU74COP@1^(Y#Q&2L4@=&Z)4,@\PGP+^5-[4<$?00;"?<[K29JD@(UK@O MUT' 'X=,FKL%3T"8*>E?"BXVKA((1EAAWY5."&"0.*GU "9*L&2Y!83TA6_ M&1"M=Q>!!Z0E@Q4)F=#&1\O80=-,R"(P3L3# E&U>P+?% ;;^ &_PPV)4R@X MD+V+#P(Y6+I_MZUF%0UF8.F#N8[T569&&P;Y*.6J90!P_TMP68I><<\>;1/B M&NQO#:;V7MD4!%GODKL' VP *I%"2Q)02H2+9LP3H!P 7F/VI[9^K:&9CJX- M36UH:D/S/ U-GTEILX^AB6]T3;!.<:,R/Q(;,-NNUDMX!51_\6=I)(ZM"1B) M[Y8HJX7?C8( +"BV7'G!FC%AK'9?V1% \5&$2%1H*HPG!*;2>,(?4. _")& M%9$E!B(J P9G%]XW$ZJI.Z.997!&!#=L1P2:R(1PT+Y 2&X#%,DHIF&I[D"S M2]/9SY&)BJ#87A1@1"A$>1J)B%0.B1LP(2Q1$*\1L J (A#/4NVDV@6>32,] M/U@_II(2 )3F&:UHB +RA]Z/AGU/2WD+>,F "*BY/Q)?*'I2O1$3AJQ $-[+ M\$.=#WP/A@#H,!O[YX>Q,(O( $897C2X0$S U)_8'?-!Y1)Y7LLGI9Y_G8TG M.61DCC96\%'#*_4*];5J+])S,@*;6B&*+A1X"/7VSP2H1L9J"OA_V#Y%IBT" M>%JK45-J()-H/:KUJ-:CYZ%'KY-;P.)036KU09,N\#PD2D5V'M4'V4G^K)#] M*/S>VCPT_D$NS*_B\$>X\%5ZT>K7Z$6KG^J,*'<,8/>3K;\FY5$\T@E5,- 5 M0RB$([7,H2@HA8T1YJ&]9/=!^!5G_@-DUX9;(MT,=&7!J;PU @I8H'B^C3H; M@VV<+KP'_>(9_3J@5 6 X]#9$REN<2"/CCHX>O8MF081L"4=V !1$S^8H?*S MA8L*7FVT 35, 89,(Z!5&N)"RU_D >[!BNIN]SD",9%61EH9:65T/LKH<\U. S!L<=Z>NQDS MYG&&Y[?HAI#8(.$54A(2R *AOSK&+(GI^36+XZ[\>*%99I_ ?+B M,UT@:Y#$+^;\&W-?/C,<<(CD*M![^+?,/,:_J]HQ-,UD_>OS).K>VO;JQ4VN M=W*3X6/@<0>4XF=@TE<>.-5_^[?_]E>'?S5-TQH->OWQ\,4KS#[X,/^H$.7: M=W^/V(=Y>CM:1,.LQ;^SH0SN_O3L+?JV[I>>.>U-AN-GY,?! Y_8_*=G'TWK M"_R#LOYS8$Z_]$WZ_.QOC[MA+W5O/E@:(7$$:FJ5)RXK=_!0]:GUI-:33?4D M1JI(X:!1#'+/97XDSINH7Q@E@U4E"E&>5>+;8$VG]G&D?)'9U_L,28J1#@5! MN8$#)2)S"&&8&OUXE)R[DJL0#'J^\M!_RW+3X'>V4M* "K M1 LRI>BHVZX.X(HLQYUL+&E(H?&0T7DN':OFA*NRR*Y]\"P]S,8(0C+=W@+9 M<[0ML_N?F4.*H52#^;@465BV+Z*<8P#*@^\S@($[A*]90XQBMJI-3%@>-%MZ M1 FPN$^/_.D8/5B*9$BY4QO02/(Z6,CXE#"&,PLZ/3C E$Z%$55GFPC2KK-H^60C;W M*"AV)5._4)B@. !O>!.T7/!*L66',MU(Z#1TRL&G)H%"*3!7.=NBR-P/LCP= M&J=!09:2AI/R="F?^"Y+D:D>722-9)&_=#+*&E%.TE#\(]R;HGIR@:YZ2XXW M^O"IUU]\O.R23R[")?^NA-2#^>FP]KBGLM6_+!==A[VU77$N6_:SJ'P3=3_" ML*CU^X3#A*ZD2)9-W;VL9$N)E8..6]I?6584Q#)!3?YR%"7+E=2&%$07V;5" M9Z)[A"J6"J]$D1H6^(E7E=1C^KM8/(<2'U!'".K>$;/0(?(V9(794@8%U;:/ M]59N$F;'HJG++0T%]%CCA(P/H?\=4#Y1;5'%2*"60.3AS)8GQ OV.:F=!=2-^"0(7\T+ M 7F7D?^:*+OYMW!&RI[&5'L:WZVGD?. (9A NQI:@9_;\EW&GGU'[H//-HY; M_@%?!.$_*/%;+1KH%!+SL+HN%L54I,NRIA.IEG>5',9(U"9L*%/E;.%6"GT: M*\W+!UTK3YP6?*4MN:$WCW\K4K9A"[MY&Y=BLG7Q5+L_- NU4+GN MC0K?_Z+NW@]X!%N4%6GY-IZ1RNIM<6B>3Q:D!A+BV'M-&\8.Z[@ M@$L &CYBX$-YXLIX%T=%T27R#LN2#C&,DMD?%%,)Y-#<4?P1X$1J8Z#%G!9S M6LPUS0PVDA@\:JI>QYK(M+@/-ZI/$F3%Z(HLK&,(W2[6.X"M7M)"9U( 49Z:1\/*O2_\ M8!?;%.&>I[23['!J2Q;B37[&!8+I0Y:6\Q]5%^K+P 963H&_/W&@'.O"78,Z@[<]VNF$64)O-N4)LK@1#P01@VWMW(O,20#W6F MPPXL,35S<62K JRB;W;:BS#S]V!CR:9M&%47KH[2XU@-G0$LPAR)Q=R4B(RC7AGO=L\L MZ #T \24./[FC-2B3UDQ6(?PEHE.R;([79Y%*Z>9K167K *&#- ,"/+K\C8( MZC-8@J*2WR4S@8D('8;:1/X4R].B\T*0C>*+0E:12$4"%+')4 VY5&^?FD%3 M%VZ")&(R#"B2D=-6CFFV0JG=SD*D41L+,!B#$+U?;YWG)*2-!]+X8$#+4MJ. ML+"^X@-3U7*^1:0WCTGG7#KJ>697U5%-QGW?8A$WP62PTJQD!!-LZ!2K$579 M0@A%X=;=5\(C71\9=BVX\ H9 @?V)ZT_CG6#16(B%]L4N=A$_U(Q31'&A4WE M0@:V/96$+H-CYQB*!AMRL;#K5-Z$$GM\,^HX,A<+)B1/$&ZDFR!O413;W9E= M=MZF_2'6N6K=W[!;?/E3FJ'7K)Y[U-/F_'=KSDN6 #F6545J$UZ;\.>V?)>Q M:U7[0I0XR6Q#D0LN;+L9-L:E&#MVP%+SI8LW641B9W:D*N;"*,O>IOS'.^9A M$9QX%=LHLQ!3M_F_1.M=/'I@PF(&9P&[,,MSABA94=DM)7^SF,D<$ZKP0O,E M+55;!CY'ZTC8^+TFPT_>Z5'7+L99<(9)XLQ)9"'8G#MX0'V_"%*$ MQ#,YVL#U(CZ(&?-A)W.%U'[5>0$WP6G8M[=8!![+.U1$ZF<2HED:R;M2,$$& MAP>+-$A"1ZX+D\=1A7[8 I- );%!=L*C72]:AS([IJ?\@MS=AH&0VT8?+>& M0=IL5>$';1AHP^#WOH:TPX2ZG\<+X!C;A=T#T.(T08:[+D#OC2/,21 -QQ@H39%+U#O ME#-,,9H29;.#H8$W3F0Q1M&M.J%&_QO=G/%"V*QOS-7-57[_@$\_XVG0-:?B)DKE"[6A4BJ?E%L4 MA;6/1(G2G-:L!7!U+T?9JCYK!ZSTG!*U:")LK5[1X+\@,KDOTU^3-.8K>WY$60>F/*$,WE2RJP1PX@PB:Z6!7WIYS)VE[;3R MS-Q21WY!%62$&7/LI=H4N-A4?GN[C;/?_%IV7_3R78;L?I,?Y/CR9J]Y>J6# MB,%$@9<=$$J+2[8M4OICQYMB%D^LQ.D)ID3A+I=Y3O(RKOHF=5?&WX-[$%BR M-$#I.I[>*BR-0+O0@(S* 9BWH@YQ3)RJ5+8'F!&1Q"T=!*Z"?&?CSMA.U:6Q MF31%Z59 M=(CQ:>5F'@HJB]X N4S"QMY<7&6 Q[(@&R(0')BKC>GL="8M+!3ELFLZ-Q;3 M*X(0=SJ6%Z[P;/Y:_1;/>N4OE.:)>>\V-NEV\Y8A+*]5)$"%?RNL/Y)NY.6Z M),AD2'B"FL4!!6?G:33]\T7'LM6ALD(1A0$0HR#R$!USJ]X[S4":V3 MC9-W_>2^FUOA=:FWCO&2 MN*O+"L]$8&=/YTRM;JQVRJ@6>P^?;#,C$"6TB X6KI3#867U5':'&O5(-'=AC"DCB;ME2U?=I =H0@N(9T32E./+L,<(67ITF7:K+\B7L 9:J 2:6KP.<(2>BV2 MM4C6(GE['9#G;75>Q?:DJ^#1?O-=O ZL967Q'[WJ=)S\UBCHYQEB(O7EXEG MP]?%XX>T"YTH[TM/'X24+,B) !O+I=V:;$I\1K=5%)I+,>MC\W3IJ,(K,F>T M3EYD;;=7(+*Z:)C2*0A.D%O+% G$#N$RZB;S@D7J96JS+J\V+Z[,!T@;#OMT ME2@*U<8.^A2QW@D%4S/$ I.!#!S,4/I%J2U.L,#N\ M($E)[X4L[7=.M[O/N>>)4V$Q'QBK=EY';^ MYH6,50"@O:LI11QE> M*,!/XZTR9%G;-HKT#!5;D4#'G&6@A2,K@#,U27$9'(E:=104AKPB$J,7= %Z M&,PH?BQSD?'2HRS\"JX&+H&@IUV0H&CLAB#%U1,CKM9?71G*V5LA[JH4NRFT M26=5^J=0*QLZ(!7J6Z5ET<+%^*HK0XNE:35\1<* 5Y2Z\:H;S2T,[F M8J6,F]^8N<2S-;J^)'M)5H]1]ZZTEC(MR"-S @-D9$X48N2$DLQ=S^97&L3( M\#]+L]+E@+ M62BC\%*&,K._4Z[)OI 4CE^"(1&C"9#RFQCMQ**A@I<;;0SD@>Z"I53! MF[STA7JE>JB'8#;KZ@!VT\SV73(; E3^#\]&SVK83RZ8-#XDTG_D[RC\*&L MVRIS8]4/ '_AZ\L7@\V- 70U65C)TE7<>AGVW2$U>9\7(6/&K_#H(C)^QOMP M+ZL,3R]DUG5!:9W2N*Q2ZSJMZ[1AI9GM.V"C0Z:: [5E__3$W7=X2G6 UF[(M[L=AIYV&/;BCH8VY,&;X/LU M-+$5AK8OM5CS\*7SL#8: MM-&@(PU:X&J!JXT&S<.:A[71H(V&,S4:=*1!"]RG*'!W9=4HN/[)<1B;SU^> MCMG-#48?7_44YM^3V66QY6!RI59;GD[RE8;<=J(.QES]?J33L_J/T46NRQ9I16G9D;-C)H9-3-> MIJ+55IRVXD[&7-9XTAE9YE-DL7 !\G!C63:='WJ#Y#-0/JHB#-H9I#+Y!#M8."869STK$&1R8+:,VLY=X9 MRCW-@)H!M>(]/\6K.51SZ'ESJ#8- <"NULE:XGUW$D\SH&9 K7+/3^5J#M4< M>MX,]/\6H.U1QZWARJ34,=+]02 M[U(DWEFU'NU=#4M<>53[4F8@^VWG6J]JO7J)>I5S8": ;5A M=X::]^FI66W8:<-.MSC5>E7KU=W)G\]C&\1:!3T7.IQ^=(]' MU<]$<$-LUI^>F<_2,43/8,LT_P+KC<]T89V#)'XQY]^8^_*9X3#/DVQ![^'? M6+=L%B:K6_DBBF,_7 M55+I,M13%8#"_. QX.@T?NE>2-99X+F5[Z0,01UO%98P7@=1O+WU; M9MKE?L%C1FL&0*Q"V-M(,^.[5SIGOWR7L8$+^\I5]I6#^PKE:<2C&!B+ X8 MMA',C3D#:%B+Q8MN/13=JT"L1=QD"CBVJX+HRJC%G*!S>9R$+.H8L+_@&>X[7H)8Q:"H M .R0I7^XAAWA.TD8XF<$.@!Y")__;$VGG2&X>?CEGZV^U>GW M38 S)%Q\6!=C"6N]B R 9Z_8:N8+6= M#XL,NHO>A,^C#N 5+1BH !]O75 M)5L&.Y6]:AN\5JC_22PK*8$-RJ#:,M 6P;G MMGR7L74_Y[K56,%< :E4L !X%"4 %*G"[HQV7$$A@BX/YG/0_2&H3Y>'='\% M?$39&]KT!^DPU7) !2@M!K0*0/6!XKPR;A+4O3"?[>,/=Z#YZ550LS NF O M5&YJ/[!P"5HS0@7#HP7JW9B4:OJ^X8*JV*HFSYYS],:_Z.6[C(U_HVSLE;U& M6RS:MJG335S8X1VQ3Y]CG8!@3; +4@)[@H3&WX5]WM@=""B2(,JJ<-84%9[AE/@M) MJB'!2< P%Q[@GF?,P!1G=I2$N2BA 4B.*+,(8;: U6;D$04@+8GA(X3)!DA# MFXYKD,0(+( ![X@WNN"YX0XD$@N5CASRZ&MW'L(J<;"?0Q3#@"+X//@C^CPT$G U>'I C#5GGKOQH\?G M+'79&'AY\=JP[^TP>XR%#H_0742G43ZGHHX>%:H9.Q14CE-"P3;[RN*<7O@# M/ A>5/J^O[EVY)#AK$#[);F%=P$ZHAY"53E$NEQ(^2HLM%K1:D6KE<;V)!IN M26;W%78Y;$W84+17I9(@>U-$45)I"?L?%KV;J1=4#\(8)$/OGL<+$4]*XD40 M@JN),1+C-N'B=[F!WU[?O/K_V_O:YK9QI-OO6[7_ >7-U$VJ:(>DWNU)JIRW MW>R=F?B)O3/UW"\IF(0D3BA20Y!VO+_^=@.D1$J4+-NR34@]-;LC2R0(H ]. M'S1 -! B\!EPH"+C,H?4A'J"PM=DTYQ4<@>AXD::6BK\#&Y#!"KDQ5^IZ_4U M:>&!D/:'N):(M4+&"5)55( BF'MC]$700Y>O"@=4O5^%C 0H8\F3FTI9T$&" M)U&9IX(('%&F/6:@N12L*([8;Z6>7*WJM8.3)8^)_I-/XB15#GJ%1V.9Q#\X M&A/C6<6OR@T>L<]0L$A2#O;S@L3+)N#6E=179L'R\"'PORAFPPQ#A J+MV]#-'H*)SM[5=6P5!-M2-SR"RB@;P" M>07R"AM[A9G2+62@YOJGZ]$/C2X'6*#1<>RFL5'\$)0QWD MF4C.L8-N7:,8T!K%SJY1_ ;3U%]B( P8EDS!@58G2#)^<7ZC#6GXQO]"C'*_! MH-E(5 J1:O\#2 CE5OTLF4709DOU^9P!9 3(ASS&ED6Y),'0&BB%5+OX60#* M8L&0<4SS[:%;.M+LH7Q\Z0[M<%53=)AU-DW1W;!4\RA3.PN@E-5M&()I]1P) M Z3P04^>CMA9G(+.P%!L]6:):S;0?^K&+"H<_VQ:#PV?!WDQ??FL*960FUJU M036@YMK@$Z'.,K>J_BL-\&=?7*;%->G 6887+5EABBYVL8@.5ON52@P>H-H%1)A8[ MS6C.))?73/.9[-V&<1C&UXJQU"B60L=+\]#FG+OSX5_#6%5?6'!.=>!9^2&?2FAN\6G9BD%TPO3$GO5Q8E^Q*/QXHK]@JE$8RH]/3DJ5PK>,3FIG M]M6:/<;[3@:]14?O.SW1>\246>$YP+:#1'V/R-*&N%V)86@D5#%Z<] ]6(%G M2DUSZSO*N9?4[[5AN_QBP_U02\Q+S<\]Z6*H?T*^E7TJ\[#39BT:WJ M5Y?T*^G7)X$L;L,@V4J$NY^$2Q@F#)N.81(-)!J>7C2L/Z.9")<(=S<)MU%I MH>T%H \JX+\CV/,U[&[[R/[I*9@WB'P@W6-V:!\Y+5Q$WS_N_2/?P'9W_GQ: MF&W3I^ M,=Y.@Y&T((&Q,6 D9B0P-@>,I 6?2@L.^BVKV^WN(\B(\P:!1P D !( &P) FE2H247/[5BV_<"T MEX0K(C8B-@(@ 9 2 D )*T>WYIU^W8).R(UDRAM=W=M4P1XJ>@NX^S#$/Y M*7V;'FL:Q:E*LGNCCB'?H[4U8DMSV9( 2 D #8;@#0+@0H>$IZ(T(C0"( $ M0 (@ 9 :#0 2=)!!5N.Y78>&%RR6$ M$D*;C5 2A;AAVAKT'6O0>N!A:^2;B?F:%]I^] 47]ZA#H6W":Q/7 NN@281) M %P/0#_.<#>(H:1*05":($T:9#E*8S4,&.Y;:[!IP=3=Z9J(\ 2 T#(#D M>PFB!%$C(4KR$"KHV%87]&&_TR;W3-QG O>5PMVO4W58PW)_>*'@R3'T]GC> M7>7BZ-([7%K^K#JY?'5![0[MOT3V!NO.00[QUEZ/ Q^"/_D@'DB M#'-8J/OP[WRLXM]U"QB;VO[GUYD\''$^/?[(DP@*E&0#I%&XX2^((/GIB(J)4ZKL6[F6!_^;@$_?2P/_F MV@.WW\-&P.B!"[Z*X9N#,]OY!O]BEOJ+V!Y\:]GJ\\';QZ:9]9Q2=G)_9C(- MAC=U!&6&LZJKH!8C00IM]#:^Z;;$JU\%IEEF?&8,X<\1^R0NDXPG-PSXL6NQ="S8I]/S=^J]&N&7!]UYRB.?)[YD_YGZ M/!7LM_A(W75HN^SEZ?E_BC]>6>P7P24TZN5%/ T\UF^[KXY8Z0J6B+^R %_? MX5!M*86 BL*7@!\?OM+SG7AXF$G!./R<,G@T_ "_PTW3.$)/!7?"0T"G\! M.\7_8FG0[5X88V7PL=_%#=1RB&H2QPGCE^"65=G8()76=Z1);45_81^-L)EP M#.&ZB4+%55U9]] "\_N80/3L?"(OHXGKTP4T,]P/8&D[SF,VRD MXUB*2K%'#&0GX!&Z/"S0!?6 ^R8!T*-_Q"[0['X\+8"W4.,HAK[*@&:B%(K! M1GJIQLV80S-X! ,8>M)+"[IXCQT;W6B_U7>=WHFLZ\BBMW/ )R5BD$=&NSI2 M*D:;SQBE\N\L5"JE=R^5TCMT'(L5V^N@>:?J6(52KR_I?P1WAS(7ZV3G)31 M:+-OG9.YB,0?E#@!MZP\6X25 I(6/]!E $\S'[M-#7TVU-W&KL+<_+>X7^ KZ6H":T,_;%#^TKE.O% MOJKZ!:R2>OT<&H+:%_HC"\&CUSU=WO9X^4KWY')#)0SS&R"V0J)>5@40_,DU M"G,9 E+5GX%X)J@#+6]T]][ LT"AY?+SOUH]S=1T;6_'$>!!=7F08D^E0#HC MU5$('BW?DN [BO, Y/:8HR: J[F/; 6789G7,)2/V"?L"37T#@OEB%5/0#OA M<%>#J:X+08U'N1UT_=-$Y'*W,A/0,J7XJ]06CE8"8@0+1WX^"8$69%ZA'D"B MQ!,Q5T#8O_ -3 ;TD;?C.(2N58(5.S)3 Q^5L8?23',1B!-]L6YH^=2"8)$, MUN%!1<"X1G:I#4KOXH70':(8O^NL6=<'EZ#T0:YC_Y:>C!H&<52@:A)#O?^K M458TKSIF'ZP)T09W5X.%WEN6@L#UOIKN00$+%*@OL":C M&"D9:1I,=06>/9?.T;PQLEH5'LH8(T()\JG4$:EY3?Q8:+)$(K[!BM542 (] MYVZG\"YP;1'I>>F\*I@2*IC+,V71! GRI?N*\6MERA&T*P^(@)O[,XNTHU>N M5PHM9'4#X;Y9^]#G ^Y!"( /XWAN?9)J6:0$,')X57 !3<"COXHK$8'+5=WS M/K\R]_/O9^7E".G:W04+/FMX9;5#?5_6B^JZ/ );J)"2+]3MT.[MKPQZ38G5 MHN+_YI&*3#NJPH.5'K7H#00)^5'RH^1'F^%'3[,1M.*^GM1I@2<=XWJ(+"A[ M'M4'[E3S6)"PW]44YE>]^*.G\'5^T6FM\(M.J_ 9D,>).DST^$A) PFP M5 LVT*E9%%^B\^-ZB@JS6KE0:W@$")F-*EWN0S1T_DN^@#(4RI>EUQ@94 V2 MS%&5=!<>J?S-I5CPB27"1_M47(IKK_&!^;J'J+J[V]<1%(C(&9$S(F?4'&=T ML6*D036X7F^?3S,N11@(7+_%:8BB#45>B=J$!%R@_9?%+K-477\CTCGG .%E MH)J3(-6QU(*=@&B&I6B/X@TLY#K.0C_G!H:9LA(5P7Q2BFCV+L*[;@TL;RL$ MO83K@M\RIJ]A [M)7R. 3J,<3U'J1&>G]@K=21DQ2!(M#DE M(KVP,SC;2S7QQQ@]2V^FXMAH?B7WN*'Y2OV)KR/,NTF#J7A+0K%<]2T':%O( MIQ+:6GPZ6;#@D6T[T N:$)EBQ%IVJSZ%3M"G]RZ>XITS.M.*P/;H8(-*PB.B M-P?=@Q7 HU/\MB,&/+6WLQ;2YK[8>)_7/B[&B1#L5[6MFGV,?.&;]7('&;+( MU"%@LJO6GEJVM?'+.N3KR->1L"*P[3C82%B1/WYB?_P;OIU%NLIX.Y*N(E=G MC*N[[5QL"ID2 DG9[S38=G"5ZAY>>T/XCX38JV[R] /3>D3N]=Z;Y_&7+=O^H_+;E MXS%O.>W\MK/.FT&]OV03,>*'_T^?W99-I^$&Z56>/Q795EU\\8KOXX..]GHU M)B4C@7'_R.[%/@+)?B)?NN]I//M=R^Z[^X@PLZB*_":!D( MF<55Y#@)C 1& B.!T4Q'2RJ.5-RC@5(91/A8YH!2"\% M$4()H08BE"8H&&:V^Y;3?N!F ?+,Q'L-Y#T"( &0'&_S'"\AE!#:;(22-(0* M'I)/)L;;.<8C !( R>4VS^420@FAS48HB4*H8+L[L/JM-GEFXKV=XST"( &0 M'&_S'"\AE!#:;(22-*1X(3&>*8S7J*-'W:/.$BH?=/PH(=-<9#8)A$2-!,#U M /3C[#(4,S6H041J< ^EWZ.\0T?PHLG&ZGVK@[;EMIK^8AWY5?*K!$ "H&$ M),]+PHZ$'0D[.KR4W"JY50(@ 7 W $B.EW0=Z3K2=<^!N)[=M^SV^FRGY%?) MKYKH5PF !$ 2=@WTO/OG9DG8D;"C(T[)KY)?O7WSY^N4 ZW5](<7"IX<0V^/ MY]U5+HXNO<.EY<^JPYD>K&\.[(.B#'UFL&/;/X&]\9I#L'.==U/;__PZDX(" MK[P Q+X+8^_[V[__[>?BAG-O+/PL%%^&IU$:^$&8I<&5.!=>E@1I(.3''UZ8 M^<+_!./G?3R99FE>\D>>1%!U>2:2\S%/YJ6SP']S\(E[4-HWUQZX_5X+&@NC M#"[X*H9O#LYLYQO\Z]I._R*V!]]:MOI\\/:QZ6@]]RQSEAG.ZV(LH/ PC*_A M#@T]>&8JX +^'L91L M"O>J&RW&)5X=)"R(H 1U6NYUG(4^&_,K&!5"1(P#C@X+(!VO&TK/9^NRZODS MDVDPO*EU6ANYGNMQD IE,JC$-(&!C[9A.^^12EU0ZD]/P$A/YAV5 S(73(HV MBYKEB@>:%_*IA.86GY:M&$0G+#^5O8\,6[$H_'BBOV"J48QG:7QR4JH4BJ63 M6HJMUJSQ)].3;#-LD-3/&^@%L>< VPX2=8UQKG777,:A_Q#8EYC6:>6][XY?T*^E7 MTJ\[#39BT:WJ5Y?T*^G7)X$LAK=)MA+A[B?A$H8)PZ9CF$0#B8:G%PWKMYH3 MX1+A[B;A-NIT.WL!Z(,*^.\(]GP-N]M^HN3U0>0#Z1ZS0_O(:>$B^OYQ[Q\\ M27B4/C!SLY$)[%U*8-\L(C7E%9[' *-#8"0P-@:,3^6 ]_W5"M?JN([5>FAZ M9C-!1HQ'C-<4,)(6)# V!HS$C 3&YH"1M.!3:<%!OV5UN]U]!!DQGMF,=Y>8 M]*/G =IJ3)K"T$]!?E^FB-@'1J$?'UCFK"P3W34FI1X!D !( *2S>YYG4M%S M.Y9M/_#T'L(5$1L1&P&0 $@ ) 2 $G:/;^TZW9L$G9$:Z;0VN[N6J8(\5/0 MW4<)#^=XZEY^2E\@9:9.3\NF<81'*()Y9'Y G_XK#?#G*$[AZBF_4>=![M': M&K&EN6Q) "0 $@";#4":A4 %#PE/1&A$: 1 B !D !( #0:@"3IH((MQW([ M34_W8Q"HB-6:$E=^]-6.NJ-?*+;<>,8[OUM$>9J(H4@2#$6GL?>]X2MP=!P1 M,>7= 4@'MA%"":$&(I2F, ^/2I-/)L9K(.,1 F Y'*;YW()H8309B.41"%N MF+8&?<<:M!YXV!KY9F*^YH6V'WW!Q3WJ4&B;\-K$M< Z:!)A$@#7 ]"/,US, M*;2B!A%I18(H0;3I$*7I#%2P8[GMK@%G1Y-W)NHC !( #0,@^5Z"*$'42(B2 M/(0*.K;5!7W8[[3)/1/WF'(,O3V>=U>Y.+KT#I>6 M/ZL.9WJPOCFP9WE\]0'MCFW_!/;&:P[!SG&6'@^#'\(_.6">",,<%NH^_#L? MJ_AWW0+&IK;_^74F#T><3X_/O;'PLU!\&9Y&:> '898&5^)<>%D2I(&0'W]X M8>8+_Q,,A_?Q9)JE"KU?AA]Y$D%-Y)E(U";O"X#WNS#VOK_]^]]^+DI_ETE MK91PYV40J3L_!-(+8YF5[F"!_^;@$_?@^=]<>^#V^]A:&&9PP5T*VF]M&VZ @813"6.[^+0A M$17'[2^;D^7VG-NKJ,@BTT)II?5!=A"5H%?G:XH+CSJX/K/@!;"D M14< WSTYR9NK NHJ>%MRVM91F1S8G>4#&;$!1OQ=>&F<_!ZH]U=.O;\R^(3$ M=A_3DF/>MK=]3,RO]P#EN=&?F4R#X4WM:-G79-X;B=;&F\\,7OL2L7,Q3<7D M4B3,'5@,Y%+/8NE8,!1Q/+K!/\#2HS'C['H,6N?F,+Z.\,6[[%*"#N0)7.+! MM?!T^!;OY'.NP_?V\,*4@VCD<#.#_\,OU752BE0R'OD@69.4!Q%X"'X9A$I0 MXE5E"K78Y\@[LN!R]F4 M69A]$"&_!I.4C6PQ/P98SXN$VI?+.F)_!%!-L.,4OBUL4&?CJBW=ZN_XU+$( M?<5Q[/*FC(C94/@MOLI-TU>F&6!EI)X+W2ALU:%0 0DW1$VB8 AZ7@^02Z 2 M]5$6=2Z>AB#!OQ,Q@;&!;7>MOEVI[3483[TTB_T=5_L6;(%WXR0*[\W!G28\ MDCB%PAZ#.9GZLAX@F@?JGXE6%W]EJ$VZF; #4R> ML!/ 5\5@6=4%^I8@F5^#\T6\J&I?A%Y>AT2 KY,(7AB%4RCKASJ9$NKB.#^M M&\=Y7V'7PIP+>0D?5H$$"R83 8!6Q0T!Z?&UOB22V63""UI;ZLQ2]>8 *N," MH15$>IJ,K5M51RTLL98P\>,C,:M=CN!2O1%J4^3\L1HM/,3QI,!T9+3W)/%C MM/G,$#\5?O+%E0CCJ;2@.5$VA$&=*7< 1"$QOL: [8*I\IOJNVPZ#5&EX A4 MPY$G/M319U>ZO%1 [^0C- ./#YY$W CP8?A,16X>U 2C.L B((W@P7AI I[P M\#I.PEE! L5&[@'QR>! ,JEN67C4T0+A@AN$BZ!.LB";>3UG+(;1LX3+%!H9 MH62[ J*RV"A$.JE\!2PXOYA[F?H2Z_/QXL/7<_;R(T^ +B^@_JGJI ^@Y$0: M>"!SH'+QE*?C&W:>9O[-*ZQW!M77I:RH?FZ/G*N1 462MP?Z &3C^_/?#QUT M2TC6V(UP1^ )]"903S\##5#7N)EA5%^FMS_G(SRGM?XYN@M6M K= K1>^ZI% M"\@;"2(/G>%5X(.AT$K3!#T*_@S>64%"PK36&\-?UZAPE'16*OD&*^$+1#0\ M@(&WN&%R@@I;JUQE^+Q:'I_F-UE,0#%0&E>R=LJ3N=N>QM/<@>"3AS D%QKG4YQ<9T'U!708 M0!\:)-1H\&%*Y.F1&Z#.O@(0J#N@"N#0 VA5KLPX2]2T!&]%E@C Y%*0$RQO6LS:<0H -)T''6!*"U0;>SR?]BB'"_,Z!L0V4J<4:7<]_S./ M=Z3Y=$?,SM,?-4U7*7?O M,)["8!)$.#NO/&2XKF6Y,RC%9\IQ&?@Z U]X;#2XB9LV-%^I/ST5+%J[6%K4 M;-%4N+*8KS/V<.&S=FFU8DNXXT1_P=3/C&=I?'*R>N6VYO6\TH)HJA]!>U9V M Z#K5CTU7/!_#K9@3TR^@U1UCS77#=&S$DG02*AB].; /5A%(IK,5J"*+6S2 M P3F!R)4^NWI-E_FG+V'NR_O Y]/*)%^5Q+I?OA9Q42VVF%)7$1<=/<-'[<= M/("]X-IMB[DM7(WJ=%[-=OO[LF MF9M$[Q,BPS$)&680P8L&6+7[V&:E5WZ@@K/=0 VPN$GCF!C^H0*PTU%(J8'+ M+L5"S&"!7Y:CY0_G@_TP,!'!5B!QBXMH0I2*4--,U)@5W]Q;I>G8?:OGNH_O M5_8K=+E/'+&]&../V?\&.X$5,RC@/D'IBSC%W7"U^SX>M.2QM?FK.2BAQ9"G M6Y@EE!'*"&6D@[<"$]=J#;J6>XMZWA&4$!<9R$7;B_[N%_1,QE@# H,$!X(# MP8'@L(-JEA!B/$((#F9$@W<%(V9,@-]S.::Y*XWX1FPB)3@0''9%,9I!_R_; M5G_0V543[Y\]7U&$<*?M>ZH/F< C[#P17*FS?&F^1NZ:IN\$A[V" ZDW5&\= MVW+L++/:G?ZNFGC_[/GT M<;==.BK/#!M_7LQ_])CSKUTR+SGM)YB2-^(\.T)-,U%#)R$:X6%>=GMMJ[V- M([?WY2A$,^SZ].$];667K/R$5JZKX&U'Z_PSCOWK( S7 F2+L\+=P@4=XF3N M@7*+JD-ADOEQAO,K0R7K[O+4^KPOVP;-G>3J18G6[+ZKCK9>[6 MG9YSY)+7(Z]W!["5Y/AKE2&ZIA9>*'@"ST_'\TJ6BZ-+5]RV];&U?B!1,O7M M)E-OIOG,<)K%I(\%DH$C\K*0IP+W]+)T+)CXX0DI63Q4?U6.M6=IPB,Y%$D" ME\?@R-0ED4CS!0E\$S\>15!E7^TT202 4PI\1U^7/!4>/BD15R+*A+KF4D1B M&*2E!TXNH::80'HRY='-D=& H/%LM/G,&,\7,&R&<1C&UW 'RR*>^0$.LVD2 MP_>@V=@PB'CD!1R&?*2^4:-Y%%Q!E<5P"*,2'J&&WWL]ZK3]^J[3.Y&,>W]E M@0S4/3!*?X?+X^1W^ ;^!M((], M7S7FP ^>EVFBB-B_>93QY(8YH(YMIZ<& M/EYS*40$5?+"S(<+@VAE%9"&<$E $95,X3\312M0'=S9IMHCF9\EV -82#I. MA":8""7L!/I^S.#*(/:AR1$^[EQ,H9A+8+&6K>MUW$RPWI=6]HD_2@/: V2( M9-XC2CK/IFUJ\E[4;+'[<=I?2N-=3/6K-:_8!^XXT5\P/=7C61J?G)2J$XIA M6JI,35Q]!W?-$$!71P[V>I?%#DJ=9PB&0R.ABM&; _=@%8F8M>2>" MSX42-[^BII%L'6HND]<[VPD?ET7<@P*Z.[M'@8CYR5+;N&TBX?:VC7) MU!2X>4)D."8APPP26/_&W]-8M?_89J5W^*""SJ!OM0?=!MC;I%%,_$Z>GY#Q M[,@PBC/,\ ?D^??%TIUNQW+[@P;8VZ113/S^T* /I1UHQOBO!GK"6$K&TS0) M+C/]SE8:XUO DSABH?Q9;YK0 MKU"^.;!GKV#J34Z.C2?:JFL.H!C^$?W+ /!&&>0^K^_#O'+[X=UVX M:-/^_/EU)@]'G$^/WV423"3E>W7 N_*R'P+IA;',$G$!//0NC+WO;__^MY^+ M.\Z]L?"S4'P9?IV=*__9%U$:# /AGZHCYT_QU.D$_HK\7P)^&81!&@@)OV43 MX5]@+69%L\!_<_")>VG@?W/M@=OO=P_P8&GDP*]B^.;@S':^P;^N[?0O8GOP MK66KSP=OJP=LY^<)9Q,8,U E?;8]AU\]7AR1/4U$&$R@E/9U>&\2?@UMNFXJ99^; :C\_B-/D^[1^=ITZSI M469-=&[%;E%5C7'HW(H[SN7HW(J[P.<32K3?E42['W[H^ KB(B./K^C3\15; M9Z#W^2L+**([<48?\S^-]@)K)A! ?<)2E_$*0]7[#MY MT)+''NZ"H\60IUN8)901R@AEI(.WDY[":@VZEGN+>MX1E! 7&N?N2WHS['OJ>6"55+)$>"*X4HP4'4F^HWCJVY=A;D&_-M/'^&90.7]]M^WZ.KD24QLD-S;C(2^]!C(7@ M0' @T;8@V@8MRQW00;$[8U"*N>VV?<\2,>6!GQ^H2I,M/^L2;&VW;;O61)/H:=OU GXXJ\LF$Y$E-*TB_SU'D1:" X$!Y)O MBX$WJ]WI[ZJ)]\^>3Q]WVZ6C\LRP\>VVMLX*+>H.A0FF1]G.+\R5++N+D^MS_NR;=#<2:X^ M%W!(L=X32X[5Z;:LCKM>YF[=Z3E'+GD]\GIW -LF.<&WF/=^1R\M?VYBDO>? M7V?R<,3Y]/C<&PL_"\67X5? ZR@"L/N??1&EP3 0_JF*^9YZ?V5! G]%?BDW MSJE.C7.!95X X-^%L??][=__]G-1]+M, B:EOET&.!+.DO@3#NC/T1#_@U_- M;F6!_^;@$_?2P/_FV@.WWQ\6K3X? MO'UL!EM/5QNFK#?#MUV,!10>AO$UW,&RB&<^4*H/9!HS93(V#"(>>0$/63 W M(AL%5U!E,1P*+X5'L!3*>1]/ICRZT734=YW>B61\C@46#]GO<'F<_ [?P-]< MLF"H[BQ?->8^BSTO2P" #/[^-X\RGMPP!YR>[?34[A*\YE*("*KDA9D/%P;1 MRBK@H?D8Z>/8+IG"?W!?BL3JX(85U1[)_"S!'L!"TG$BA'I.A)YI GT_9G!E M$/O0Y @?=RZF4,RE2%C+UO4Z7D<)SP?6&I],(>>%MI8&=)Y_^Z#*Y84:4Y1> MU&RQ^U'-E[+S%@J^6O.*?>".$_T%TPJ.9VE\DMK?1HP+&@E5C-XK2,2LE;2%*?9V:5'(N8G7WP@%T]((A=/+O[^\/D-/I&')P]/O-PD7KYE MWQ,%<@S$$ 5RB$U(Y9'*>Y:LF+;3(TE#)$1!"T+2+B")W!FY,W)G1$*-G:%O M[ZV ?)M(Q_[)(!B:03UGLWUKD4A9(JY$E(DMO,3^4%N[)IF: C=/B S')&28 M00+K7^1Y&JOV']NL]&H.5- 9]*WVH-L >YLTBHG?R?,3,IX=&49QAAG^@#S_ MOEBZT^U8;G_0 'N;-(J)WQ\:]*'3Q)LQ_JN!GC"6DO$T38++3+^SE<;PJ,DD MCI@<\T2,X] 7"243(8[8K@;4#_H+)Y0[;GXJ>5>=4.X.\'/O MX.T?03IF4/JT=#QVR[([MF7;MHZ[J .HBRTJ*=0:!W_E=_@_-A:AKR0'N[PI MGW"-AU3'V6C,?HNO] E';E\=1#W 8[6E\+($VHA!G\J9VUI@Y =C!Y$O)E$P M!%[1YW-? K?DQV%7C_16AV'CWXF8\"#"@[)=JV]7:GL-OIWFO!(8N_&T1$[@R;@EY7[3D>)4*=U6^JW^F?*[%**OS*X*KQA M,*CU)B!="_68ZX7:E#<$X<'ATR2>QHGJ GU+D,RO@?JJB\HE'*U%YL;P*L/T MA&^*'ZSUP<6%1QU\J3POY!#[)2^I M^.K)SO2O<;?F>M*Z"M[V]F[[J.R6UIY=M^X5<#+BWMJP48AG,:;SPQ^*G&-2O,"X@^3QFAY.4MKT]#4+#20FI#& MY0["=C'#2\6BVTCFLG""D:I@_IV6-.5ODD)/S+]2-5%?%+)GCL#T9$$=G2Q* MH]D7N5W2$^.#3K1@L"8&^6A@'9 G>A^JN&I#7_0#MKWQM,+O2 77WA>SVSI(GYB7F-99Y"<.$8=,Q M3.J!U,,3JX'*/A%P2\*?NTTV(A%2;Z2?#50ON)V M,I*M1+C[2;B$8<*PZ1@FT4"BP;243D2X1+AF$NX=#LKYA^<),1R>&!+_FN6N M.J+L55MGV:_\&IH#=P4\?-A9Q6:BRC4+5!1AW64P.F:!T0R&>]AI"(8"J?_X M2*+#&*""+<>U!GUG'R%F%E>1X]QE,)**(S V!HR&,:,9CI94'*FX1P.7TVI9 MK4Y['R%F%E>1XWQ(V'>H_GE$A.[I&H<9)/--M8O:>Y[UAN=_WA"^17R:^:Z%<)@ 1 $G8-]+S[YV9) MV)&P>^)MSIVVU6O9Y%>;2%KD5]?$D9\B+Y\YN8G796XM9W@]]\;"ST+Q93B[ MXWV6)/#I @M=F>UU8-OWR_:Z]9&U?AA18KF58&^F)?;V,*"-J*_4!918[HE> M@R)]8-@@H5/;F@.V'23J&N/0,9D-95-\2-B7SI;> M9P]*B>6:CR3BMP6 MQ%,8(C=G(8_2T\C_^%<63"=P2TURNN5$#7V9Z]SJ*GC;@3N=H_+ 9W=VC&3$!ABQ8#;&(Y_-:,V"!J3WL>X3 M>YUGOY0R4^Z,=FJ\^9ICK'O8H,(SHN"9M4E@=\-J-.@V--_]TL$NFFHQYVNM M/*[8]C+<=J_8IU\<36'K0 MMUJ=AYVRNW^#F.B='#\AX]F1811GF.$.R/'OBZ7)\1.]/^WII@HNG8Y"RIWA M8@Y&S!C^%T*F<.W\S:V',\'NFY:&/\&!X+!+<" IB"N'[8'5;F]!"S;3QC3D M:<@3' @.! >" PF"3U=M3$.>ACS!@>! <" X MD"#8Q,P=VVK9#\N7T6 3TXAO4E1H]R.'9HSY]_%DFL%-M%&(QO]>+001' @. M) "K9F[WK':ONZLFIA%/(Y[@0' @.! <2 ]LM$+4M=K=+2P0-=/$-.*;%!!: M'33Q&" \&!X$!P, D. M)!RA@IV.:[DNG9I$0WX?ACS!@>! <" XD"!8:>:6V[(&M^1@,]C&-.2;%$7: MCU4L,P;^+T)*QCTOFV0A3X7/?#%-A!4@E&O4PZ#N*8_O%#PY!AZ>SSOKG)Q)EVZXK:MPW4] M-LOL]6!Z/0Y2H5 "E9@FXE#!@>T\BAMO/C.E8L B^ M81-XRE@R$?G"9^=BFHK)I4A8"XIW;:>OMM'!AYY5W5TG?DQ%) 6[YI*]Z+J6 MW>JJ2U^T>U:_.[!8(N14>&EP)<(;B\5#!J#UQNR%V[+ZG;:^UH7[VFUV+1+! M@L@+,ZQ#$.&],*;A:KS*%U!$K,X[*YYJL1<]RVV[NA1[N0#)0^A<_!5L]%VD MT#/S>]5-T+Y!V\ZKT;'Z;F>YE)&(1,)#O9/0GP11(%-$^I68%U9NYE$%K[6( M9LHO(^OFLNK-@7TP&]:!GXZ/'=O^"2R(UQR"Y>(L/1X&/X1_3CB?'I\EL13\/HW9R&/TM/(_UB<-OA5CET%:.UT=Z_WV^T@5=48YUIW MS64<^@]!STHD02.ABM&; _=@%8F8M?DJY^P]C)G=!SZ5B=#]$+2*BW9EBQ:Q MT=.Q$?DU0A+Y-?)K#X;/!^'E;LTAMT9D])QD=,NF:)JR&X@AFK(3FY"T(6GS M'-(&5XI(TA )T4R=D+0+2")WMN_N;/T^3W)G1$+/.D/?WA$7^8: COV303 T M@WI^$5R*,<"#!9-I$E\)W-8C[TPF6[>U:Y*I*7#SA,AP3$*&&22PA3>('FS5 M_F.;E=X/@@H.^E:KLX7W@_9J$!.]D^,G9#P[,HSB##/< 3G^?;$T.7ZB=TJJ MN;=$?R&D?LFQ>'/KX4RP^Z:EX4]P(#CL$AQ("N+*87M@M=N4#XN&_#X,>8(# MP8'@0' @0;#2S$['MKIV:U=M3$.^21&A^P80S<&(&8/^4Y9$09HE0IWH,PQ^ MX.=GW/ACCGV) P@.!(==@@.I0%2![;[5Z[1WU<8TY&G($QP(#@0'@@,)@DW, MW+&MEOVH.2EIQ._JB*=]0F:.^??Q9)K!3;11B,;_7BT$$1P(#B0 JV9N]ZQV MK[NK)J813R.>X$!P(#@0'$@/;+1"U+7:W2TL$#73Q#3BFQ006ATTW*7S\LP8 M]U^&P\ 3VPP)[8=UB06>8)6@$<<8$FJ:B1JS#L#<6V'9MYS!%K:?W^95]NN M2V((DAH$"9(:A!J2&B0U2&H00]#.)L+(! <# )#B0SNB)7)%6PE.DV@(% \4%4J\# _SBY#8:JP-,-G;"'3[RU&OY,H M?"[#DRZ$"KI=Q^KWG,?W#-2M M3B08=MPWE()1KU,.@[BF/[Q0\.08>GL\[ZYR<29=6OZLVIL3VIL#^Z HXSKP MT_&Q8]L_07?C-8?0S7&6'@^#'$_.6">",/<*NH^_#L?-/AW771OTZ[_^74F M#T><3X_/DG@*X^WF+.11>AKY'XMSGBX +>_"V/O^]N]_^[FX^G.4\F@40"FG M4HI4?@BD%\8R2\3LCC$O>&8IC..UIW:,$RVE%4T9M_">,BY%,)XZ3XM.&@ MUJ9A-;9AN7'FG5]49)&UH+3293-6++O!V8/0%=8-K#I:+6XYZJ#_S(L[Q![* M*U]\5:*R)Z=.DHS8 ".>>L!\,E#;..,A M Z8#NA5>FO&0%21Y'S/OA.M;<=O6X;>>ELMJ_,],IL'PIA:X&\FOZW&0"H4J MJ,0T 89'*+"=5V6--Y\9%/,E8O_F4<:3&^9V84H#"L9BZ5@P3*+"HQO&D4\2 MX:LO5?,D%*G^2A/N"VCX=_;/7T[_\_[+X;\^GOYR\2_&);L&TL'_XF41GPC= MV'_T7=<^04I*(H42X*2/-X+] 5='N"']VYZ.@\0'7P34=\0NH(QIEGAC+@4+(B_,?+B$ M0WUUZ^ I01H*2VV"#["N0J;P0?V=MWSV8"LO ;J;O>2OYIV$5R9B%$C,0X-W M9O"TRJW0L,M7ZKFC./:O ]5A,L8M^%"?ZR =+UWOZ>OAD?$$*IC$-SQ, R%U M77T^X2/ $?24X$-\KI$%B?0\!LE-569T)HIN(.EED#Q_JM2-^ %$NX?J@)D M:B&Y2!#4^F'#3*5=#J)A FT7J+0E/FL22#Z=@I])]*L$$IW0PH/P_I?BE7[+ M !X8HW%55\\\U33W5$5EXNL(.@7*]T(.@\5GES>J5(FW)/B#F%S&?B#09-7G M'0&JF/@!]H9ZJN; SU+,K5T"^Y0'?KG<%QW;LFT;R_2X'!\934CD3XPVGQG^ MY/3\/6MU[,.6?>C:S!=#^$4RCI]$)(,KI(QB[HU\)U)T$\#6,S^S]#M2+P-% MF^EWD^!/P*@WQIN =0(@"3_&YL:IXA#-TCAQOQ+AS8QW=5F767&1(K@QJ&CV M4DWWL^FKTG7P&V#_"LK7["2U5XDO4QY$2/;<\]!AY2RJ;M*NI: 27T#738)( MN1^>ZLM6MG$B]!6JPV;B?5VW59\&U8'!@XXC)[@9=0'Y(SG?VLM\QM08"<$F MYG_R42(4OQ\!H5;8TH,"$X$PPV]A[(HDO,$[JS)AQL3PT+Q]:!CHDRB&#@*V M]V+T+[..!!?&H<670D3(]U(&0R1V; &RP&'Q9AI6?JD=<52N8R$,G-Z)!)() M>>0!N8\%-CAEYV*:@M\ HF_96OM4>U4Y97'%0X">1I%,>9K->BJO+79Y '<$ MB>[I"/14""U$=QB#DQPFXJ\,?H&O@B&[YDG"T53D3YZ^RDPD!"R7/% M9D#Y&)Z5&2ABY.>"M>9*&B1IY 53X)M\^.8B#V\%CI&E2WV@_C!6\>,E_:ID MJY:L^?B?D6HN2HO:Y4H4IDF11'\41TJ+0BW_S"+U]_R)=56O:M.19@WTA2DZ MK'BJW41=%\7E,N$VY<^*.0^'OU+="QU;.PDYYB#N9PX@GDR@V/PQPTHM7DHA MV&\QT&'_U5H":_9RP08+ .7U@C/M1.5%?*IMO7C_TFJ!VUJU6M KK1;T#L!M M!OJ*_YQ_. #@><&$AQ);^M8N+6_<5H%R;;_J:>\9SGK'.8;,:S#:?&80RX=,*'&/X6J,WA3+ ;@0 M$$"E$I&'M*5:*P@FEUDBX7?Q8RHB*;32!S&,?Q6Q)R]+4.G#YTLQYN$0]+%5 M')>384EAS%7,)Z[(YLL;B_T:@/X6(?O$KP(YME:&*=Z/ S%D'W\(+\,8%M.9 MRQ*KO*ZBYQ]*H6,,2R121RZX?X4A#JAZ@A$9"65 =2T5-IFM95P"D:B)!E8; MKE/+!!'#M9S(5U$>$/W+L1%U_0?AY=\ZZMM>=9(RYCY[X=A]J[C^A=/N6DZK M914+#RHJ9ZEGJB62BDD,GE'<0727M?IYR82X9RF]P38SS M.Q9^/GB%(8HKG@1QAIM7KH1,XR+2,EM.G2:85SZOQJJBV#67[(5SA!MR,'"# M=;?4QA'?N;U7QE/4MRT9.F=GT%4ZJ[**OA"V2_LHVZI9K23 MASPQL?HFK*[>!X O&0RM="P9C%LD@<58\T)4&]!B)B&,>7PWR;^# +0W@.P&ND-^$@=:H=@KCWLLS+\+=BX5YG!4$0 M Q #$ ,\NA9_MS-:G(:8S8\B]$U!M];H">+M?.;3[=>K>]Z=924?>?;LU:6IFQ+#_@,68LW<>=L8!XH1D+D>?S MF\\,\GR,&4NG9_6ZBQ.6&O;:QH2EU[/L-LU7:/PWSGQFC/\O$?LMOLH'>=T8 MQYV!4&Y^-,)L**+/ESRL'9-MJ]7N67VWM\IKJ]=K+D487[_2 B1_2!YTS5]C MNE+B)01@JS>44NC;D5#[_'*O/]=E M^H5P%C]<)B!M8#%'H+P=RUH6NM%M=H M(?7VU0J>8:<> !]WWZ!F"283X>,!!^$-&"Z$9A84NT$[J[TOAD-H6=[YU=:H M,P6R%$14I YFF%?M@6WL6H.^8PU:_97F$S^*TR *V8=O'&>1$FLS7_ JKSWN M[ES$V!$#X)U"X\,5!W(,@U"]!?8>5?8P\')H?0P#?)FV^E;9N? 2D>*[8861 MT_SR#R+DUTH5X\5^PF>6F._3+#]"ZILDC&W]#/52,RAT?AD&2Z^(H'H5JG4*_MYJ.6_"'Y0_*'S=C]\EXS*FU]H>':2/.9,5R?0[YB4*K8 M/O#"/K)MIQQ^ [W :W4.):B MJ(>>*F.D4AT64R.18^:!F.'P<"Y*RHX.GL! %?A=[T 2G+ MR";%O4!4&,C(H$'UN!SX?L)QW-3,'B8>>-Y%4L[ MM5778_20J[.W$CD.IF@D#\KB(U&<;5#W_I)ZZ2C0YY+)[/+/_+2Q><-!) MU M>$$1VUWN"'5T#O9!/J$1/ D#/.AKR%X&K]BO_"8WP,""+^ ;U1 <;L6IE M?D=@A.JXGC% >H@/RIO"7G9^>E6(TGSGC#K?H7;ZL*K%U3$ LA*J5%>G%;.& MA2,6X"K0M9<"#WEC(9X@ITX^4\>J7>4G_.#7ZHP>A/OL++UYS\\./"-A2YYR M^^8SU2D^F8;]0Q_R)$F_[M*HO <0-AO)1IF_.<:^S_F$X)4GDU)$K,Z?YT>T MZ4,$47@%$EVXCEC*XZ:S,PWC[3K74G]ZZL2Q>4?5O#-=U.P.+TOCN\?YF\@] M?#6Z8E'X\41_P52C5!#_Y&3U:]QU67*K:8A4!?/O]&NRY6^2XAW5^5>J)NJ+ MXE7:.0+3DX4W;D\67[>=?9';)3VAU#B[,4CJ$R8]&MBX'5Z)M<"VU]1^>)\1P>&*(F,T%?=\^ DEO M#O)WEV>7CBY[&.4:CTS7+& 2)3^="MX9C#N$<<+XKF.\^_@@IP3B]T2I:PWZ M+:O;[>X[2(F(B8@?./\;JG], ;XY8#>#??^I\]\\C#L)0K0>]N3K801 B ! ML($ I%D-5/"0\$2$9@*A[>Y2D3FH-(/2/L7)4 3XYLSZ9?4="[68 R,B-P(@ M 9 :!8 :;KP\.D"X8D(K7G3!9K$[O-TX>./::#Q^<#I L&(R(V"NP1 B ! MD*8+JH(O6T[7:CE]@E43>';86I\T*D>PI/.E-L.=]);<>UWZ_T2#6D18N3]8>32O/"U.N*WIA9>*'@"ST_' M\TJN.$"8+KWM4CHXVX1AN-&0:KSYS'#EGR/V;QYE>%)]'CF(9CG1BPB"\(NC MZJ7*"I-'3E?FXL1D.[,;5,ZD4BA"E8!9FZI)F_+$F$5RFD1X(L L-"\QD:G.*+,-<01Q!%K M.WN6*78>7RP/PWB(:5^C3._G(F M-Z'*/-9PS'JVR'3CD7N*P9U4A&P/67\970=#:G_V&68.;L$MGG9+3H#5 "5AD( MTY&+_!D+7'4K.8%71Q<+M*W2-=Z9PJIE-]K"V%,]U^JW^Z5> MU^E-9UT'7 D]?[W*C2ZFR.2ORJ 9J)24EZ\0-ND-\_E-D45?2@&O.QH/)^L=_(QI[0SRM#KJK!>JW//YN)R)GE_B8'8 M9C)7WE'GIDMS_A@Z'/ ?AK.).D<1ZV?S7,DA2E'H.7%3U#%_0"6&4,_&)1^@ M>[!&7'95%F?[WGSW25PFJK>=O+=74C:Y0%OLK3#@@]/7_/>D!!NME]UW%. MU#@%C:=Z\E!G-"]_E7MX&.V!IP:G8D$.8]T/AOA5'@FHTA*,7A@=P"SC.$-2 M@]\2421%AU\+AUX,I8)A\MM0%'#5G?KOZR#5(F.N'U.5\]TKU]2+98JA0/@^ MK] (Q^>ATBI#'A2)YNN?.0TSG7,[B+Q$=2/\5+FAKLGJWB/VGPC5;MZ]5AZO M#+TLG$G;^I)A@GO),2I;2+(?F'.]N'ZYSM@E+W4]A/\JK_FL!-!+"9K?"Q(O MFV Z9 P*5FJOB*"CB'>ATT;_5^/]$("H4 MA'.;KY]C+?L;W>DJZL39NQ#X\?#< ]>*QIZJ<8SN#!\!=A(ARR1^UII&.3II M6L#GG%NG%V6$5;TO:*Y^7 MUR4YAD&=YHH2[HP!G?,C,!K=?69/T4B;&6T^,X*&IVI,U^T_+T\6Q]Q?FIG- M=H.Q.$O1[^,&JMNFV:@F*E-MI? XTWMTQ)RK:R=H[9:U?*6>A.&SPV"HKK2/ M.NQ&\$0O)L\K#=-@\-@R\.9BZ$7+:G<=J]V!DBO>5=<.KYLI.>5N2BL2BG<7 MRP3^+02@)F 5- M4@!7%^*5(KS&TI'0E3[Z+M*K,,A24X0TVI])/Q>KZ$=Z==PCJC&ESA;!!\,2_6K^2QT;:BH;:A^4K]F>>6GW64VIX] M>PM!O3A0U"Q_C0":%_*IA.86GY:M&$0G+,]4U[-_6K H_'BBOV"J48QG:7QR M4JH4OH%0JE+=J\1T=!6=P/%D)W#0J0?TXHV1+]X AJ&14,7HS8%[L +/='K, MK6] YEZ27H'<;%*G(ED/>_^1*)1KG&(],U"YA$R<][((B1&'<(XX3Q7<=X]_%!3N?;W!.EKN6XG5L/ M%-T#D!(1$Q$_3CV>6B"$$D(-1"A--QX^W2"? M3(S7O.G&HT^"]S1/G1F4=I^==G5':I4.RC)HB^F>0I.VE39Q?S\EM27D$_() M^33IVL+K+CWC7GON.PIV'>7<>OFA*6\NMOC88(F\;#1/'PG7),R M)N03\@GY-"? )/#\=SRNYXH1J MNO2V2^ED=A.&X49#JO'F,\.55Q(=Y[&#WD*BXW*N7PY/CHJ,F;Q("(P)F6;I MA.<)O(L21OK0#KA9Y]C$9'J6V]'Y=ZOYD752DR/6S7\MTDKJ[XND3M6\DR_: M_:YE]VQV)50R\%*N26N6WFB>S*E(_%N4F=\%N 4*OLF36UZ+\&J6>%'E;?HK MXTF*&90PG5.05V4Y6^@LXV6>H:E459[J1$M0(\R3QZ&7$C&-$]67.C.C3OU4 MU$QG((X.,0&I2HYIZ13B*MWI4A:KQ73DV/+K( R+G,5%ZBJ517J6RU0EZ3MB M.EO7TN&8R\FZ2BDWEQN/U>AV^E:KWUI*2HG=C'_"-?VJ!8[8A[LEO*S6JE0C M#:*E>DF=D&O0MMS60%=,9W->J%>[4T5&)6\7]!;6IKB\R I==-VJ6LZ!/L,P M)L >9IC[.H<>6JH4K:-<6^2VR&W=YK;F7/5T7JNWUF>Y=_%9+<>UW%YG0Y_5 MV#'TSLL*T\%G&<-9FNS!JNDB:N)]"&NS^WXWJ_TR*N05S'&?,9XE7_S*,.4<&ZW;K17G4I4=N)O"1(@YM8'F\#+@,$PV?AW!99_E$*PW^)4L.ZK M(_89R27Z,XL\133J\7AUG9^S5KBU2FZ[G)"J#9CEV2WYP(*GYJEW]7UECUC) MIW5^B1\EN2VRA\<6*0CL'AZBIBYZLZ*5I7O>&K1.K* M"G#9BW9[8/6[K>H<1?G@PW4^^$A9I:H H"D/$P&J?XNB^ 1_0X>XV?1IE[U^ MQQU8+;>UZ/477;W1U$Z>V6CSF>.9,Y"VP-K-)I=QI%.LPJ"5 M0^X5!50,<3X5'C@-CX=8IZK24,]7GJA: U](&""Y_XIDFF25LD^]_[D*_HN M 9]3-R^O41'J*0B@D::8A;(D>)C7X#\$*H9ACAH8IH OU>]7@50@*/QD/$RO MT2W"D$BQDVZ?%]Y?4S@ML''_'IIB?96J70[F667P:U ?: 843U !&'B7:N;* MW@F/9W*Q)"Q[14E!;4%63?CC*<0/*D1/A")1(H"G:1)<9JH*.BZB0RB_\HB/ M%$WH89IGH$8@3.!&U<7 !M#Q4RTF@@G>!LVOZ9=Y7^RVPNKVK%Y_26 Y)+!( M8#7$?&8(K-4,7@DPYEZC1&XXW&YW$58A*O1@+C-,'YYT%>-:H7*"J&MKV:#L'\ M8Y2/FE8N6><:-HMR35^,]-)A OFX+32(OS@IZ/3;5K_=U1IC[KMS1267RT:U M@OI#@&");X10*O\^>R3FC0*M#4)#!MZ\7C4M07%7VV5*=;YPK+[;LGH=>R6A M,+4354U#],;1-P?V+#NXSF\%LN,GL!Q>$T$D^;VB^4G]Z*J(V[RA->\4>?,5^ M1I?')2:E2N/_^ MI)8IJS6CDX3I:*^G.,R0SI&CUTZ,?.TDQ7@EJM'HS8%[L +/=!#GK>__Y5Z2 M7@#<[(@"M4;RL+?_B'*)Z)4A?WC5G=;G??04I$3$3\P/D? M95'?YRG?/_6F\(=Q)T&(UL,:F-R+ $@ ) #2F964/,YH/!&A[4WRN#U%I1F4 M]BE.AB)(L]N6U7^!N(@(1R:T&1F?I#65"*"'40(32C %G#$Z[>VLZ7'+-I.^> M>,9 297W&5%U%;SU8(^:4RBY.B-ZEGMJ+4Z;%2+94WC2FV#/^TIN/:[].,.# M]PH%J;%)"I*03\C?4^33W.F>T'6MCNM8K?;Z)1K2(L3(^\/(M<>)+]3""P5/ MX/GI>%[)%0<(TZ6W75K^W/"CY.][*OR*H^7Q\,=WF#6DG'Y2%?U%G]5_FA]" M?H%U67/&_SYAOGKO=Z##Y2@J[52?*KQD.C;?5WGJEC3Q,J0OH''G:@$/K MB)M/*6CMAJ8/1DX?Z!SY[<1QZ!SY.RTWT3GR1+G[2KF-VOO[& =HTCGR3>%9 M.D>^BDPZ1YXH>=_MDFH(EIKWO&09LV4S4&E&<1& MI\DW'$9$;@1 B !T"P TJ1A1*?)$Z$90FB-6E_8T\V49E#:ELZ6)! 1M34P MP$MO+1!"":$&(I2F&P^?;I!/)L9KWG3CT2?!>WK:CAF4=I^==G4'4\99*E,> MH04-VF*ZI]"D;:5-W-]/1_,1\@GYA'R:=&WA=9>><:^[D!8A1MZ;5USV%.R[ MR[AUGUSSQ\R>H4Q?DY^@, MAFKL_S.)I5Q,8=!S^XLI#'JE% :];VY'??[V[RR\P0]YT;^J:6LFL9YG(8]^ MXQ-Q^B.0!RR+ EV25$>C'C 8Y 'PDWQS\/FW3P=O'25-2EVV_48N]>'E[<5? MKBC^=R%3X?^687-SJRYW8JOSQ)WH=I;[<,N-W'XG%C;ZQ(/D=QYFPEGNR.YC M=>1_SC^4>]$^>-MN#P;M;??AP:$/H!%=/FGD?_QQU1X\/$BQJ^^S#=HG(Y&B1CQ5'R.TB2(9. I^RYW M_R*AGLHOT3P7S%:@Z[3:@WYK>QQZ[]8OF4!^EC*#9R2!)V DJ.^6NV@Q; M=?YW"Z-LL=[ESO@XF8;QC1#G(KF"_JK'VF]Q=*5!A,7)BSCE8?GW][%,?XO3 M_Q70;"\>13!A\,MB:+FCW,KSR*GJ2A3^X..NWM(NY^ N\1J?\]6@3F M[J"BSQ(Q%$F2]WAYJ/]GBJ;!"R6FA%KHI+Z]Z#,1;8[SS6YAY_2^ 20"(=]5 MRR]WT7D*W(@U?Q]R*?,\99OU5W?0=P:M_KS#[M&@:G],)D&*=9' Z' -.FT1 M>=" #X'TPEAFR>J<9OW6XL#;,*?9ZIQ&RVF6%N;W^9>;9%NJC884QU0N3_Y8 M/ON;S^Z*BBR&>Z"TTF6SR%4^0ZP^"-,Z'=1,#N>W%1<>=3 ]U$(H"DM:C$9- M'SO]6DVD:;\BF8.C]M OF4CADH M6(PQ0%=#?WEC>!+:05KP-"_,5&?A0_77T%;0_E"E,+X^,AKA1%!&F\\,@OH2 M(='P2Z0/G,\SMZNS)5GE@0Q#T!/!%8PK#A)6S;=A3CI!&AI"E>';(3 ,##X8 MY#(+4QZIT5HN 2A/C/10A:&.OY2NO082B:^Q^"DPRP^8ZZ8"ZO+"&;BXDP!+ MQY[ &(N$N@"1P 3WB$'E_\VC##,[NX-B-V3YH<,@5'4.^;7,@I3Q$0\BN?1X M; <29R)"CN0!S0O20,SH\S\P'X>OU8Q=,I@2ITD ?/0>Z#15=<.+SJ$+QR*) MYK\#>[X'G, %4<#9R_<W^(@Y_?>_N[9]^,?A_SU__PH:)KYCQ\#@"3F, MGCC!_@X#,6080$T4P7$?^!9_&0JA^3^^CH $Q\$4:@E6%]"L*ONJ_OF5)\"8 MW7+G;-)PW7'@+[#HPM.4.F_F$8K*%ZBHM91ZSD;-W*!1Z%*G/,%JUC,%^%0) M;@IJ$]Y4KVCT2)1P"W8Z-A9_S](9 (-$6281:=Y^!24<-'#A))#H5)6G!/[_ M$QRB!_X\8J?9"-AI-C)6.D/6_$7RNP6HMADPG05OU\1,'=MMN\ZV@\]/LTJV MHGU/&G/&_FLOQ9SONP1Y<1W?>PFR\[1QZ*?IV0UW&FS0LS =N?_RKI$;$&[I MV\[BJ*^/?'][/W.YY>Z["%+<]_,9YGM7@9_Q$#OR&XS(_\E0-@359:#[4T;G MB9=7'FEM^>/\-1?][&5SW+("^+QFZ-6QRQ-TT]./BM9FZT$$W*+'NHN;F!: MNWTP.NXSHM$+OL.SG6[;;?4ZQ] XT+/C+\D9J/K\CU/OKRR0 9;\SSCV_PC" M4'V%DXF%SNLN+U??!K?E=7WHB =5ZA%:M>2VBU;U2JWJK=_TT^FV.NXVVN:+ MX/A#[&5H]8N;J5BH;@\JO.$:L&,?_L_/KQ?+*YYQ"E_X^.6GD(^6'[*T3VW% M0X;0 T(_I5+B8E/TUI6/D?\!@YI+CUO:Z+KBZ_! ]AWGL.,\'($])BGR/O M2%>I[HG5VKR'"B<\!,4-&?0OD<<@]F/+C@@.0F"JV MW >5YRST/LSI\^WMVA.7]@XNUVB1#8O=-H,-I40;K#EH+QAH30VJ=?TX$1C> M'?TSB:_3\6Q!9[&2FW)@FF2B7)':XA=J\ ,G89J@:S8*JL??@QU7%5Y]^#ET M9/@N7S):?NZF-+G8[$JQ-1XTUVE_\$1MV/\C2,:_2F>Y28MCOKO<0@8" '<96F^ M>"DJ'C7)_#6(;NV$:59M.^HZI[3W[RZ-W%[GU.U^W,2ZV^BVVSIG\-R=4[N? M_SZ=\S60WS\E K?0J\60KT M#^PA&#KN4?\!7?3C,@F#8RQ?-1QG'?.O)_J& MMX&,VZ[3.X9??WY=_0FN?3TOHZ;$G)*7"]5_Z9_O7*KJAU5EXH]W+K'*3O,+ M5!A)5&\ SR'4FM<#NJJF#/SZ@XCB21#5%[YYERT4\WJQ+0M]$0;1]^-A'*>X MW>(7^(/]4%\E,:X:C=-T>OSZ]?7U]1'>=A0GH]>N;;=>X\^O\<*#_/H4$/OF M0.1.]("]+CT+___M_P=02P,$% @ )*-M35\--B@="@ &V, !H !C M:6LP,# Q-C0R,S:;+O X;"@)=KF5:*\))78>[C_?D-*LO5&F;+3>''REU86 M9X8SSR,..53$-S_/P\!ZP(R3B)[UW(-^S\+4BWQ")V>]6(SMU[V?W_[U+V]^ ML.V/F&*&!/:MT<*Z0 +=,^1]XYFV-3CH6_"?>V3?1 \X'&%F'_;=U]8_^T>G M@]>G_5?_LOYS_NF_EFT]/CX>^&! * ,'7A3:MNR$>U,<(DL@-L'B!H68SY"' MSWI3(6:GCB/5)C%B/O0VQ2@04ZGJR$[Z)P/I>8!#3,6'B(47>(SB0)SU?H]1 M0,8$^ST+0J7\U"/?^OV^^_+H80XSL3G%?G4NGMR/*BP:[OU[GG(BY/4%HMA0?(SY2HFF# L[NN_; 7>(>Q52P1=$1CKV# M2?3@I(U2[55)+68,GDB=7MI:H^AC4J\##37NX;DWK9>7+34*A#Y@+NI5DC:I M-"@J440\7J^CFFKBX,2K5X &*>X6Q8$ L9AA7DN-:JF)A8L9TW0"+34*/IXQ M[,EDH'UB3AS$/!8%&#SPA(WGLP!1)"*V^ "_EX!$E,9AO1%?,$=Z[("0#5*8 M$6^IMUZIJ,"9J$("-_/!R1R$*(T@,T$:4+]F,T+'D;R48_!4QG,/UBUY\JD9Q& L%%BV;F/QX02Y9H+20<2:::7 MOP0;5F+$REEYXY1-9%9CCOTA?:NN@50.-I2&'.ZI5BI2I[$R:";OH<"+ WT' M3@'F[7!_'U$?4S -%SP*B"^?UW5-6:LM*C.VIJ(/X%D$B%U,L"/AERDM124/28!.2K!<%VS_N24MQ6B+)A^/A M3"X(0;-I(&D4-&0=F9&U,FI%8VME=D]3&?7A^$Y$WK=I%/BP3K_\/8:)P82M M6CT-:<P]7*3(2:M6LIL%TD: ML@FBY _5&:ROWL6<4,QY.?^M%]-0\DHNX CW@HC'#,./O"4+P8HNL]7Q7'<7 MAR%B"TA.9$*AK/<0+)H]53T2.KF%A]LR):DYE;M6!JV512LS MV45BOF /2KL'(G>"SCW(YIRLRAM=HP;ZDS+TB?X7I6_E#'01Z"OZ ,%$;/F8 MYV_4 ^KVRX#F=+J(X2V+((N*A2RWX6&:R5GN!HL$3UVC!ENWC&VFK]+VTL)/ M%L6BBUCGANMP?$4%#@(8S3$*,IP2U->+:? _+..?LR1S==[6DILN$O$9!W)= M!V6M6-PS1#GR1-=!%M7I,%^)J%N/MR\X6X M]2*[ZN3^G1G^]V@4M&,LU=#P5:EEV_"5F.XD6YHB*4]/LXB&CTHAJZNF.HU^ MKB+*(UZ]K4&Y4K/F-#L-K*:9E<0=& MVZPAP.BM>K>G%RVF[AK,=07%H%IN-X'>T6)""VMQ%V2=E(:"ZDOT1@JZG'(: M_GRDCA%S<0TUE7*[\6]/_N\XDO_(+Z$_X[&EOG,^E5]OGO4X"6>!_(A9W9LR M/#[K%3[=MK-OLW^#V [F89#)RBX:OF-6))?A2#W(3*1?KC9_D U&U"H*6'&R M*'J6\Y21 0=M(RO2]B>-*T"CMG&!"@[^Q"'!X]\VI-*(>>+ G-RWRT[QJV:( M*F+"HK4G+.A.$T@.9[B./&6F047^LC,]6]ZRW4-[X![,N9_ZUL*!553M',CT M6CI0?SR"8=>9@NSSV*2WQF,3-)VJ#FL5'1P(GMVQ5Z:,XVXXOJ#)F1JU]-I> MF6CM1-V1$"9>Y/6R'_;*2'L_ZHZ8,'(DK[C\M8TKE9,HZMS@6BUUM?;;#Z)*ELM:=$=+&/F1J:4N "_ MZGM/3[E2W3@G+P2.)2%6,]"J=193[!8+G:5 M%*PJ2>3?*ST_9NEA-90$@?S3ODQ65L"%!?%O9O[P&"Z)B.7=CRR*9YES!-RJ MC?.3.E%,UMCYK0NL-BYDS>,1L8MP6[GU5%%G.S_*?#':,((\B]BB+MXQ"GAM MP,EB76P>;\FA-7$FUZ/DO!7H@&%?:M6$?PL5%X9U4]+9N0>BR7N2"PQB_@5Y M(#ZF_A- T(9S8Z_:X>#CD08&U<\5YS$8C^73?*L\_X*"&']%C %W_'*.F4ZI14K)D,D^TA^YEZ ?H\C_"LZK6^S9QTEK[YX*EG>($SX(-A1 +G>-P]A-\NC)UD!94;.YX0_9[U7[%?CMR].?0+.JJ&R+H(+ M-6J?=2B7NVX//RQ@_I$=K*TRVW"F5G,[R$OK7&D?W-_C8"%W7G87D\:#C>9% M'@>RN-_-/%CJ?/-Q_A63R10R]CG,K&B"/V/I.(SS:S+&Q?&?>?C=\U>S2YN' M>D5E!N/$4S7T,Y>K&Z_B>6C,!RO9H%9M1K[SC.0UH<-$F')U%T\^C\S"R[E()H&MHVNQ0V?JT?:Q?B5BJ@SZV%<0*@(NH$S;9;Q-7IG$["1[ M]6__!U!+ P04 " DHVU-*H:_(C<) #9? '@ &-I:S P,#$V-#(S M-S4M,C Q.# Y,S!?8V%L+GAM;.5=47/B.!)^OZK[#QS[[ #)[,XDM=DM$I(I MJI) D>SN55U=30F[ 5ULB95DDMS5_O>5#&0PR++LX;#,/L$PZG9_^EJMEM16 M?OSY-0H;"V <4W+9[)RTFPT@/@TPF5XV8S'Q/C5__NGO?_OQ'Y[W&0@P)"!H MC-\:/230$T/^,U]+-\Y.V@WYT?G@/= %1&-@WFF[\ZGQK_:'B[-/%^V/_V[\ MKWO_1\-KO+R\G 12@4@4G/@T\CSUD!"3YS'BT)!&$7[9G DQOVBU5//7,0M/ M*)NV3MOML]:Z87/9\N*5XU3KE[-UVT[KG_=WC_X,(N1AP@4B_E6>?DE0=-U0>,AC"" M22-Y_(5XF\-ED^-H'BJSD]]F#":731\_MR6\'SZ:743^%91HC%DB ,T"AF"E:6JI9RT9? MZ_]I^Z-T%8B "#Z8#.;*":65^P"1I?A@:*X1G]V&]&7?8#;T[@O+K^ +RA98 MC?6N_WLLOZC>ZH% ."QH?YZN?=G<)PO9'Y1AX*7LU,GOR[8AH]+CQ%N7!#>R M!^:*N0<0I>S,TY78[*/0C\/$Q>^DA2G;X56 =*E@;;W2NJ_8D$1VZJ>>%ZI8 M2EFZLU:/2P+F!/%Q$C5C[DT1FK=4W[4@%'S]2]*;7KNS"I[?K7[^TN4\B4A+ MS2$:0Y@\[\MV@U8EAEW'C$EVE+4;,7RN37W>(2T\_JQ8M'D=1 MHLW#,F:LY2>,1OJ^6CV0&BV-N7PTG2NU*&PV* N R9Q"IA0O@*O[-);6 MCL ':?DX!!G=+$:24YVH^SA\<&>W=YR+#<#TI'UPB18;?@9@!6\)\H,0OR%*V @=HL^,K M&X*3\6R=60]E1BNVTFLC;28QI\DR&>YDX.L3@<@4R]EQY5,@;E[],%9[6)\I M#5YP&!JG(AMQARFS ^!D>+2@IQ84Y'7S]YIN;FVMQ_]"2_0[C,8XQ (#ER'F M45#_>49#V5-# B<3*'E M3 ;J2,*2('WSFG"C-][)M+D7PQ,=3";8E\%^P#9#O\4HLA"N"64V4/:4^.4;7S\PR#& ?ZT@JH<,5KJQRD!+XG R,0[:*Y(GA>0<1VM:5\%;: M1S4[0[N0G,PTKFD446+%TV[3>I.TB\?)P=0- KRT:(APT"?7:(X%"C>L-Z7W M%L+U9M$&H9-IRDC5,! (;A CF$RY7*/$D:( @NP9L(APO7FU06B?O1QL3RJG M .C /G85&0Y6%6%/#!&^G*DZ!F\KIN;0 ZF =4O/ZQ,! M#+C@?V=8E+ M&M/=Y&,$'&0_J++ZGAS<(4TJY596&V.64<&4$X&>,>(90ZI]+D M>\2>80.F@2V34#VH,B%PS&?EIV6U9*1YUB:FNBT^?G3414)Q"W"+#E4 M[0;_B;E0$^A@\AMB#!'C*ZPY#B5H6LH5Q:\)&N-+1H*,@\XU@ M P@GU\#OAM^J=<4,@O4.V&^4/??)D%$?>'$NBVBK#[E%4#EXX)IS+\S1O$OK M HADQ[D,C)5@I8/"AAKK5X57@)R,?JGZN#D#'Z-EX=D\3%)4M>,242;P?Y/? M,S&:BDGW]HC:N<3^H!=8&+A3OO+UUC4G+CD:RJ2$!C+Y9H X]&#Y:3K-*Z2F M@KH599ET&K6L"*[>?I%4],G[GFK7%W+!H8J@S$4MUDHJ'7YE*-64NUB#=3): MU[14J:";UK%*:3.\;T5U T]&J9JS9L16A]. 'HS-&PZ:UC7G3(O)R:.UQQEB M<(62Y"-2QN8-M2R!FC.6!:NJ-W03>\;;]HP@R8&'2":W29TV\I=5S7EG!475 MU93-;P-M?\?.08-I.B?KD]W;&XW1U4:\IG07 ZFG]X>*SX1V;=\X*BA$;$KN MZ!A-H=-3^=$Y*E=7%*YO5M%>55B(8SN%1T>^'6R]5WQRSBML+D@J%=+-"H_. M*^Q@Z[WBW+59?>W;97U *W]TE&M19FUD5$OQ4=9@?3.EI8JR.M5O%^I@JY2$ M?^L.L5;)L>X0:\$ZN8V!:"Z63.[ M@V#[_N,B1._*'AN_NPC=K+E,HMG2Y.!6=LS&K3!Y)Y994C6GTHC-R4WJ#,RW MF"#B?^/\JU5RK/.O%JR3E">E3A:K+-Y[][3:M.56[@-R<%3?MO-N\6]B2K"V9(V)M"UF!=PDJBH[) M15[$A\%DZ^T8$BQ_ /7W&'(NJBRKL.;$EX7MY!\]V02SVE&Y>07F8_.%#F:Q M(R)X%YR3![Z;)F\&ILUSZYQIU5[%$=%K!II_^&LJ^WW_ ]P__0E02P,$% M @ )*-M33*PI, ',P '5(# !X !C:6LP,# Q-C0R,S-V/_@]7RV35W T#$]$YB+@UT;6*"[=V)CHT)( M2:'7*HE74F'HC?WO>U*J E55GKQ(F95'C+]T8U"FSG.>5%[.+?_UWY]FR;M' MEA=QEO[^?O!QY_T[EH99%*?3W]_/R[L/^^___=_^ZW_YU__VX<-7EK(\*%GT M[O;YW7%0!C=Y$/XHEJW?C3[NO(/_#<8?SK-'-KME^8?ASF#_W?_>&?\VVO]M MY_/_>?=_#[__OWRKBE:=_CI;/#C[]K^_?KL-[ M-@L^Q&E1!FGXVHIW(VHW.#@X^%3]%1XMXM^*JOVW+ S*2DU*N=ZA3_!_?5@^ M]H'_ZL-@^&$T^/A41"]RP3-1^?*:9@>[G^H_ON?JRK.$7;&[=Y6DOY7/#^SW M]T4\>T@XPNIW]SF[^_U]&/_8 4WLC8>CS[L5)SL'HQW^QG\YSL+YC*7E81J= MI&5TR=+\AYE M:<32@D7P0Y$E<<3'XY<@X;1>WS-6%F92Z_2W/=DO@QPT>,_*. P2VT#6.G>* MZAJ^;<9'0W%Q=_' 9PT0V08U6,?;07-Q=UUFX8_[+(E@SCOYYQR&N4U0XOZW MQM114-R?)ME/VT0U^K6%Y2*?!FG\=T4_S#A?YD6](01$/?#4Z9V4K.55];4?F M5B-"LTM;"!J#[N+N+"U9DL"0A%B"Q;AS6ZBN6,)W-;"'+I_AV)L60=AY MFZ';I[5U:V-OV6XG@7?C7%+3'8*D'^>RMEOYE;W9.PW,9G%9[=!A9H"M.]]: ML+3KUL6@VPI)D(=+,(L?FV]Z,7W$:?DIBF>?%L]\"I+DO1(]8H19VE"X]66W MTD756Q=QX&SF_9AQ?H%@45]MY%W#0K#ZU^-\L.*Z%@=,9IM31_@ZY67@)? M/$LC%BU?PZ7I;E2L+,99N/*FA-MHLWP33[%43,'"C]/L\5/$XD]\0N0_5#/C MAYW!P@[[+_"KR?+5C3<"+G96LEFQ[#X);EE2O72B:C(9['_>VQLO=+55L6^" MVU>&U2)7C]?B?MZ@]C!?%1R&UK+GQ2@SFKOO\FQFJ+_%VS,##/6P_2V$Q0A& MXDE2V:5@Z+,I_^'U[TE6L.CW]V4^!W7-"X"2/?#>^&*5Y; D__Y^8$K@4A%W M07%;:6->?)@&P4--(DO*8OF;=387OYZ\6-*.DJ H%B;"PZ=8- J5;6J=[#GA M53(;*GE>(VR%8WU08LZ&V^>L*>'QRC(K(&OSX1K0KA.6L/7_E2)]?8MYDN 1 M$S3J*T&3U1V9,Z)6]Y1;8.H5F)BQ[:UC-]"O8NWBCW"YQX.!&R)$&U&K*]<* M K'&=YUK_! DB;@TITDP152^\DPM\;!G.A=#$"M];VO#_)+E<09[W.@8OF3% M>%]YMD(P[.O %T,1D_%Y:V2A B.F9'_+ ME-3#19^4QO,UDE&O:1'!$1-SX)R8^CA^Q:9Q4>9!6IX',VS>$CU:R3]R5AQ_*92]*0@]L=]W0:T\&%D.;^ M,%[+>#)C^13D^9IG/\M[D/@A2.4?D;!%I8O=@U[2) >$\./^Z+X0[JF*(JB4 M66\5Y>1L/%[#W^DG,S@:A!;WA_M:LNM9D"3+&%(I(RM/UN+W[6 O X+PL)RP M/ZTZ$%VY%#4B_GTY>+Y)_(OXPY.A\4BV*#/F7!0_.!F.G0QHH4M1H3*%D^E5 MWE_NPU=_PM"-4TK+=2BC2,ZE$,:;<1:.'!D;+3@*N9ZU74\CU,[80P?A:$C? M.6C(CG6G8'>6#HL"%NS#6VZ."TL)0ZL/3H9>3HFM%B2!Y)8\A+;4OS#Z:+.P M]OQDZ,6P(M&OC B1\)://P8)%4<;GD4Y/DS'%O_#)*Y M;+.FU7XR\F*55-. 3&7:F"RY'2U\5G6J5W'%0@8"PR;GG)4+Q+*O2])L,G*S M\79$FA**)7]D=ZZ6"4S/(*"$F^9CDY&CR"XW7&R(;LGEV%WWESE[".+HY.F! M'^C5'XCP^8D?+V1;-G ,MOR/EK<%NMN!B1\'9.L9:D-V6QY'V]\%+'X7Y3W+ M:XG/LS0T_%"P#B:C?FS<#-#87&ZM.!+ M@<&6\]+&ZE\&Z32&_,9]YN)A)KV&=TNY@,O:XD1O8S(TP*%Z4?-O7M:WBCRS7"OJY& 0KZH'*P1?''CQ.4V.1(]/QEXM M=:WH07$@S'BP3QS/V4UV<7<7A[ 7.3-Y4#C6U(VGHR]6O3:?51ZJ! ./=@G MC!8ST:3NU=K7\LL2HD X\1&S@-?>D3G]\%:3L5<+GX5=HPH<0IZ1,4)29&GE M3Y/O%=YU+*S"PA4 MC+TS,DNJ-4$BU!K9";IN)U95JW$Z#/N8^(G"]8FB^TP M(['07DPI\HUX!Y?"9->K!)A+9"WYRE/]UE>WK!\=LQNJ]I:JG0GT?.3 S<;_"ZI3ONHG0.' M0";-:4-$95H-TF)RX&A#H)_PA&I;DYT&$#(93S;Y(9/[9(TH@LE/=C,[#]P< M@QU-=U(89/*CNB81'CC:&UO([#S S4EB''22I#J30F9VL\6.:G+S8/5;-1[# M884[1?DAIC)17K*\*I.C;5O'.I@<>/7P&^W3#1"128]:E;DN;70X+V&9C?]F MHOHT>@TG!UY=_!UH$R(ADU'5,!6W^.0T6D\.J&5>X\3IPJ&3>+5114SK4Y.T MFAQX#0!H2Y<0!IW\K U)SXIB;D91W6)R0"T.VX">!@0Z:5>&A0EUFDT&.UYC MK[NQM %$D7SET[Z-7 [=,]OV<*='QNVAH[%M7-!K1]>\74G<<_NVW9)>._0L M/S5)AJ:?"@@96 KR$YP]',U NAU;&CTS-F*(EX/1:BZ(5;5J8Z)BK M-S":+%T QNN2U8H@! 4=T_2+@&=IF,W8MTQX98'D:0!$+J!78R>Q#H".1?H\ M2[-5*9>%S-3[/65;T$V/V-*$0ZH\&,M9H;'E6WMR,AQ^WA]X]7%K*EO,% :' M3NTO%%Z;SZG&Y]6SW8DN-3 ZI<1.@SBO?/"'T3_F197:?7'W5Y#S^QAE:Y6T M78W3JWVH$X%ZX.C4*CMGI=8&8^4Y6)FI1?W(%JM-T>E4%UN-23J.'^.(I96I ML:Z-^C**=*Q*YIV!WJB%W4F8;(O/1DDR[63,52%Y,2W&7WQQ=\P :;246D!C MJWY@0'M=[MIRLLIP!^AT"I(AJJ@GGY>1?C9[:/45"[L!%7A=*^VPWQXYG2)G M*ZO,X6,0)]Q_?I,UXG@6*:I?@B(.=9=:=4^@B!ZY<5J!HU,P;9GUOPP[K83D MMO0XF9?2P$%%2]@:4HM-D["H!89.B;2_6#R]![D.'V%;/V7G*<;/'ZQ(:6I,EIQ4'0R8\=$U$922B\'D8XXZV;^9!HKC.D>N%,_"YB\&IDEGX68&00!F0!1I"BADAEI.\#H M==-LS)(&&C*1I>NU!I54B1L *J]&0F..9##(Q)3RPC1G:0';3SZ-*W9WFP\# M&GK9/I(M'8: 3+3HJH#GP4Q=-@EK L@#944&#'7A$4GO-09=U2F25Q^FFE<$V&FE#H1)9:Y8C*]&>3+.64Y\%88;<6QMA1\HIK MAX<8")UXTZY%%\9#-WMW&\4P*E4CMED$"9W+:BT00V:FL\>0JJV M(@$HGEK2A&3L;%4I-F(^M3,M*OGJXI7'\QR^B%JH*OUJF7)U\@3;O;@01G-V MZ W04LN $@R!S@!MQ'%VI;.N?FF-3Z0[P$LM^+,MH5*$-J[9]9EY.!Y2JQTF MF7H%HM.Y(%=G75@,(F559..^>";LV,_%K>Y643%"Q26[)$*SX>!U%!3WITGV MLW=5>L=['LZ K4.R]]SL'(U#LO?4-_HT).YY2+8=9\R>FQU?)XOD'AY9CX,@ M$WIMT<[_V=&VH*LO9@^]PU0*A4S@M56*R!@H+7)%,.SZY(F7+H'C^GV==L6% M5DQY6!-0BIMCD:-93XZ#3"BV2$RMCTO>$,:C[[A%.0'ZI*V#(A.3[9 Z*M.C M&PX)7FWG*%=OS\U>Q-5&40V&3(RWI32P?=_QC!HZ1SXS'!"9*&]K)%&9#^VS M13'.^YR5W 9TF6>\[$[TY?D/.,N?I2^%60_#,GX$]6O5MS?O#)8(K"-K!B.$K8A\D]G[8%V\#G3_ MAD:+.PW1"5L_9@\Y"^/*^\]KU\^RO(S_#A1A%Y)6\%5Y+=[OCC3Q(%&J@DX@ M_%IE:'Y@DW L>!H >0UIVS:WJ HH!D.\'H-:]L6Z]UU1"><'U23LX!/1O7_&\I8!"5H[/WT M.P%U>EW.[>[H3''321:02'Y8%$RK6+AV'P#>ZSIO2I,QV2*X=-(--@4_#,-L M#K,DS)$L?E0$H.@TAUG-:S2K(3>Z!&- Z:0R;,I\EC[" ICEL;1DJ;0=@/0: MRNJ(S0V$=#(?-H6]S-E#$$?'BWKFRPM$EF71*S48\:O3(:C%:W"L(^+UH=.I M."U1Q;@6*\'-^=+-8J93L5I?!VZ#)[Y(L3M0F&8SUG40--J M!9=U"%^$UVL!VI!HNK"K\=-)=]A$L9S0VHX"0?O)^,"K$\TEZ2A<.BD5^L=3 M*ZY3@/^&_"NFN!5Y%5NDW=E%>.-=KZNY77[UT"*L>C"M(>CY,:2P%0\AZ0Q4 M22[)V#@>0HD/H=N#20WV$LOLKO"?\SAG@ 4&>OE\F< A2T&#^9Y6*2[8#3K M=P)S&$5+JI(P,?VFN!':?=S9MB[Y65H&Z33FVTK5*5W9%L!ZM9PZ)ED,%TE= MH1/1)H!O9>8&^!27ZY9LF^)&:/=@C>-B+T9H= I:JGXN5+5#)*TFP[WQWL#K M:FR76QVL")\>;&D(]M,X#=+0TD9,TADHDERI#^.-F!(?0K<'^QF('C(6%7Q@ MGFVI."KSP"(!E M%W=K%VBG4?T+!G^L?J,YE^IW"&KQZGIT-].:Z@ 9&AX,6$T4"SO;LAB4]%0K M:080O3J5W-$L1HJ0Z<,\U9"U.3DU Q45BZUN%Y/=':].)']@@1TGU9K#0Q6"(;QKU7_T-[VKH/@QH[0K\' Y=8]D.8PO+\&6:K MRFMJS/M:>P#MU1>Q'<*%H!&F?533FC\\U,7S@F19^%#38($H-""/)@O5H".\_2$'Y\=6>ED6"O?AP7O,+H/-?= M^7;I&A3;([>/';3(P/!2F>NEM/E MAHV'JN'M]=#K!T6D#52!!4AS(-]:@'Y M(N<&E<4_&F[E:C=V<;=( UFXGG7=)>IA(M8&, M$",3F7;Q"Y#MJ"GHT:J@7[,L^BM.DJ64@@'0J;\*],AO!)_E(6!''\@@6!Y? MMW2!Q44^#=)%*2783WV9%]PM7RR2$;*T.&9E$"?%#;QA#G+V[!:+P8[/*UL- M;[$8.#(EFMYB,9!MESXCIP=62Q M<+UNI6G$_( @(7.-A05>R%4C[DX0P;LKKN>W!?OGG!=;YN4^EI=S2#TBPA: MSXT'Q-4,)X-!YN(*@93J"V&P-H#-^ZT],JUK$]6$0^:B"NM4D9D +7-&\&** M;1<2&.QX#>LTV]J;XB)S>T6[DNN# ;6Z^')NUD67WTNQ)>O!]7PV"_)GV '% MTS2^BT.>EEQ7D>'WYF9)''*/3&U"Z)WMP$?ET=:V@P$1V\$ M9B*)/YE.VB< M,P8$;0>#-K:#P9NR'0R\[Z;EFM8_F@XH78%I@1Q20$+02;,YE M!X#:D>54>Q'3)Z<=N4V@"JO0V^27ROJW/:)5Z^+ @RGD9/:09,^L+H]90U$N MDF@;6'*\EK0Q^>:0/8T<&L*;E]L+>>&"F5[\_>;# ,>-?\/14HDA0 CQ '9:Q;.\RKL7,FGHB4 ]GP=M][7A9@P=< A+!J97+3=_+5$ M?/"N%_'6].VK.@!,GF_<;D-8&XP(;QZ,+H=I&4=Q,B_C1_8ZQDZ>PF0>U;?: M<-O&O*R4<'%W$N1IG$YYPB /)V M A+&9!QS8DWK^[O';ZIPQ)B>+ZX[000#$DZY4MDWV+I$ZY7OOCQ_#_Z1Y144 MQ;QGT OHP4T,D*.9T!@:F= %B>2O"G@DF5>.KB7-5D(DM$0NJ-=NHF@)2 MWY$(SGDT&3[KFB$3F>)X#%!98@@/!J4#J'L\BU9V[16LF+(D\Y>_@] $,S;G3K>V9JHV3E5.'! MC'3%"@:P^8UEQ^R1)=E#%13]] *D-G/I>T ++E<5=RPK@&%3KC&X2S+RX4' M]>)N_: D6^ZE#0&FWUN_C!C3P:((Q]B2HZ^9FMXH:=_7>FY[?#!V MZ>UIYQASB7^Y]!KF_UV"F0V[ZO)\8B!OQZ6W1SC'>!<-6<>0O!V7WEX?YV@F-(;VRZ4'0]U1VJ4;E]XNFDW2"O@OEQ[7 Y7IV]]((.C2 M6][HU3B_*69VI 7@(YA^A,_B4AADW& B*>N;XM2?J+(M8/6=@"1E09\X 2PR M7BSG%%*95UUQ:=<)U:I,Y5D:MBA(^=(*4'A-HM7\9%8YTL9%)_-YB?,HF]W& M:65!/=>!TWJ#D.>_IR#G\Y9&WYM3 'D[8;'[ MOD,%%)H6TX,A>3MAL?MD_/\6"2(8%BOPH<-)-SO-\EFPN!#0+)!CO37@)F<] MP)JC:)Y)K>*"N-]F0^->A MJK$!VR>8:[C?)M=P_TWE&AXXVO'9.%3M&Z6R':!;O3X>J@Z&/3A4F1+4CT-5 MV^R3?8)F(WR&D\*@?&2RF;IPX*N(D!8+^L0)8%$^(MFED,I$Z8I+JSE[?I)/ M#KR:(C2_F%6*M'%1SM03)D% %HC9S= C_7 MV<1,.2%P%=0ZIF-6A'E<2=YE?$BZ!0V1\_IW&!5*I'1N9ZT%_\[*^RQZO5#J MXF?*\N(^?KB$S2?\.YC*[#7:?0!XD M(6[)T+V,[7Z]&ZMO5NWAL$>78@V';O9!IE;M2FE:5NU*XE]6[5<+V'!(K];S M$+_P6 'DS5BUAT.ZEV)5FM8VFE9(WHQ5&]!0,=98)(B@5?LE2^LJ^/D=@.9Q MD!3GK+RXX]68\T=I7+ZZ,:"FEB4N6<1T\9 Q>K$S M\%? M?D9XKEP/-]FNKIZW5LA50J4^QV MV"58SOOB[BX.V8N\:-R0]'G YM4 H?UQB=F38"(3+53?Z,ER?::0%I/AV*LE MHB-74E1D(G:J D;?@_ >#J[YBKU"_8$IF@)2K[7,NGYK6O#HA-M\8T'![K,D M.IL]Y-ECM8,KE"1*6@% KUF['?E3(J,357,ZST&[\YQ7%#N-G_A/:N;P1@#/ M:UAL1^)4P.B4UD:!?LWER=;RA@"36B"KQ)JI@X5.Z>O#,)S/Y@D C([90\[" M.*AS;A\25JDYC9JWE+8I?&?K%: Z:I&KDF%@%S6=WZOF-2H6E]S\XNNAWLH^MME\S5CQ8)(NAZ.PWB_,\@F;,O MSU6]6JU[>K$V@-&-8.'A>9['Z9178"K^ M2+-;'BW'89^E#_.2UR5.PSBI3PQ-D.J[6AV]$C3KNWZ)@G7%4'&B#S(>OS2&'$$W)'H<5AIL%2T!KU=SC]NIP]"VT%0)&<]FTZZU9LZ2T"YI!?C( M&8+PL[,2"!FG)H_&!U7P6]..V2-+LFI,+6YMD5 E;0<8J6422\C2@$+'=?F5 MI2P/$CZHHAG/M2AYNO,C4S.F: E R>43X9QI@:'CM;QF"?0Y!7&_!_D/5L+/ M:L+P1@"/7&Z0Q)"HP$$C\;Y11N3BCM<*2!(65:]G+]7D /!%/T$G0&!H= MFSHN^:O=@V!/HP9$Y2M\";LJ:,?DX<#JF;I\#@,KT[6\D$+1 B\YQ M2N,SW@A0>K61M/H\Q?RJ0)*Q)%\&SU4X^DVVJ!>\CESF1E"U!:SD#"GXF5,3 M#AG;LH\GP,[FR+#)#@CDV MA3EZ2Q:S*U:%,%\&,'54U3:#D+^@\&LH0Z32,9NIFDZ&^QZ._-?A/8OF">.5 MD\0*__*\\A>5K:U-?S#N/-2*T2,$^:[:P^RW'0^!JSC12EJ!4BB<8#OPB;C] M%(C)&/T0296G&&D[^'8<9;YI'UJ5#!@1UX1%QB[HC#HJQTU7'!(T'=87H+[N M[OB;U!.KI!4HB$(-&]L3JQ(Q&8LA(JGRZY2V XR^R]HH&3 BK@F+C*W/&754 M)E97'!*TTMW$)9]^SM(H?HPC.#,JIE3A\X#-C6O3[V0JP4K&1+5^A MY(#OXX>;["0MX_)9^74:]@1Z\%UG4<*/)J$Z$,F8]+Q2365JW@;GJFG:1^SI MRZI27ZC#JS9E*3=(ZT8)B=H!6 IWMMJ>MS4PTPE/79-1^>T*GX=3F^]]KX;2 MQ6Q) -$IH6.-)2KSJ'VZE+.FCQ(1]UE>WK!\=LQN2XWBM\+G 1R%:@/69TD< M*YVR-AM"*K\\I 4 \QY]B2M4G MM5XSFZRNG!U7ESD56@0+\L*_SJ:Y[F\EJ*Z\61XX+7* M<)=P#EUTB--^RZ%13?'JPXJG^ZP6>1E_!3GHN[S(K^+IO58*H;PAZ-K#?D$H MDRK<"6\$(#Q<_JNC6/$GH$+2[[ ER^F'!P0\ZTK"Y)9#,2@R44F=4]YKB8ET49I%&<3DT7M4930.PU4<7R M(K>!S$($41C_V-G9&>R-AZ//NQ5%.P>CG8J@E3]-%J(47_E_7_>"#5:DSX/ M7E-,S*G0@&,A#,A8_T=!&O*4)7T&7EI,1CM>,T)L<; &R$( CS$+)T^P_XD+ M Q9>6H#07H^?MEA8 T0F#*=*&?H2@&#<,P9K;!TPQH6>5JOHE^?71Q:Y9(<_ MX0![40D/N![BO Y).$OK+"2I_=SZVR;#X>?=H=?[/-HO7"[U(0__\6W3&+P5 MH\9HQX,QW;918[3CYN3;Q:A1*=;8J%$A^674>#WTC';3-!#WZAA3!!!HT;7;5#CJ'\^5Q3JL/XNT"GE ML[ID&76D"C*96EWQ5=:+EXVUZLY!!V^;C :431 .AQ:J##*Y9%T1GF;Y':NN MX=S&P5GP-M G9Q>=1G%5P;M"UQGDHN.;/'C3V8;*S;XP9NC#:= M['%C-&12A>27/:YQ7A\0R#A7$F9JCQN@P2Q]M,<-"-OC!BJK^ :2MV./&_3! M'F=*$$5['&R:67%X"5VR/&=1);&R!*ZD%2P>% X4&Y\&,L^I@-"Q<%62?FE% ME+ 5X'-4X,T=41(@KJQ%15XV2()_K1,$OYI<\8,#LD]8^3M )%#-P&Q/( #@ MRGJBKVQTY*\] 8/#UWW? KTABFV*ZLH\X4:UOA?I-CI6K<+=$[NT=/T]>(IG M\YE4VRO/\'+M0TFD%+2C4WGZGE]G(_I:Z:A>+2 M*1?3-6][-"10RZ+=N1E#0Z=*C,W$W]'8][TVF+YUV%D'0J?0[D#T.(\97Y3&5$G54W@1A MHSC+]I3N>^*QJWWEI./E BO;-<='0S?FNRULOI2PZ)1?<5.>>C3VG3*MI,"( MN28L.E58G''G>[IT3:)J AWZJ%D[ORW8/^>\R.0C_$>G_J*X!6B&P(W6+;V] M,D@(5SZ\\YMBJLOX86U@0'IW_N5 K# 9K YHA<#U8^XE1 @IAS(<;_U4\;BFYN#.Y3$K=&.#Z MMO0IJ$#XTT2&$.G#S>^>2$HSJ2-&E9.JARR2RSQ^A*WQ91*$U?Y8&;LA;@!K MAM\KB34_*3%],DP(55YR,EQ<9#$:$D_/U@@'Q8$A['FPK=BY!V$T]&U+T5"Z MF"T)((0E#U84:RR16["4@YBQ+]8(/-YZ=C':])KE*/@PQ-0@" MA X/)A'#<%!Q^.2NU^108U)P$ @O'LP??[*BC-.I8K_0> H ]RXP%(6!\.#! MDK$03;FZK#PW&8T<35/::_^&2J6:;XJ-Z-Z#3:*U[JFLZ&U)4*[;= ID\*16 M?H +[]E%BD?^MN@%9F2OZ06"3P,YVYAB0DBE4YBB(?K-S\P"J2^]@ *\EE^T M2.H:)H14'\8'M>CP.AO?:J,?4((C ^_VB5U'A5#KX](=?KTK2R.5'6GE.=!& M[V(')4 0-GSG0EQ,C H#PXL&H4*]RZ@BEE>< M=F_CD@1 $#:\W-NK*")48%6$7F&ET642I%H)'BY>!P/?Q9>0[F?7I5,9L?B9@> M 0:$" ^6FI?0BNN0I4$>9[IQ6,WG 7W_XZ\V 2$%JGRDTBQD^R,M'E@8W\4L M4F]!L38P!!V%.9K'7VTJ'6%)#@9ARDUN'=!,'0H4' Y#V.7O]8#CRG7BVJ56Y]IN"(_KW8"WIH'\J\U5[(I1S MDYLZ'.=9^C_G05)-E,T:^^@>V:3Y9+3G-3Q4--Q7^3!'@[#CIF#'?Y\GS_S/ M9J0(6TV&>^-]OR<94SKD.! B/-@&;N*2I]"M]_'"3G:0EOUM!M?P8]C09C7U'GTH(TF14!R+" MM0?[@E>NJ>Q%MD&Z:M>R9V2VT%X7CT >>*O,EB=O &NYUQR)5M^7;*T4 T1( M\6"A^,Z"8IY71_FS]&&N4Y<%:\)OR?X\=+.3V<)BJ82%D.;!-B$253ECXHUJ MA+ZM@$K]Z].V!@LASH,EPPUQ5!8V5PPJ%S,/-I%UH2_S.&1_9GRA2&!Y4+JR MM-I7^%VE2.DMB!J?EQZKTP6'L$GMO&UT78E8+ MB\8GB[8!<%Y3LCJ0*(>$\.7![B.$N+PNN)+\Y8_%XJ_%0#;]MND/E.(U3<+R M7:!Z<)$+I'P4-!&!N)B711FD$4Q IG0WF@)4+]?(.&)V QE"HI&YR+@8_5^, MR\*BPT>6!U-VQ;@J0*1O\9UHFC7O!+#1"^"3LM86(\*?D>7(F#_8A<.Z7L1A MM7'39FRU&+8Y$J!!6?&4X5?.X:O]2/309??9J$^BX86E@0"CPD1$D MVP^?LY_5GUH?'%XZ -A>S_J.#@QK^!!:?51C$4M=S0(=6%UM#Z![>M(W@(=P MZJ6^:[,LV3*CF!N;0/J0I24LPK(@-8WF )G"E;TM&-5'AQ#JP7@CEKE8'F:7 MN>+&G&[T ,![:JXQ H@PZ\M.]ZNIWLN0LMXM1H6G<^Y6B_NZK5& MM46R_#I0:9^M0TZT@0PP'Z5EV&UYE*5P\N(NRHL\GL8@$O_MX2R;IZ7,B*1L M"V![:E;0A(9<@>VWVNW+Y*;\W/%& *]GI@5=3 AE/G*;5+G\6"K_:1#GU0[S M$+:7LWJN$;D.51.]RW>#LGMF]]BR:I!QZ.,"))N 3YX>6,B=G2^!"ML*W M3T;[?3;W;$,YR&CT=*/TZ\I;_P1"O]ZOW/39Z>].5!V!&GIJ5VJ#$Z';K]E0 M1F;S,8#0?VO1 @5"A =#W^N1>.6D7/U']I5)F@'$GAJ!U*@0XGR55NY\2CU+ M:\OER\(A_1H=O1)4VU/SDEN-((.-3LEG]89D!>=A&BTW(S<9_U7#85^;2UQL M& U% -7WV6ZU-0TA@].7L=0I[L/I-&=3V#4K8P.\RP3D]#18R[/*D/'LHYA4 M1T5\741NU(O*USPKE+9_NV\#A?;4_NM,&>+1=>#!8GR99R%C47$*:N-GDB#E M49#KUUY*?88Z'4Q&!STUOIC@0VCU8%5>& #BVX2M'5X:9H _'I:6@F8BJ-!# M8-P;**2GEI368!'VW80G2N.(EN%ZR]AFD<^_2W> MV>VE^YH$7:-;*-=V:WV M)];(%?<&:'MFKND,%J'65T'U#@:$D#MXU;C;+^63+*2Y.7P]*LI 2C^/ZE5QDA!R,CT9?!N MLRB?5PO0UQL1*OOP.4UV=[BST5(..GAS;IQF>S-9LS^DY0;D^C AVK M!!EO'FS&JX:+H^ AAJU!O1&]8@7L*:JR!*?SJV1WV--E MKA-@\3 8[+BI%;@\9KR>;6$JU# *(.UJ%#W[OLV08?RXR0-?E^9Z?OL/%I8W MV0W+9R=/Y6H5/FVZQ-W4&'L6W M-)#?!1@K"1NCK>-J"Q9^G&:/H#I^_N.1;'U6NVK$'V;+4WQ881Z,'J^AJ0'_UC M7@O_NM))YG5IN[J\8$]WVGK(, H]&"F7LL'\7U>(:AP*URLY2A@UZ:960\]F MV4Y ,;Y]E42L5WY^P0=?\]-":G<1-@!H!X-QSV9:34@86T:&MM8'*EY:OCH7 M1"Q2KHMMN^+7LNSM]XR^SF Q8I<'S$^OB@!!?JRJAO]F13=L\;*EF"O:^?GS MY\?I'#;9T/*>!4EY_S',9I\J!?%DWKA:&O@L9'#:^_U]F7.C.C+P/9*U^/JKF5CW M-MGU-J 0-V%;1M=*"$F2TRD&(B;)@^&G*9[NG=F-AP&-HU@9\ZMCQ9H6TX,A M$?/B8::SP N5.R$L$J2\N7S[1'W+BN)U67\^#F;!E!77V1QV."HWI[(M8/8: M!&2VA&G"0>XBP_=EG_C;N-_\W_X_4$L#!!0 ( "2C;4T[J0*0D$ '"> M P > 8VEK,# P,38T,C,W-2TR,#$X,#DS,%]L86(N>&ULW7WI<]Q&LN?W MC=C_H=:S\2Q%-"71\ASV'"\HDG)PEQ*Y(FWO6\<+!P@4FS5& ST FB*]L?_[ MUH&[;C105:T/,Z;(RD)FY2^SKJS,O_W[TR8%C[ H49[]_:OC5V^^ C"+\P1E MZ[]_M:ONC_[RU;__X[_^E[_]MZ.C'V &BZB"";A[!F=1%=T64?Q;V5"#MZ_> M /R?XV^//N:/<','BZ-OWAS_!?SRYMOOW_[E^S=__D_P?T\^_#]P!#Y__OPJ MP1U4M(-7<;XY.B(?25'VVUU40H"9RLJ_?_505=OO7[\FS9_NBO157JQ??_/F MS=O73<.O6,OOGTHT:/WY;=/V^/7__G!Y$S_ 372$LK**LKBC(MV(Z(Z_^^Z[ MU_2ON&F)OB\I_64>1Q4=)BU?0-J"_.NH:79$?G5T_,W1V^-73V7R%1F#(D_A M)W@/Z.>_KYZW\.]?E6BS30G;]'ES:91X/.DN)Z\V+H9PQ^NT-=O!_^O:;MW_^ M(YUJWGSW]@T5:?"G7\_R>+>!676289=0H>KY(KO/BPUUYB=W)9F%JJ9K*@S] MX*]3.ND&9,!_ _XJ5-!0DKIVE4EE?W-U4>_W;RA$H!2@QH M'$#%A/,Q7F@3D-\#V@@;(F[F!2C&P]Z@Q7C,W4&FS\%9OHD0YU![@HH:.P2) MD%<=.EA#K_B0C_$8&/(!=CFQX-4FO, %;D-/8F_":;/M]DD0R@ )0EIIN'& M7S/;<(._.%AN<;\:<+ FCL%0\R55/OF[;T7WQTZDV/[ +:;($_REA'SM?1JM M)9HD@2]E"L>OKTWAX"UNE^W)W!E>8&@,=-36L:6..96: M+&N(=V ).17W;KW"$1:9L7!X%P? >U3&4?H?,"K>X]_H)G"NM6,0\-Q*8<": M M(6T,:^@2 9:1$4),/L" P,B.9P&+3W H@AQSI(U XB(% (1EP."\%P+P8, M=HSU":X1.;K*JH_11C9+B)LZ@H.$SS$2ZE.YKAT@#7UA0#6X??6K1G9AS9]B MU!51>I$E\.E_PF>EZKFV3G7/+NN'N T(WU@L[A?4]@7!4EYX(\LTFS^@QX\U#A#5VM:M(] X)3%+/ M"DI"MU.$6@;9?$&IV.'P"C!"T*/T/'T8Z$4PEQ@H96% G6]@L<:?^Z'(/U.G)2/WUBTA:"@]QXM-498TXL% 4Q[@)PNEDC7T 2E9^%0''H\Q4^H1E:+! M=YS4I2+20=78A_XO%=$-/0Q<^@UIT ^Q% S<^+H#Q$E9PJHTF''T"@>.1 MNQFG#123Q=XL/L+B+F_#YO?EU"<\Q0H?0U.L;=>PK,\'C=')M7<.4IYC,0)6 MH#F[#06T>LX;CJ- ,"Q!AQC*$F@X##>-RH>3+"'_.?_7#CU&*6:G/*E.HZ)X M1MGZIRC=J19BAO0N@U(-)>)PA E E"6 _M C78&H @TUH.2^;&(?V6;G>T>YI#P0(TTJB=-@:!L/P,5' MVYB_PWDZCO,=9N03C"%F"N]I/L*J]K6JZ5I)YG+65O//3=YU<]"U7P%,T4[G MWN;PB7(4;7NO\[D!BKAIW0!"[NS@(GO$W\V+9\R$ O?#9@YQ/N)OC(?VSQ3- MOD!LR"2"W.)S;PZKWF/S90;1I3V)T#BV'Q$4W=G+=0&W$4K.G[8P*Z%^PI"T M=VA!,H['**C;@;JA]YG!EF_(&GK=WRG1,0:R$AJ>3BQ,3RK\G5#H3R;\^%@= MDS0K"(C#/(HP.H+P[6SQ+N*J>H %8^HC%M/2^\H[\.:.%3)I_#,]B*"TH,%_ M1QZ&S[80[@QNR=5B0,Y;AS:U-]=!S:4-Y5M85,_7>+QI0@V\"=^2NQOU@E]- MYM1>E/SS5L*:KP EH%;2DBRS24C@/]?;COF1%B!%RTM:(A?^CLJV%>RJ)9,X +<;M7-(<=OXUCC PN7>5;II#66SJMZENL?7 M)8KN4(I7?K#$*P#ZF.,A3Q-8E&0U4#T;A'^8=^$0HQ9RC0'3(VW7>GCUZC]6 M9$:9^L1?UQ+Z- Y;&([-QQ:#7@S,/*)*1>3'B/012KW&(058603_OHI_B\R"!%2T#@T M,17G_.$[:PM(8\!:>S<>&P$:XV^N@*FI)(U4(BE<&HD61&.3T"+(Y0HL@^75 MO2GVQ#T$8P>1]S3 M%SV(9BWK]('6&!P?XD)ZB$N"5&*D.C_=HR_G19[L)!UCK*;^F@*L[)_FLQ[. M6 \>#V#GE#:4ZXJ]L2HN934!J$X#6-E6GO*F>RDK;.TV-%7 K2 .M3Y8J3/R MT88K<%&6.SC_BTOSR%,KWDO&^W]_\PI#B6P\0+_SPCF.3I5!21"**L.1VW57G>%0^T*<:^IXA37B4[0FZ1)0+@OWJE?D M<@:>I3#_3@'SOX)OWZS>?O/=ZML__Y'.D?B?QW]Y2_]9-T94>OK'O,M<25XM MWV L4Y<,WKY9 5KOF+0Z@W']VV/ZVS^O\*Z]W,*X0H\P]7I_+D.J:#DG@JG# M6\$DH7'&47H=H>0B.XVV"&\0>XRI+@,-B%W> 9K(PAWTMT2 4 &4@9IN-4@3 MZ^W&;T^AR N"(RQ4S.B\7NT98XV[T3,&FCO+^02K"&4P.8\*DB&B/(GCW69' M3PWKU;["T%;O<*W.*?HPV)ZFG),1;R#8KK?KXN MA2A4= H@?1^"&:H&G0N[85RBD@P;]HQM9WAWPJ1\0%N\=,1;+5A69 U9[NY* ME*"H>.:ZR/)*Q=:+#(,\SRH,B91L@)I>5V"#,KR;PETUOWI)!@;WV$D"-]N\ MZ'V4##UN4.8;6*$-;A%C & MO;#VI19+MO>'IE(P=Y*.9 EE/K"%F6T8NX>T2F$9=U5(\YE,58-MT>4:&NZ2RE\(D5:W5V" ME0"*O&M&7HN7:>7>Y[Y5NHX*$BU$=HGT6/(:%K2DD/%%D[P#;W=/"IFTUU&8 ME@6WT0,!2DZ*N[#"4>'G,%QA9,:N3]BK!&(0\H3?P"630@JZN M2G82X%6A3"5J@,GTX>4"<8*+,Z+V<\UHX=R&-X_!>C8+52DNU<+Q:5QU/B.' MIJ3R S4#5R:LKAB&'S-0@P).07DPQ@R+&;"!4$/A$SXMUR;0D05&>,7-<-RU MF!D.ND>\J$N\FI'Y1(ZZO*L8/IX+N]KH0@ND/8JZSI$3+,XWL"W59) Y04KA M-/.7C&L^)19I"7IUM((HN:<9=CX5EG+,73J?LKJZ)\F:Z/$I+!Y1#,N;/%7/ M5W(BIXY'P3OO=DIZ=42;LX0N-0$@%)XC(":)LJ:BE+B17Y>I0Q#O,'7P<9C] MK4,%C4-\JC@?HZ%MVZ2R#J$ XC0!0J@YH 7-&.):Q+@, MRRPA%I<4B#J#CS#-:0K=FB\%Z#5T3H,QU1+P<9BL?1T4WU(TMN O\G(/.9*. MPF_DI0&:^*!+ R@YO V&-) (<_,A*GZ#/3-570@KB%S>":MXYZZ%66.*G[9Y M5WS&ZR+<3I HK2-I-DUCKY?:6@!Q]]I:]#A=IM N-_:!X@'W,IA7!].OR -%WM4 M98=E)>?DU_7C -8^S$ ,H\.*99Y:+A#\\<\RX=\-(6@]"Y_&8 RNL6D8(\MII2+Z&D:_H.=:NJT_-.)2 M4)"'/1_R?&YCP2D4<^KV[?1ZB@L9A!0E[T M^LE8-%F:?_O#7[XY/OZKG4PNS=W(9,8F;V0O#J<[6!GMPD?M7$YK(PZYJ0Q6 MPSTW.!D]VKZF#[:];L5-A$CQG[QMDR;RYW1V%4&5FU%%./7U).H,/:($9C3$ MB=6$;FW>)+YC2F?>GDX9RJIY3@7:;OI%SKN> CA1F$7LODA-"GOLJ6Y@0=[F MGS2QB>0?[T@B9,Q;14O ;H=I++T>3DP'N_H!F@W29TV'-&2#E):!9*5Q=7\& MX08F#5\"DYW8C_.T2.82Z@RUI26KLH12@Z0F7VH#*3/-N62TDA9PL=E. M6B5(NO&_/I#)9[PR6#7+_>[]!^O$M=N92="&@* VQ5N5@!Z0FX'2<#97(M+3 MCO?D,4(IV2?>YKTG7'7RH'=1B6*%Y5GWY&O7;"2EP;ZZZ8:XU?X3OK:0%.TK M@!WV9(')'I=+^A;7";7)P[ZZCV#VP>8 5NZ4S='KSE";7*A-,@#*!HG51>FN M4KZEUE(Z-$2]%&,MC GK MQ:>1&8)O;%2&R'-G1#]#M'[ 7S[!BHW6\...Y V]NJ?,]=XHF]O6U X=FMQD MF;FKB+HC4/<$6%=DYU!GR^AU)S!27]8Y_P!$]0#T#;<# MOLNG58\PVRGC@KLF3A],M7SQ;XK8G_R]@=*QYO=UTU"A_$.FH38=OEEJ=G/8 M#+BTJP97'(;T+E\R&4K$UUIK#B/([" HO!9(D@HKC7'OA6S4Y0&%C!&\@]GF M&;TMT&3=5=/Y0)U$ FZ/P"#5M0LA Z^)%J2(4JG X9YSR(4V'Z^DO(2$=7D7*K>'8 M>B_*IH6%ALY_*38I7$95V(ZZ*FQ2\+A:PN\KRH5>%)=V8(0MP_IKONQC7-5* M:Q@R H\EUJ3XX9>S)?7(UU%1/=\6459&,9G+-0Y%2>5TWE1QST^>;/:AS4&O?0#. MQD /_%2D58)W'&E]D(;./Y:DWDB!I@ \DI$^#!'ERS?512RUU?Y&[1QB9LRA MI+3KUPL7\-O" N7)387UIENNZSA^!]*?M#$U3Q[OXT5P)U\8FN!.1$K0GN@@FY MCX!X>B:-Z&'TU9:F4/I$RJF6J()U;O-KJO!/,,[7&1(]A!B<_3GBP.E)LZM1 M5;VUJW(P.O<%W1%V78GDZ(YP /HLK.H+DIJ+%6CY:"H( ,8)Z+'BY[F]OW&F M^10>:3Z%_!X\PK)J7BF"?.L]K9ACJ^9/YIV:]*S/(BD'K#+2V:[ /IE]EF8Q M:#(7G#_!(D:E,'1TK]ZL;@WDE M)J1TT8'-O@D0I8/0Q(1^9IT 6'?BQ1',@&GQDTI_@+9[6+FOFNL($D3?;1%= M5P^P\_<9_%QK'3'H)PSZI!%;[(*H!!' S8? M)NTN%" MM1X,;272"7T%MH\<2[K'CK#N2E+:=&D'-Z?04[/$A;9)$\)XRG9+B&$O3R=. MH_+A?9I_-DD*I2;S\U!"Q+_R?00A )0BO%<14F4H'D-(->$PUE%*1+HS-AT ^Z>P0O2$UZ2O@1=B9&NMP#R(*VH]XS;:ZI)$JM\\S6ZC+./PM M5C:B9QND?-\F+RKTN_!8<1! KJ!R&HVOXIX/R.]:K_!Z=INR))>TJF2/= 4^ MYMFVR)-=S/[I-8W4=!E9;>[]O#K1 XY\=:%'FK3(3V3@H#$38VE^%III; M796F%=WD!5*K2<(S27:[H]//L&X3R5^;[A(V,65YA6?O;?1,TO4%5-&ICQI- M5:<^9!P>N K#:U1'K1("EX>L,IZYXU5)Y)J?(#1SMLEU6\UVK&#;Z5FP$B?< M*; 2)/,&,9!/W8T_)7DI(CKXW:\[]T$,MO*:&@6)WY2\&'*>@6QND24&U<8P M--4FMK@S3X*_D8#1#R#JO==3\$,>)-)L_>?U5G\>]O*^NK6X)#)IA.GBU<+ MV?@U;5W6X$5#_I*L"+OCG3:!B?>SG;WD/'W _\( '1[#E"6L6%F@%$5W*/5_ M)&,/5'YA;(O2(,SPA.IB/RL<]Q&&$7*26=L@ZR%L$]1*^:(A?MG54L%2'@5J M;6(\6AB;&(P^;>TDCLF<7GZ",42/9*]O968B&Z@-L()6=U9:;Z(+8ML$BG/RLS,>O0J_T8RFQH M6'5OS7U"OSXI[2DX:YLH_AG5H$9 MGP*&>EM38##$IR *^[+I),BG'P(<3GCRX:V\[GY2:H.K#^.YA\SP[,'IW?K( M"54YUT,L96?^K5$MJZ55MIV%]9QB%M%%L@5HF0;8-;10 ^"ZLU2\(&YR%L3_ MVJ$"8FZQ!ZF>K[&2*KQ.)CF8MJ2)PD)M.G%HF5:RC6'9$--T'8P<-/0K0'M8 MT<50Q,3..K+ZIB,8FS(1J&=*Y%E%FL*XVD5I:U=!69(,:UH#D@$M MQ$7F+(O+0!>5\RPF@]KBF4LYV.*A5JZ@MW@*?$Y?0'HH*8 9JUU!\A[+3G\N M=7G&E50NRPLHN>>B@PG,FN8LB+U'X&OW-4&&J"QW&RS";DO>L\I%<)JP7P\D M+FV_'D7>IZ'W*(NR>*:S#F5G_J!JOV5E,3EMDK.-[?YJ)NR28HV;NZX_;S+G=U :$'$;)PV"7%;IV]:;.):I30%[OJG36GP^,* 8C#X0>XERB#^SRE>^B%3"(]H/&%Y MS+D:U+0US5Q+VX> ;YT ?:#C_EA6>R'WOF N!(\*[T+D^%FQ-+4"KNZOBSK" M@CZ]/\D2]@N(_TA_8[B>L>G0TVK'2F;U>J)?:J'MK"ZR12XZNO[8+WWM,Q82 M?[B<:L0O19+Z6DW9 URUUK)'MQ^SKG/"-_4BE)<]2C)/)BK@7XW$IK[!N:PT MDP]+LY:B*;_1K\D1BB')(*4R%QF>_!A%?PKNIRC1;%O,N_!D+!JYU)![,5@@ MOAQE%/*9:VX/$0?QOMVS_V0'6>94[ZF#IL)396PFV SQ 'N6@^M #ZSG.:@. MZA[57$IZC_IBUTBV[TU+M0]LA9>[$S$; MIJ'.9*#!&N9;;@1YQ '/>3.(EJ(S3O-P5[)J! M"'M/A$5=5UZG1$ML[8#I/G,_*6R)G9["MKB6'C+V=UQ*L_63)BMP_D3R MW?1EJG]Y<)1VZ=I=#!BP%$K1PC)^T? D27N'Z'&Z:/\ M? -OHR<2JH%498NYEFX?VH^X%#RI)^6::!,*$Q//#>!$4 M!$_@13APNQDA$\1'EHJ[BP_/$L&IQED[(.S7M>--RY[C((0FZ9.6,:++ MC.[]!-G@",-5NZX#6' M,"JXJR.VY!*<#GH_B9C#%$0;H3GLP&6U[SS^C94: M/U;M@ ;-G%;S'O G+"L!V-^];574+/9#2O ,L,';*QI0@?!?%S.NJ(/=A]3]ZKSM^BM(=O+JOJF\:J*=-A.8;TN5X!V2C!7E[--P+_]H?C/[WYJ^S_>Z)'PK0# 5F\%N^6UJX%>S"6 MWLN-/(.1BWL+Q[XETDXR[7[N\.6L>HZIW5!JM3DS<8.W9!6>+8U8!>99ZT+B M3Y_V^3@=\O%#GB<_HS1MF!"8YY[].:\,:2^QP$39-=559Z-@;*2 = 0^XYZ\ M3;MSRZTV4M(!$==_5L$AP;_.+E[*L%.Z6'U?%.LKJPNBG>5;F*4J:HNG7 M6(!F9*_NZX._*+W!OZ%WM28I'F;JW^$29:X1&0.GW^\*#'INGF2U?1-HM;V# MKGO%(87+.7Y6T(QG_5D1RTKO/ M9K%R;J,^M6K@(T"U.O *(Q,_IB;S"R25SQ(C*1!'9:(+ S!Y=$K20@D&KLF MUFTB#JTD@@P<_8H?PX(?@?@K8PT)4E*8J2< M-GY,KMN0L"@F:]3PS% _S=% MG\8P#<(_-A>8F+%Q#(W5,LZR'X>8M95P#-J&GJ*5#R\+;OTW2:-CT$Y2I]-7 MG!*>S):*!M1N7WL:2"-X :J 8B .U$)1@I>4IEIRF+X3'7#)\PU4XQ_E-FY.:M> L">F=M3P#! _S=! MDZ;P#,(?TN=6#WF:P*(D"]OJF10),,EC]K%9IA,@C/=YIO-JAB,6I9YD1'SY?E]R#J(@&W# ,DG\ =11 KN](AB/C%'2L? 9NOOO+S MX$5Q5#W^-QN1:;<8LK["N,F02FIWFR%X/[\*S#'LK7:+JPZUSAU>=VRV$2J( MC[@JL,UN\S)*K^XO\VQ]B1YATF?.Z/YC4GT.AWN MZHCV%3C*]]$\=Z&RA]H='OO -6'Q$]SF11NP;;#>LZ1W>=QC*!%WU,/H0$L8 M*DBM5,8=\=CHR^45S"/,=O 3C/-U1I_SFD/0@-;I=8M>$OZ2A=* 'E&HX#-6 M%'^O8J@EEZ K(1:?I*P_P]RE.8T3.G_:PJR$VL6K$;53X)E(PT./4=$%:H\. MU(3AXM!8=SP2C17G]*B0?)]N]^HKR-.\M%EF&O?@]G#04"K!J6!+V=:NH[2A M(M)2@X+S0!OUN4/F>51D>*% RGCR]$BS_"/,7L5;[LML>_*:9E!:SGY D*?!T^)!YV$BM.I M^N5+\DU3KCLD#\^'%3@=-W2(0H[',<9^9 ?.;9-0824>[#%HQ"/M#A)GJ(S6 MZP*NZ]0?]7[H-KI+C:Z #>D= LA4(L$U2(^.0*S9__Y":4/!E97&QG"S4I?# MX[[X 2:[E&1JQMXS0>FN0H_P!L:[@I8B8(6-8$+J#I,5Z:[)5#->+!B=#2[P M,9<'B4N,%7?J6'^$9E3O?09TWP'-AUAA[]ZGJ'OFEJF!F=%RD./.-A?#FP\# MK4_*?H?)18*7-N@>-9<&;7KU++E$T1U*J73X;[L-3(PGE-F_Y,4TYQHEE5UV MWP#=1[CZ!^0 K?%E#M#*I7+N+?$*U.2!X=16?W)7;*:\ -(W[)6T(;!4#=,3-(0%0W-E&6=D M",(IBM^\_!P5!>:VO"H^H?5#99:R0J/RI]*;4"39N[M(*L#5ECW19B4KGR\7+6;Z)$/?R1"UK M0^,7,RWGAJAA[4/#S7#\#9 S'/S)V"F+JH<;_*\Q9O"OR&(YV<7557$#BT<4 MRYR+O*D#A"CX%.QP2#/VLK-N6GIT)[HA;M"@&U\G(" /0YLQDSH-37NWR!JH1OX4UT,NL&/H)QICX$95X,?T!)BB.TC-( M@=NP@* IIJSZ#AB6R#?GT"W&EVL>+=J'.'=:NHV<4%UD" MGV!RFU^4Y:X][C,X(3 C=UECSDP>KFX<)0,U':ARP"B_+NOSX%4HIPDV"N.J MNUEH*QP(:@\=3#L("(;2'88Q$ ,XH+!3G"T89SJZL'\TM-FF^3.$O2-<[<2M MH''Y4$C!.?=$J&X[.,D/8M;4CC_W&$@W^&XKTI0T,Y;!W"EJ[+CZ#,>KJ.8, M:Q3*_"3WG,Q>(6HXJ;3A M\NDU9JJH2-ZA,WA7=?'B6FQI*9T^M=9)P3^Q;BD (>D_.0AA#C/4"_^0VD@I MLYZNL6^6]#'!-2:%10$3.I4:'JGI.W!^CF8@DQA19?TRI26JET?A')B9JDM\ M2F:J*X?ENO=[[G*R(6]I%7YNIOY=%@&?:42X>N'S/-%: ?8%KP7&YP0-5XM\ M3L2X,Z3W*$,5I/G9QLD(WSU_B/Z9%Z=I5)::/8E5+PZ-PDZZ,?09=9W&CZ^& M=/<,:!> ]A' 'F>"+L/8L[T#CH1;]Z.*LB9KGW\NWH'*)IY@6,"(=]6:#1W MZ$F]VX-R=I" >A7.5&"J'#.$SNCLC4(9/^'!5@6Q]O[N*%2QSQ&7#9/\S7-X M*C=B_/TZ.VX:$-R/_]>3TWCA:'* MV6L(7;IZG0R&9'80Y;H( M8/6K&7:#A!5^5ITB1EA*&/VRTX#6,X3&DI@E3FG(@EAY&BO(!&)"[2P6XGZ1 MQ1."V7M47L/6^]PK ]1QPX"NU90*T$><IIG)4I@P=+W MD$+0[**/Q=;AR19B+%0EC;@C*:S(#^1MLH'3FN4K'MS;/*,C=82][E=@\ '0 M^\*JR2W1?H0%=[($;,UW?(76+SM4I&8D'HV27J?'_7Y#F"9F-![9A#*CY03I M7'IY\+ W)%F:DGG\B;#C,%V(> SV]AK]U(Q-OP?@)@@'N0=G\\CY4?AVK3Q_M;\.RV6N55E,YHJ2(9;\DWP!:S]A"5\""G[.,9 MS/$X"./C,]%&[6&9,A?M:50^U'GK'J.41&';F>NL'_9KX/..H9E+$*1?CGJ! M1[H$S-BGX&^WN17KK\_G3KYC@YF15/]XY@EM3$FCP%S- H9HX)P6L,(#=6LQ\47X.?,!KNM"E:!HFWTQ MSD]CMHNZ0(W-'J8C;/-A._)\O>\=J*OKCY@CW]9^\DOP9*KQDPIZJ Z+,Z\E M/11G6X?ID@:.]KJ VP@E=65BW/ZJ>H"%-DK'$S\'ZM)L1MS3DH0-DH'*K3U!KPDDY2:[V'Z12[P&)7J\[!%P_4\0U' MS9&KD[QU_2)6B.H![87S?UG+0('U+;N/YDS/:T1XV113K MHV\6$\]1^H\(% MTM@6U*PI?8U,$$&*U"P=D&8J '4#*+;93@+PW0^PNHBB_,-O,Q+ MR]!I'O#D1?M^9P78!VAE6?J)P(QC#\@8F,P>> G(D,9LG\$R M+A#-+;Z/^2B[#=)FNKSYG M>+W]@+9XXHOQOZ.UZA3#H@^751$L)..J)# (,V+04:] 2P^Z#KQ63;#5'U=% MP59Y;I/HTP"93]'G#Q$V'A2E)=XK7=U_@B4L'I6'^R;$CI/H:V61QE>M "8# M+=V*G@+@=49#ZVMW,4DJ(LJF:>R[)H 9OD0U K*15&%C3#Z =T?LJTA5 &:@[XZQN!>AC.>_& MM]<0M'*O"740YF@/8*E]VJ/7G<%*[][?F53@,Z)V:)!FTLA".^I EV&<2S"U M]RPT-4:BA9H"0!YA29O(RH@Z!.0-I)F$O R6EGHRAA[O*(<5GV\OT[S2XE,?]G<%O &-$P<_QS"FEZYRSI9Z.?\HYN MOD^X+$,PW[@(4IDT78-^W^2^O^Z=8K[?O^ZQVPJ\@VN4D3 L\"["#>(9 \GM MGH8L.'*7)(HBZ@U?TOL '9"HU[/7N@\SFQ57(6)FFW*X*(I0\5.4[DBE+/)J MQ:CNIIS&Y9)(P3EGXZ1!.!4S=6/.K8%T ^X!+W5U0[S QRNRY(J\A-H5!79X M)-RT_#'+[\@5%0D5NLBVNXH\E,IBE#+#Z,NA+YNYV"=]H'7^<5."/8#+@*4A M([66A? 2P'Y#NVW54H:PXY!N8)5;CB#VL8::,=YN^-K1DO#.-(5QM8O2ACDM MN%1$3J-I%+P+WBVWC=O%>Q!0TJN #Q31C;\[ -V0&ADL./AL1WSK-2Q0GO0C MYM_GQ0WVLRA6QF[9=N00:-8RCL%'.VA"RED7@/6QJE]=K)J_WN<%:'KRBATC=9I2':(W?H#)+H4DHHKNWJXC;$LTHWH4T]>.[YX'?]%4'IK8GTLL3Y28 M@W3=#PLM9-M_2@#Z?:W W?/HS[_0'KUZW+VTSD%\'Y6[G.C)4]V;"O-!UAN7 MY$M(6S=22>5TJE=QS\_U]*5YVQPT[0/8^QOH@9_NM4KPCB/M)EY#YQ]+TNVT M DT!;*Z-]&&(*%_;W%M4$?]YD27H$25X4:OQ2I+V#C$DXYB+#"'M6!7DIF4 M/D@YWF.L* ?;(T9^1M4#G5?)%/N MK?Y>5:AZEGKB:Q[\HDKK93<.Z5>8Y*1 MA#4/PE5-5*$6D&;Z. U#? AG(80VP%>H2SA[AOV>EJA2>IR_F%8E<,=&'Y8X:JD@C5 MG%[/'N0TD.@\TX8YN9''NQ,0F(^1&Q#8CHDCB-%O;]Z\.?[3M]^\_?,?J9V_ M^>[M&VKE@S_]6G^M_('\OS!KEZ:] WO6<3S&1],"U$U%9XD(+O!L M!)0&Q.Y0DN3QCAQ^1:(T61-&O\NC]KG!34[3(Y7@15XG'@0[HI>78,UZ 0F[ M"JP>(&".[E5?08L8Z"EQ:VEJ8:(]"F]&VN=::J9M(]>AMO8\JTSU?5[<0_KB MPA3>S[7,M-=NV41AF MJ^)99;92,?P9+0<:M=$N@YAI1JO2@HW1PJ:?&8QVII"3.B4O3,A;=)B5[#*7 M"+*&+,=*U^0Z>B:_.L&")E=,QO.G+2K86?=%QL)I5 $I2WS-9;C*(J/%!;.0 M+H[N2!^@_QW0^Q")9.FWJS\&Z-?PMGY;![STODC3<-%O^GK\XV;X%&ZQUX'7 MB)_EC(Z+!UK.X@['2?6.&YBW7M!%";YU0 Y*-%)+NJ?>]YKT[_',()YF)>9&Z?*W4AA^-QZ<%4.V/H\A$L\K4#\KKBT5K2[[(O M=BO".G'"[*ZHP@LQ;8XC-\/G\F%>E]<8G/JT@>9#9[GPW0'=C6W'U(852"O"ND?V]VR_%Q\G\Y">5THDW79 M$RSV'?\N8HZ1\7HNOS^>K5Y4*L%\.*N(FO6N M>B!]SNH5\Y MSE>>5B=#ATV;GFV#MV]6@*!]U=PH$;I#7E%(;6S^\VR)@3GT1]A%PO+D&G<) MBP(FU$UJLUPHJ5SZ""7W/&1):W "VO: 91\((=6%@2(X^.FUX!I([R8!24+E M'$@R[B5 >A.H*-GJ7#M[!64:;7ZK"-*ZV....TRO[N7ZNB$1QH531\BT39 M2=Z=JQI[BZV3O#AOP^K\/3/7CZTZ#LWV@;FUFJ5/Q-7-O:E:^MB[4[;'Y]TF M8ZQ6N*^'VC>[NQ(E*"J>;R+RI)PN"32Y)Q0T+I=R"LZYA5S$4E#4JS?OV2>T MH\ZMW'1#[A Q'0,?HPW^L?<47)MXPH38)89,9-& *8"L$N8JX7!EK ^7&5_1 M8U3!ZS2*H6&B5S&!T_RN$I[YM*ZT(6A;!K&75 \YG\%5-=XN@6)U!N']\,'P MU"'$PP:;4X8PSJE^8@7)-$N902N'4!AR-T9 _=< %BJ"41RK6S"$SK6L77>, MVKG7M'0UT>HZ@'6$<#0E^O:V81'?Q9#;%K)VB1_@50;UY]$VO?B_#)5(9W[- MR>XPZRX [B.(666"+@VOYE2*# FKMY_S&;#:ZR4HK/:EFXI5W,>!8)73I3U6 M.44&A57\N3D\ZZ"?L/ ZD' R8DDOAX)97J<34,LKU!UNST@&3)@ENH)=HW8. M<3?F<(RK]N\!K/>%HSE&A' H/6A]K_=\P M< ;C%#NF1#LAR0@\8('C608)T+0,8AI1#[D,(>+Q=EA&ELY0^"N:B6'4SF5! MUQ&'7!$[\G= &@0P,PB'DZL!*AI+[VO8+DZSE 5J=HQG"2E,1BY#])=9BWS. M_XIXW_'BGA_\:T?RKS,XAS#7+8D3Z]CA/4#B.8^MQK$J:'QGKI4X7$569._^ M5ZL!HQRH?ORRD!6M>U52^4:0U-DI,!2 YS/0A!&.O)W^-_5Z;F*8107*=:%* MXO9.GS:*.>:+R;$_!^!JE(/,/\93C+#+*H;LZS]FY1;&Z![!1+]^D],XK48H MYUP&DA7HM0["L6C'GZ\9J!E\AW$D]>)*XTN&S5S&C0SYX^)%\+\ ^7L KD,T ME%Q\B& R@.P?;.-T/0MC'%P^\<\^U^[**7.I/\.7'I& M:$?N//A=*P^7%C;/0$M1AX_5-%Y/$J>H21PO;Z:C65'U/W;I,_FS'9@D5,XQ M).-^#!W2CC[O#A P2@V(<;+\\-LE=9Y7#;/B^Q1_99=6D2+26D?@'-4"GKF- M>-LD("3+QEH,8ME .SY1KZO47QPH+_3'8N+:5R?;4LX%T9VE( U7@': MG&3]8?E O)]4J\9?>-RL&GS/IWY-2A[*6_O'LOYK>6Q['JCOS_=)H8'$%J73 MFMYJD'9MRK:1URQO>RG=Z.C15..+/)O]&9*/P.3D$1;1&GZ"9"^#LO4ENA>Y MQ"F=>'MBJY%-^O"VH0,U(6@I 2'U/^G:*$_]2M>9YJ95#+'4X">XQ;R1*\BN MBLCG1IE1K=,'EJ_Q<9%6!LA+%/T7ISMRFQF3>K(CC7VHW;4M FX9C M)V(5J"UCP?&?9@M:/8C0CUJ5/!(JG^5QZ/2F6V77C5POJQO>A.MHMC+QOF@> MC)]PE3P8O$#RNGZ$G^F?U'>:9AV$DK^U+Q.'&'I$R2@!(VV3P]?E1#1(I<>! %*O,$(=B??EZR=]$$'\B M20;P9H_,_6O57&A&[NVEOU0>S0"4"M+G1M K2G?\"N; MH[,FDMT:@8(>O(-0))4Q#LON5'35OE$(#XM2S9G!4:HVQUN .WW&X3M)QF'R M2!\F+-GPU3U;9N@V$[-_SO6V9/[Q6C*/./MDDT*<)I2BG_6^39<*K2NG85DE^*N,#J;,4^ M;(%ZH'9__K2%,5YY_92GN)L45<\N+5_V]4.U?>EH.K3^A@?0,?%EF;\:LHLZ M #5>?>U3V$^8K8NLK IZN]H/'#/?M.@[\K:#,9!1NYUI^P!=)\TRM+XK"&=S M8ZI4]4['5*,>\OT,3^OH_ZF JB3SD0E(S+\T+=!J7'9HQ?X30BH8E2ZD*8,4 MBCBTD]6F+&SK\E4N<[E/'MP)JW#<[U9!WM4OA CO M$-3BR?=HK,%E>%$>0YB4[[%6R"XZRLC#I7$5'65TD5D'3H.+#&7B8XL8(2 8 M!0TI"7_@2B/Y#2RRT1D?5V2C,)5JZ!7PA\$SK$#WZ=4PG95/0W<*V+'9.T7KX1S8]/9]HU?P@WP1 M"Q[/&'-P0(K7-.%,VV()=!Z"!G7V?7(8IO'N8,Z_0Z M8S"G?D'W%%HD+CAK^K]GZ)_.G49;A)?];%?_"99XOP"3]WGQ?E?M"MB<2BMO M':9TY^V!L[&\VM?.=4_-X6[3%[C/"\!Z:^\MPGG[;*=N]4-H.UW/F\*[/HQJ MTCC1N5'X]-Z0SGW2;JD$7+9N=GAYU/J-K^%Q>;\J<(S ME?AV;EHWWLU$*I^!U=2TX#8'A!JTY.'9D5J-9F;E0(?[69FQ+HG116VXC,#P MREJS50XJHEG8=.8S-=_\42OU 4MTET)?P:<"%@YH&V4QKMZ"Q'K,?,'!IU(H M.PH D^+8UDF4,'ZUSA]?(WJ50ES$V_IGXAS>]IP#^^VO%_0_A,UNM:&^>C E M=&"(QC*,S:>C:.?C<99R'RBWTTF#33N%>$%48]0%&)=[L$W8OLNU.%9YJUXW#586E M?-),W60^9QT,STU[?0#:B<_Y?(HRQW/R%$TZ3E;+9G]23([,^UFIO&*0$+A. M1ROB69Q_-B_ CQFJZA4EH'7^:AKO.6>E(R],,BL=]D5/27Y&U0/=<"8PT!/>3I1&4\KM_B#FD*\L&WB]JM!5]542>D2.M]"O#3@!E?_4Z,,&/KZ+?8U[HSK[+TB0M MA6E)[Q%7,HFT$&LJ(/;2@?FLH#E)8SKH*=7E#X6B?('64%1UXA&/2MD,0"E) M4ADD-O5ZU %4KT27&;C*.,T)>[=XM?@.?^FWD[NR*J)8=2RDI'*:?TO%/9]^ MJVD-2'- V^.U6DWA%64&>N"3;VF5X Y'EWE9GN99A;(US.+GLV@3K6%YD^_6 M#Y4N7-2 UB&F3"09(XO0@![1"M1D@-&M_$=?&BMH##-3[3#9+G$7[%_X!W*C M^H__#U!+ P04 " DHVU-B30:C5TW #O@, '@ &-I:S P,#$V-#(S M-S4M,C Q.# Y,S!?<')E+GAM;.U]:7/<.)/F]XF8_^#Q?'9;=:@D=4S/A*S# MH5U;I974W3LQ,<&@2*C$-HNLEXRW]WGV^.'X_7_\^S__T[_] MRX)Z[W+5W5?C?ZY> =_&\P_G =/Y/Y TD^# \& MQ^_^ZV#\Z^CXUX.C_W[W_TZ__O]W']Y]__[]%Q\:R(H&?O'B^8K MLH./__?KESOOBI_B3TW*\0D M[-<[M 3]UX=5L0_T5Q\&PP^CP2\OJ?^>RB")0W)+'M\5G_\U>UV0W]ZGP7P1 MTFX7OWM*R.-O[[W@VP' FXR'HZ/#0M ')Z,#VLR_GL=>/B=1=AKY%U$69*]7 MT6.Q9%/HI3X M\$,:AX%/E>R3&U*N[IX(R5*U7LNTM[^^W[@)2/")9('GAET#J37>*ZH[&+"$ M:D,Z?9PNZ%0 7>Z"&JSA_:"9/MYEL??M*0Y]F,@N_I&#FG<)BMW^WI@Z<].G MRS#^WC51E7:[PC)-9FX4_%W0#S/.ISP-(I*F375-HKFN>GZ7S^=N\@I4![,H M>(3!"'.FY\4Y3)K1[ ;DYP5$L?NR;7:%X0_B97'R'-"U_-0#-4T#]04#;:2K M7EY%SZ!_<:(LSJV*7?7F)HE!F[)7NCX"V 4=&]UY!FO12T%1_]W+EE^ MO8_)9-VT%D2#'B$--&%JI(#-OM#S"M!([41M[:?/BHHE;&P_O6ZD.I)-]K#V M-M(/5OV>5]]&_12UM9\^-]((R2;W=AYM@T6Y\;[/JFW R+;9W]ZNV4X";Z;W MGJKN$#CM]-[79BN_L+4]6 [: %!HMD"R2$@*A8M]]1?H^!8D*$DBG_@K4/0+ M[5U;A3,R]K:^%%+W7YQ(2V_K3P[O!A,4''?5&G,'QT61R MO)2=% @JK13$57@J4^+],HN?/_HD^$CQT!\*8!\.!DL_Y;_"K]9]J72A.,$Q M0/"*E]T]8E!]FFQWW4V\5=OPXP[/VV[698F/B\(_]L%["L*UBCPF\;RU=)<] MBQ40YBGT.%[0/U#=CA,8P;^]AWD&4#^2)"'^EU)F**H"4B%857I7[#ZZZ4/1 M7IY^F+GNHJ28A%FZ^DV=Z^6OG;7OYRQTX:!;.K5.7X*40;BP3BF3B1[6I$)ODH24D5V&=QW,WB#CL[A8NI7"HAU9YCMC<VA602(M0D./!P"C2=AG B=O"P";JT$RB M3J'[/H5P&;HSA*FM,B7,H754L4&PN9J8R=4*^0U)@ACV?/XYK!R"T;55MH ] MM'>8L<&P.3PRF\/+(/7<\#^)FUS";T0+7:UT"=V^,2B"PV;RV 8F2]64Y[)2 MOH0_LIQ-%B VGR=F\EF>H6_)+*!'YRB[=N?8Y,HJ6H >F75$E&&1BP4Q 1R8 MS. 9R"!QPZO()R__F[QR*:R5+7%K,NZTYA #@Y"X'T..,HEG>9)L+1'\?0Y6 MO$!_:-^D*L2#L+D?BTW#(7D9A"0Y Q2S..$/R*V2)>9CZSCD04'H,]0VLYQ8 MXOD\C@I#T]T3""V=YAF]F40O7?&G5TY%*I'#L;5SK0PRA&M#338EL(LY268 MXG,2?\^> .;"C?A#EEFC$.#AB:7L\B$AM!IJX%DB>BG<\4680;E3YW.Z4[R4 MV8&MA.)X$#8--0&5<.[F;ABN8CBY1&Z5+#';9_[A04'H:V7]^5CWX/?GU9>X M^JG+;SI]O PBZ$< 9_NX'#H&FHQM''9X-+*ZWY%'7R^;-%D%C36&_]&0Z66W=ZWU6D M0!9G;FC$B(3MPC1[(DF)]3J./,4ABC7@C&S9*BO@Z2JV0/><7%ZDR979@&T!BJX"$'SR&$2%%?IS'OAEFM+][YLR-YH%L"M^,]Q['\/PI"[GQ)7=\::?)[*S$NCZ2HL0>\HE^!W@UJ3SU.9PZT> M:XTSZ&H3)=P].6/-UGM%FU/1WZZ"!G1NE+X$[D,0P@Q.Z+7VW5OZ$D9$V2:< MH>;E4\E$K(2JJ_@#O9-I!;*\"1FOY(PT+YI*% JU@(4.X=TRP]/*O';COE+; M&L@*?I/DT/<=]!(61XE6G+%FF[. 5KX54A8@HAR6V;;.EUV]I9YM^'\@87Q& MZSACS9;G1L3SX2!1%Y89N^B22/.C2S+,*NZ,-1NC&Y&+(D%X53:#:1Z^.;F/ MIX^/@0?+WC2I+H(2XUA8V1EK-EHW&]!RN! -L,P0IK2(LY8RS0;MAJ.:B0-A M5-GLI?/$QDUHCL<"X+6&G.,GN23(_)P]%JE;1=6%6>>=$LT^;00O"']I]NZ\)[^ 2WA5& M:C@GFIW0.$.2C%9PO)$;PYWFI&60'HW;?=>9&[QK;P&<#ZBWFYX;"COJ#4F*O'72#@2L >?$ ME PJV^3). VXF'1F%>^:_3)%X6F>P3XB^'MS !6R7J_HG)B2H4.=;286G1G' M._42-1C@$K6=$_-R>^!\RP+2F9:\4](5QC6GEG.B.0JD*5Y%T$NR[HN$.1ZIX0S6$XH%)OBA[@'"E:*4W7W(&1B63'T= MY^H\,,N\5Q"D:M\K0-AMAV]KX!L>F'*(9+,C;>(K@+P1^WM#&]_PP"PCG\R8 MK/7>;FO[+7DF41:GV?219GDH(E9(\AQX M)+V+0_X!#ZL$DC'OZ,YA5(3D3>3N_)S$:7J3Q(_<2,U**N,J5L>T*+9,DV63!IDM Y(17> @1*A B!O(L7F+? ,J3Y8\]A70GC(BG6 M$C!W\>34; MUW$4;^-;):(5;["%=4&J5C$M">AM).B\BC("I$CLL6LEG>'PZ'B@V48L216; M9PQ05QD]]1)[Z09)$51SZO^5IUEYT>1/-Z&OQ_.F:FZ]4D::K5FM2)>#UU7F M4+TJ@ JJR6Q>RD:S:;H5]6)HK=.$GI2T1V1&8PON=:[H))/:F6V5@PV-*4X_ MN95ZM_-=9?S4_#A")2+V/'@.?!(5QOCR48#US"5C_U1O#"1N7K0X1PN:(M2= M_U,ZX< V0)K4E-!.3Q_/"4C)7R%F*$&C=F @:9[FFS*ZK1\MP+?.&;J]$)@U MC]2"GJ[FBT8S"+,9$)_FW6$WNM,<>^NTI$:HSM;*>OKL!B$-W+B/*T&BRR0. MG]PT\&0W&.*60(A6N5D;P>LJ<:G.3!W;9T%T_MB8L#6Q3!&G.@/0 M&XG5+X4 NXQ%'!6;6ZX*40)*<2!VQ^W7< E#]YGEG;'ND"<) MGI#M%(['[B#^RHF@S(/(#2:NE04!:+;,D#=Q X!F:;N*8!.9%U<_^?NGW<(@ M"5,.H<)-$]9[N[/G;*.Z=N?B5(-8%1"'YATP1I$,H74<=J?+N25%:O ;-\E> M[Q,W2N&01[G@#U!.+1"*6=!9E* M9L!:>1"**>NC%*,<$*UCY8UAMA(2>!\CANU59 ^-8)C32P,%;\4Z,RUDD-[2 M)['2("/+A"DW!:Y;XL6SJ&B1ZQW82P^ .%/6 2GMVZM8.KLXT.BY2NE8\ )9 MF7;U/$]@-)9PBBM-JVM,%R\D\8*4&7G5HC60DWFW0QCJTQJB-1<#$&QE^M;. MM %I#F1E7J*RINK Q=CZ-H 1_BZ9V70I &$V:^6VZ!6[L:XGC_M;?=@86U\! M,$)?FMT@' ]-"1J4(IG1^:Z"\_6RU_3 :4H@8*,#)Q[\IVRV*X\E%Y&N"S@= M'3='5DVY'!!=Q<$S>34F$CZ=/IZYZ=-E&'_?>P[Z2K3UN@]J@>\[U9SQ9*S1 M6JH:[SXQY72,BE)@,ZW@L#S,O1N_\<24\VJ%&"6_\00]C5KC7NS.;7RD>V>) M^4%:Z[W=(>[7)*,'O)LDIOED_$^OOZ?$OXK6*69/O2QX M#K) ZH$#]<9@^3)E3-=H18VTC1"^B?3X#:YI]OMKAS>KNYQ-)MCNMJ.> EQZ:):_K\BLF4XG\0)2KX1 M$+KF;6VWBJ**O*L+(KKWL"CJTS0E4BGXI=L P6G>[ZJ2K*PJ+,!=7;TP35-. M/2_.81:%U9X$SX)@))GJL#YKCFA19%96/3"HK6]B&)%,?1?O5?0,PHZ3@/L, M(K<>"$ASV$1/NK"#\6T\QK +]"8A"S?PSY<85B\9K1XJ*$2HI!TR#8)(-7OH M>U(;>?!OXX4&CAB_!.Y#$,KZ!-0: E(T'W]ZWZ*@J-_&S1!\];UQ7^G22RW2 MGI?D@&8CB48[%UZ#,!8U1R$T40'5#8U8 F_C98A=":PFXJ8ZQ*COC$\TQRWT MJ3(HX!Z?@# RYJ636!<0W9OR2JLB1Y1&V8BK]55J-F9Z0$B["I/B- 9TF'(A MJ$V8E! AHBJ6I7.&E79U5]O[1QXD!.0 @R-[O0G=*(,%F(:#+F@1CI+(-P*C MS$SKKI!NMO*H(D>4INE3N:8HS17P&,T"NF43G;^%=4%0FJVY/:L(&S"B&?+6 M7",T@\IM"=._!,$6/Z>B1$Z<6LYP,I[HSL/7K4+(H$6TP;X@7$FY=;(#@8%D MIH^YH:*H(D?N1BK']AJX>;T,(C?R.MJ\,^60 M7B\*0M \RKLEFXT/(5G>1&K$CK**C4Z)--<+]#R0Y7NK#@A&L_>W/^(90!$- MD#>!&J$!U:F,IHP#09'IX\W6$_-PTBY_0>"/Q6\DUP#Y!D&DFEW _:T0JE) M%,NR6->J!):AFZL4EEP+!J<:B$>S>ZX_)6%C153!-C-H!6=U4JV&? LV&;)- M.(<'FMUQ_:F(&#>B+I:%M\I+L)/3*8C.3*]<0Y5118XHC7J2<8V&C<+J%_GT M?]0G\.R&=)B4:93K7FT)TT:3YH 24U)&21DWFF-$%,8R\ZD*_HY4!<:;9O]< M<]+;*U&)'LE'9I49E8WZ%*;=)'F%&;:XNJ2L,[7Z("[-GKK]* L3-J(ERA94 M_0^Y[$M7-/MF=.D*ZI@9*YM;=6?7OLL7B[!8O]UPE6KW*GJ,DWE)ID3:8[D6 M0&Q6Q1 IP4*TP;K0U3+E GW8 ?;SW"#5K9+EY5C=SR2J$,;F'(.%T&M9W&EY MO?[>?:&>HX#WJ$FM9"D'W0_P=4$O&Q9"KV6FSY50KN/(@Q\W(061SSB%GP>I M%\9IGLB>3-LT#:18Y8+O!B^B5I:942O/1 UXNX!*L7)@:39O=<,ALC=@@47H MMLT,6HIKFE C[_(?E6BV8@<\?5Q>3UQ&O,F$[;1H%IBPRL;5'BNB2GMZ@7$O MBE2/F%T)@C?'-&VR#,'4'1[26BL::9M8*(BRF??&(X [JR(]VT;Z.8[]/X,P M7"%D*%*K]@J!C71'HW:L1=U(!,G_;UD&6H%L*[?G.YBL6*T5\ASJ=@OJF:>X M\D#T2]DPN[,>[O&YLVDR(>E.53R ] X]>52PS+]"7G4%$'HUR&1F1RL!44,-!A">1&6&N%P# $YWAF>!X!%;B (ZN\?8'\0#%7N�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end